

CLINICAL TRIAL MAGNIFIER WEEKLY

A WEEKLY TRACKING OF ESSENTIAL CHANGES IN THE U.S. TRIAL REGISTRY

Vol. 3, No. 29
July 17, 2014

INSIDE THIS ISSUE

| | |
|--|---------|
| New Sponsors | Page 2 |
| New Studies | Page 3 |
| New Results | Page 9 |
| New Study Status... | Page 10 |
| Studies Opening a First Site in a New Country ... | Page 18 |
| Studies Opening Additional Sites in a Country .. | Page 27 |
| Study Sites by Country | Page 41 |
| Studies Under Planning..... | Page 42 |
| Studies Ended or Halted..... | Page 53 |

Highlights of Changes This Week at ClinicalTrials.gov:

New Sponsors: Twenty-two sponsors registered studies at ClinicalTrials.gov for the first time this week. Those sponsors are Adwin Life Care, Amaranth Medical, Balanced Health plus, Cereneo, Chase Pharmaceuticals, Clementia Pharmaceuticals, DC2 Healthcare, DySIS Medical, Evolus, Folia Biotech, Igenomix, Lyman Orthopedics, MedMira Laboratories, Neuravi, Novosanis, NuvOx Pharma, Oriflame Cosmetics, Probiodrug, ProCore, Spirox, United BioSource and Yolo Medical. For more details, see **New Sponsors on Page 2**.

New Studies: One hundred fifty-eight new studies were registered this week, including studies sponsored by Abbott, Allergan, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, H Lundbeck, Hoffmann-La Roche, Janssen, Medtronic, Novartis, Pfizer, Sanofi and Teva. For more details, see **New Studies on Page 3**.

New Results: Forty-five industry-sponsored studies posted results this week, including studies by Abbott, AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Genzyme, GlaxoSmithKline, Hoffmann-La Roche, Merck, Novartis, Novo Nordisk, Pfizer, Shire and Stryker. For more details, see **New Results on Page 9**.

(See **Highlights**, Page 2)

SUMMARY OF LATEST TRIAL UPDATES

| Week Ending | July 17 | July 10 | July 3 | June 26 | Total |
|---|---------|---------|--------|---------|-------|
| New Sponsors | 22 | 10 | 8 | 15 | 55 |
| New Studies | 158 | 177 | 143 | 208 | 686 |
| New Results | 45 | 44 | 49 | 42 | 180 |
| New Study Status | 235 | 158 | 198 | 180 | 771 |
| Studies Opening a First Site in a New Country | 291 | 165 | 256 | 379 | 1,091 |
| Studies Opening Additional Sites in a Country | 399 | 378 | 569 | 869 | 2,215 |
| Study Sites by Country | 690 | 543 | 825 | 1,248 | 3,306 |
| Studies Under Planning | 311 | 326 | 323 | 326 | 1,286 |
| Studies Ended or Halted | 26 | 20 | 19 | 23 | 88 |
| New or Additional Cities | 2,479 | 974 | 2,157 | 2,574 | 8,184 |

Highlights, from Page 1

New Study Status: Two hundred thirty-five studies are reporting changes in their status as planning, recruiting, ongoing or completed this week. Among the sponsors are Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, Hoffmann-La Roche, Janssen, Merck, Novartis, Pfizer, Takeda and UCB. For more details, see **New Study Status on Page 11**.

Studies Opening a First Site in a New Country: Two hundred ninety-one new study sites launched this week in countries where the sponsors did not have study sites. For more details, see **Studies Opening a First Site in a New Country on Page 18**.

Studies Opening Additional Sites in a Country: Three hundred ninety-nine new study sites launched this week in countries where the sponsors already had study sites. For more details, see **Studies Opening Additional Sites in a Country on Page 27**.

Study Sites by Country: A handy table that lists all countries with first-time and additional study sites that launched this week can be found at **Study Sites by Country on Page 41**.

Studies Under Planning: About 10% of the studies listed as in the planning stage are replaced each week. This week's 311 listings include planned studies at AbbVie, Amgen, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Merck, Pfizer, Sanofi and St. Jude. For more details, see **Studies Under Planning on Page 42**.

Studies Ended or Halted: Twenty-six studies were terminated, suspended or withdrawn this week, including studies sponsored by Abbott, Allergan, Boehringer Ingelheim, Celgene, Merck, Novartis and Pfizer. For more details, see **Studies Ended or Halted on Page 53**.

New Study Sites by City: This table only appears in the Excel spreadsheet version of CTM Weekly and gives details about all trials — under planning or recruiting — that have opened sites during the past week, sorted by country, state and city. State is only available for the U.S. and Canada. This week's table includes 2,479 cities.

NEW SPONSORS

This table lists new sponsors that have never previously registered studies at ClinicalTrials.gov.

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-----------|-------------------|-------------|--------------------|----------|----------|----------|--------------------------|
| NCT02186977 | NOVOSANIS | DEVICE | 1. PLANNING | 1 | 33 | 18 YEARS | 35 YEARS | INFECT HEPATITIS B |
| NCT02189499 | AMARANTH | DEVICE | 1. PLANNING | 2 | 50 | 18 YEARS | 84 YEARS | CARDIO CORONARY/ISCHEMIC |
| NCT02185053 | CHASE | DRUG | 1. PLANNING | 2 | 24 | 50 YEARS | 79 YEARS | NEUR ALZHEIMER/DEMENT |
| NCT02190747 | CLEMENTIA | DRUG | 1. PLANNING | 2 | 24 | 15 YEARS | N/A | ORTH MUSCULAR DISEASE |
| NCT02184988 | EVOLUS | BIOLOGICAL | 1. PLANNING | 2 | 365 | 18 YEARS | N/A | DERM WRINKLES |
| NCT02185482 | ADWIN | BEHAVIORAL | 1. PLANNING | NA | 150 | 35 YEARS | 60 YEARS | PSYCH DEPRESSION |
| NCT02185599 | DYSIS | DEVICE | 1. PLANNING | NA | 9,000 | 21 YEARS | N/A | ONC O&G: CERVIX |
| NCT02189369 | IGENOMIX | OTHER | 1. PLANNING | NA | 120 | 18 YEARS | 50 YEARS | O&G INFERTILITY |
| NCT02185001 | LYMAN | PROCEDURE | 1. PLANNING | NA | 40 | 10 YEARS | N/A | ORTH JOINT DISEASE |
| NCT02190578 | MEDMIRA | DEVICE | 1. PLANNING | NA | 1,500 | 13 YEARS | N/A | INFECT HIV/AIDS |
| NCT02190552 | NEURAVI | DEVICE | 1. PLANNING | NA | 100 | 18 YEARS | 80 YEARS | CARDIO STROKE |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

New Sponsors, from Page 2

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|------------------|-------------------|---------------|--------------------|--------------|----------|----------|------------------------------|
| NCT02190565 | ORIFLAME | DIETARY SUP. | 1. PLANNING | NA | 200 | 18 YEARS | 40 YEARS | HEM ANEMIA |
| NCT02188810 | FOLIA | BIOLOGICAL | 2. RECRUITING | 1 | 48 | 18 YEARS | 50 YEARS | INFECT INFLUENZA/FLU |
| NCT02189109 | NUVOX | DRUG | 2. RECRUITING | 1 | 25 | 18 YEARS | 70 YEARS | ONC CNS: GLIOMA |
| NCT02188771 | PROCORE | DEVICE | 2. RECRUITING | 1 | 18 | 45 YEARS | 75 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT02189980 | BALANCED HEALTH | OTHER | 2. RECRUITING | NA | 300 | 18 YEARS | N/A | ANEST NAUSEA/ VOMITING |
| NCT02189551 | CERENEO | BEHAVIORAL | 2. RECRUITING | NA | MISS- ING | 18 YEARS | N/A | CARDIO STROKE |
| NCT02188199 | DC2 HEALTHCARE | | 2. RECRUITING | NA | 10,000 | 18 YEARS | N/A | ORTH HIP/KNEE REPLACEMENT |
| NCT02188589 | SPIROX | DEVICE | 2. RECRUITING | NA | 30 | 18 YEARS | N/A | CARDIO SHOCK |
| NCT01511393 | UNITED BIOSOURCE | OTHER | 2. RECRUITING | NA | 6,750 | N/A | N/A | ENDO DIABETES |
| NCT02190708 | PROBIODRUG | DRUG | 3. ONGOING | 1 | 36 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02187237 | YOLO | DEVICE | 4. COMPLETED | NA | 50 | 18 YEARS | 65 YEARS | ENDO METAB/NUTR |

NEW STUDIES

This table lists every new study registered in the past week.

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|----------------------|-------------------|-------------|--------------------|----------|----------|----------|---------------------------------|
| NCT02184429 | PFIZER | DRUG | 1. PLANNING | 1 | 66 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02184585 | GSK | DRUG | 1. PLANNING | 1 | 84 | 18 YEARS | 65 YEARS | UROLOGY PROSTATE HYPERPLASIA |
| NCT02184637 | GSK | DRUG | 1. PLANNING | 1 | 120 | 18 YEARS | 65 YEARS | INFECT MALARIA |
| NCT02185066 | CJ HEALTHCARE | DRUG | 1. PLANNING | 1 | 42 | 19 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02185300 | VIIV | DRUG | 1. PLANNING | 1 | 15 | 18 YEARS | 65 YEARS | INFECT HIV/AIDS |
| NCT02185534 | ASTRAZENECA | DRUG | 1. PLANNING | 1 | 84 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02186483 | JEIL | DRUG | 1. PLANNING | 1 | 24 | 19 YEARS | 55 YEARS | CARDIO CHOLESTEROL/LIPIDS |
| NCT02186535 | CONRAD | DIETARY SUP. | 1. PLANNING | 1 | 20 | 21 YEARS | 50 YEARS | ENDO METAB/NUTR |
| NCT02186769 | LUYE | DRUG | 1. PLANNING | 1 | 16 | 18 YEARS | 65 YEARS | PSYCH SCHIZOPHRENIA |
| NCT02186977 | NOVOSANIS | DEVICE | 1. PLANNING | 1 | 33 | 18 YEARS | 35 YEARS | INFECT HEPATITIS B |
| NCT02187029 | PFIZER | DRUG | 1. PLANNING | 1 | 27 | 18 YEARS | 60 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT02187627 | HOFFMANN-LA ROCHE | DRUG | 1. PLANNING | 1 | 34 | 25 YEARS | 80 YEARS | NEUR ALZHEIMER/ DEMENT |
| NCT02187848 | SANOFI | DRUG | 1. PLANNING | 1 | 120 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT02188303 | ELI LILLY | DRUG | 1. PLANNING | 1 | 72 | 18 YEARS | 65 YEARS | HEALTHY/PHARM |
| NCT02189174 | NOVARTIS | DRUG | 1. PLANNING | 1 | 157 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

New Studies, from Page 3

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|-----------------------|-------------------|-------------|--------------------|----------|-----------|-----------|------------------------------|
| NCT02189252 | OMTHERA | DRUG | 1. PLANNING | 1 | 24 | 18 YEARS | N/A | CARDIO CHOLESTEROL/LIPIDS |
| NCT02189343 | ACETYLON | DRUG | 1. PLANNING | 1 | 20 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02190058 | DAIICHI SANKYO | DRUG | 1. PLANNING | 1 | 48 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02184988 | EVOLUS | BIOLOGICAL | 1. PLANNING | 2 | 365 | 18 YEARS | N/A | DERM WRINKLES |
| NCT02185040 | CELGENE | DRUG | 1. PLANNING | 2 | 140 | 18 YEARS | N/A | RHEUM LUPUS ERYTHEM. |
| NCT02185053 | CHASE | DRUG | 1. PLANNING | 2 | 24 | 50 YEARS | 79 YEARS | NEUR ALZHEIMER/ DEMENT |
| NCT02186119 | ALLERGAN | DRUG | 1. PLANNING | 2 | 140 | 19 YEARS | N/A | OPHTHAL MACULAR EDEMA |
| NCT02186301 | CLOVIS ONCOLOGY | DRUG | 1. PLANNING | 2 | 200 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02186821 | NOVARTIS | DRUG | 1. PLANNING | 2 | 90 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT02186847 | NRG | DRUG | 1. PLANNING | 2 | 168 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02187302 | CERULEAN | DRUG | 1. PLANNING | 2 | 110 | 18 YEARS | N/A | ONC UROLOGY: KIDNEY |
| NCT02187783 | NOVARTIS | DRUG | 1. PLANNING | 2 | 90 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT02187861 | HOFFMANN-LA ROCHE | DRUG | 1. PLANNING | 2 | 156 | 18 YEARS | N/A | ONC HEM: LYMPHOMA |
| NCT02187991 | US ONCOLOGY | DRUG | 1. PLANNING | 2 | 252 | 18 YEARS | N/A | ONC BREAST |
| NCT02188251 | KGK | DIETARY SUP. | 1. PLANNING | 2 | 100 | 21 YEARS | 55 YEARS | ENDO METAB/NUTR |
| NCT02188368 | ONCOTHERA- PEUTICS | DRUG | 1. PLANNING | 2 | 45 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02189499 | AMARANTH | DEVICE | 1. PLANNING | 2 | 50 | 18 YEARS | 84 YEARS | CARDIO CORONARY/ ISCHEMIC |
| NCT02189707 | DANISCO | DIETARY SUP. | 1. PLANNING | 2 | 228 | 18 YEARS | 70 YEARS | GI CONSTIPATION |
| NCT02189772 | ALCOBRA | DRUG | 1. PLANNING | 2 | 82 | 13 YEARS | 17 YEARS | PSYCH ADHD |
| NCT02190604 | NOVARTIS | DRUG | 1. PLANNING | 2 | 260 | 18 YEARS | 55 YEARS | RESP CYSTIC FIBROSIS |
| NCT02190721 | TEVA | DRUG | 1. PLANNING | 2 | 50 | 1 MONTH | 16 YEARS | ONC SOLID TUMOR/ CANCER |
| NCT02190747 | CLEMENTIA | DRUG | 1. PLANNING | 2 | 24 | 15 YEARS | N/A | ORTH MUSCULAR DISEASE |
| NCT02184195 | ASTRAZENECA | DRUG | 1. PLANNING | 3 | 145 | 18 YEARS | N/A | ONC BREAST |
| NCT02184572 | GSK | BIOLOGICAL | 1. PLANNING | 3 | 1,734 | 12 MONTHS | 15 MONTHS | INFECT MEASLES |
| NCT02184611 | GSK | DRUG | 1. PLANNING | 3 | 454 | 40 YEARS | N/A | RESP COPD |
| NCT02186145 | MARJAN | DRUG | 1. PLANNING | 3 | 160 | 18 YEARS | 50 YEARS | INFECT VAGINA |
| NCT02186873 | JANSSEN | DRUG | 1. PLANNING | 3 | 200 | 18 YEARS | N/A | RHEUM SPONDYLITIS |
| NCT02187003 | PFIZER | DRUG | 1. PLANNING | 3 | 350 | 6 YEARS | N/A | HEM ANEMIA SICKLE CELL |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See New Studies, Page 5)

New Studies, from Page 4

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|----------------|-------------------|-------------|--------------------|----------|----------|----------|---------------------------|
| NCT02187159 | DAIICHI SANKYO | DRUG | 1. PLANNING | 3 | 1,200 | 18 YEARS | N/A | NEUR FIBROMYALGIA |
| NCT02187471 | DAIICHI SANKYO | DRUG | 1. PLANNING | 3 | 1,200 | 18 YEARS | N/A | NEUR FIBROMYALGIA |
| NCT02187744 | PFIZER | BIOLOGICAL | 1. PLANNING | 3 | 220 | 18 YEARS | N/A | ONC BREAST |
| NCT02187809 | H LUNDBECK | DRUG | 1. PLANNING | 3 | 40 | 1 YEAR | 16 YEARS | NEUR EPILEPSY/ SEIZURE |
| NCT02189629 | GALDERMA | DRUG | 1. PLANNING | 3 | 500 | 9 YEARS | N/A | DERM ACNE |
| NCT02184624 | GSK | DEVICE | 1. PLANNING | 4 | 570 | 40 YEARS | N/A | RESP COPD |
| NCT02186665 | GALDERMA | DRUG | 1. PLANNING | 4 | 300 | 2 YEARS | 12 YEARS | DERM PSORIASIS |
| NCT02187042 | PFIZER | OTHER | 1. PLANNING | 4 | 220 | 18 YEARS | N/A | ONC UROLOGY: KIDNEY |
| NCT02187055 | PFIZER | DRUG | 1. PLANNING | 4 | 1,080 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02187614 | HAMAD MEDICAL | DRUG | 1. PLANNING | 4 | 573 | 18 YEARS | 65 YEARS | UROLOGY KIDNEY STONES |
| NCT02184416 | PFIZER | OTHER | 1. PLANNING | NA | 750 | 18 YEARS | N/A | ONC UROLOGY: KIDNEY |
| NCT02185001 | LYMAN | PROCEDURE | 1. PLANNING | NA | 40 | 10 YEARS | N/A | ORTH JOINT DISEASE |
| NCT02185482 | ADWIN | BEHAVIORAL | 1. PLANNING | NA | 150 | 35 YEARS | 60 YEARS | PSYCH DEPRESSION |
| NCT02185521 | PHILIPS | OTHER | 1. PLANNING | NA | 3,000 | 18 YEARS | N/A | CARDIO SHOCK |
| NCT02185560 | BAYER | DRUG | 1. PLANNING | NA | 200 | N/A | N/A | ONC ENDO: THYROID |
| NCT02185599 | DYSIS | DEVICE | 1. PLANNING | NA | 9,000 | 21 YEARS | N/A | ONC O&G: CERVIX |
| NCT02185898 | R.J. REYNOLDS | OTHER | 1. PLANNING | NA | 72 | 21 YEARS | N/A | PSYCH ABUSE TOBACCO |
| NCT02186041 | MEDTRONIC | DEVICE | 1. PLANNING | NA | 250 | 18 YEARS | N/A | UROLOGY INCONTINENCE |
| NCT02186223 | BIO2 MEDICAL | DEVICE | 1. PLANNING | NA | 182 | 18 YEARS | N/A | RESP EMBOLISM |
| NCT02186561 | COVIDIEN | DEVICE | 1. PLANNING | NA | 141 | 22 YEARS | 80 YEARS | CARDIO ANEURYSM |
| NCT02187887 | RAND | BEHAVIORAL | 1. PLANNING | NA | 600 | 18 YEARS | 34 YEARS | PSYCH ABUSE ALCOHOL |
| NCT02188095 | AESCULAP | | 1. PLANNING | NA | 100 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02188173 | ALLERGAN | DRUG | 1. PLANNING | NA | 1,000 | 18 YEARS | N/A | OPHTHAL MACULAR EDEMA |
| NCT02188290 | KIADIS | | 1. PLANNING | NA | 270 | 18 YEARS | 65 YEARS | ONC HEM: LEUKEMIA |
| NCT02188355 | TERUMO | | 1. PLANNING | NA | 17,000 | 18 YEARS | N/A | CARDIO CORONARY/ ISCHEMIC |
| NCT02189369 | IGENOMIX | OTHER | 1. PLANNING | NA | 120 | 18 YEARS | 50 YEARS | O&G INFERTILITY |
| NCT02189525 | BANYAN | | 1. PLANNING | NA | 500 | 18 YEARS | N/A | NEUR HEAD INJURY/ TRAUMA |
| NCT02189863 | ALCON | DEVICE | 1. PLANNING | NA | 24 | N/A | 70 YEARS | OPHTHAL PRESBYOPIA |
| NCT02190123 | ASTRAZENECA | DRUG | 1. PLANNING | NA | 640 | 18 YEARS | N/A | CARDIO CORONARY/ ISCHEMIC |
| NCT02190149 | BAXTER | BIOLOGICAL | 1. PLANNING | NA | 60 | 13 YEARS | 65 YEARS | HEM HAEMOPHILIA A/B |
| NCT02190552 | NEURAVI | DEVICE | 1. PLANNING | NA | 100 | 18 YEARS | 80 YEARS | CARDIO STROKE |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See New Studies, Page 6)

New Studies, from Page 5

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|-----------------|-------------------|---------------|--------------------|----------|----------|----------|------------------------------|
| NCT02190565 | ORIFLAME | DIETARY SUP. | 1. PLANNING | NA | 200 | 18 YEARS | 40 YEARS | HEM ANEMIA |
| NCT02190578 | MEDMIRA | DEVICE | 1. PLANNING | NA | 1,500 | 13 YEARS | N/A | INFECT HIV/AIDS |
| NCT02190643 | RAND | BEHAVIORAL | 1. PLANNING | NA | 48 | 18 YEARS | N/A | PSYCH ABUSE TOBACCO |
| NCT02190825 | POP MEDICAL | DEVICE | 1. PLANNING | NA | 10 | 18 YEARS | 80 YEARS | GI PELVIC PROLAPSE |
| NCT02184156 | AMPIO | BIOLOGICAL | 2. RECRUITING | 1 | 40 | 45 YEARS | 55 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT02184767 | TEVA | DRUG | 2. RECRUITING | 1 | 30 | 10 YEARS | 17 YEARS | PSYCH BIPOLAR |
| NCT02185794 | GILEAD | DRUG | 2. RECRUITING | 1 | 92 | 18 YEARS | 65 YEARS | INFECT HEPATITIS C |
| NCT02186496 | CHONG KUN DANG | DRUG | 2. RECRUITING | 1 | 32 | 20 YEARS | 45 YEARS | CARDIO HYPERTENSION |
| NCT02187094 | TARGACEPT | DRUG | 2. RECRUITING | 1 | 44 | 18 YEARS | 70 YEARS | GI PARESIS |
| NCT02188771 | PROCORE | DEVICE | 2. RECRUITING | 1 | 18 | 45 YEARS | 75 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT02188810 | FOLIA | BIOLOGICAL | 2. RECRUITING | 1 | 48 | 18 YEARS | 50 YEARS | INFECT INFLUENZA/ FLU |
| NCT02189109 | NUVOX | DRUG | 2. RECRUITING | 1 | 25 | 18 YEARS | 70 YEARS | ONC CNS: GLIOMA |
| NCT02189304 | PEARL | DRUG | 2. RECRUITING | 1 | 60 | 18 YEARS | 55 YEARS | RESP COPD |
| NCT02189733 | ABLYNX | BIOLOGICAL | 2. RECRUITING | 1 | 24 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02135042 | NRG | RADIATION | 2. RECRUITING | 2 | 924 | 18 YEARS | N/A | INFECT HERPES SIMPLEX |
| NCT02188082 | JIANGSU HENGRUI | DRUG | 2. RECRUITING | 2 | 336 | 18 YEARS | 75 YEARS | CARDIO CARDIOMYOP/ FAILURE |
| NCT02188160 | KALA | DRUG | 2. RECRUITING | 2 | 150 | 18 YEARS | N/A | OPHTHAL DRY EYE |
| NCT02188277 | MERZ | DRUG | 2. RECRUITING | 2 | 64 | 2 YEARS | 12 YEARS | NEUR SPASTICITY/PALSY |
| NCT02189577 | CHIESI | DRUG | 2. RECRUITING | 2 | 98 | 40 YEARS | 80 YEARS | RESP COPD |
| NCT02189850 | BRAINTREE | DRUG | 2. RECRUITING | 2 | 32 | 12 YEARS | 17 YEARS | GI SCOPY |
| NCT02190786 | KISSEI | DRUG | 2. RECRUITING | 2 | MISSING | 20 YEARS | 64 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT02186171 | AMGEN | DRUG | 2. RECRUITING | 3 | 225 | 55 YEARS | 90 YEARS | ENDO OSTEOPOROSIS |
| NCT02189837 | AMGEN | DRUG | 2. RECRUITING | 3 | 80 | 18 YEARS | 65 YEARS | CARDIO CHOLESTEROL/LIPIDS |
| NCT02184520 | GLOBUS | DEVICE | 2. RECRUITING | 4 | 360 | 18 YEARS | N/A | ORTH SPINAL DISEASE |
| NCT02184546 | STEMGENEX | | 2. RECRUITING | NA | 75 | 18 YEARS | N/A | NEUR PARKINSON |
| NCT02184845 | NOBEL BIOCARE | DEVICE | 2. RECRUITING | NA | 84 | 18 YEARS | N/A | DENTAL PROCEDURE |
| NCT02185703 | CHORDATE | DEVICE | 2. RECRUITING | NA | 100 | 18 YEARS | 65 YEARS | NEUR MIGRAINE/ H-ACHE |
| NCT02185911 | AMGEN | | 2. RECRUITING | NA | 300 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02186912 | NOBEL BIOCARE | DEVICE | 2. RECRUITING | NA | 56 | 18 YEARS | N/A | DENTAL TOOTHLESS/ EXTRACTION |
| NCT02187549 | FIDIA | DEVICE | 2. RECRUITING | NA | 332 | 40 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See New Studies, Page 7)

New Studies, from Page 6

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|---------------------------|
| NCT02187653 | DC2 HEALTHCARE | | 2. RECRUITING | NA | 10,000 | 18 YEARS | N/A | OTHER PROCEDURE |
| NCT02187666 | DC2 HEALTHCARE | | 2. RECRUITING | NA | 10,000 | N/A | N/A | ORTH SPINAL DISEASE |
| NCT02187770 | INTERSECTION | DEVICE | 2. RECRUITING | NA | 100 | 18 YEARS | N/A | RESP INSUF/FAILURE |
| NCT02188199 | DC2 HEALTHCARE | | 2. RECRUITING | NA | 10,000 | 18 YEARS | N/A | ORTH HIP/KNEE REPLACEMENT |
| NCT02188589 | SPIROX | DEVICE | 2. RECRUITING | NA | 30 | 18 YEARS | N/A | CARDIO SHOCK |
| NCT02188797 | RAND | BEHAVIORAL | 2. RECRUITING | NA | 168 | 18 YEARS | 24 YEARS | PSYCH ABUSE SUBSTANCE |
| NCT02189161 | COVIDIEN | DEVICE | 2. RECRUITING | NA | 10 | 18 YEARS | 75 YEARS | ONC GI: COLORECTAL |
| NCT02189551 | CERENEO | BEHAVIORAL | 2. RECRUITING | NA | MISSING | 18 YEARS | N/A | CARDIO STROKE |
| NCT02189798 | ADVANCED BIONICS | DEVICE | 2. RECRUITING | NA | 25 | 18 YEARS | N/A | ENT HEARING LOSS |
| NCT02189980 | BALANCED HEALTH | OTHER | 2. RECRUITING | NA | 300 | 18 YEARS | N/A | ANEST NAUSEA/VOMITING |
| NCT02190305 | MEDMIRA | DEVICE | 2. RECRUITING | NA | 4,000 | 13 YEARS | N/A | INFECT HIV/AIDS |
| NCT02190591 | TRIHEALTH | DEVICE | 2. RECRUITING | NA | 184 | 18 YEARS | 50 YEARS | O&G PREGNANCY |
| NCT02190708 | PROBIODRUG | DRUG | 3. ONGOING | 1 | 36 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02184442 | EDWARDS | DEVICE | 3. ONGOING | 4 | 5,000 | N/A | N/A | OTHER SYMPTOM UNSPECIFIC |
| NCT02187510 | PARC TAULI | PROCEDURE | 3. ONGOING | NA | 40 | N/A | N/A | O&G PREMATUREITY |
| NCT02189382 | PROCTER & GAMBLE | DEVICE | 3. ONGOING | NA | 70 | 18 YEARS | N/A | DENTAL TOOTHACHE |
| NCT02184091 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 1 | 41 | 18 YEARS | 75 YEARS | UROLOGY KIDNEY FAILURE |
| NCT02184247 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 1 | 22 | 18 YEARS | 45 YEARS | HEALTHY/PHARM |
| NCT02184312 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 1 | 96 | 18 YEARS | 60 YEARS | HEALTHY/PHARM |
| NCT02184338 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 1 | 48 | 18 YEARS | 50 YEARS | HEALTHY/PHARM |
| NCT02186002 | ACTELION | DRUG | 4. COMPLETED | 1 | 40 | 18 YEARS | 45 YEARS | HEALTHY/PHARM |
| NCT02187523 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 1 | 32 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02187536 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 1 | 16 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02187562 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 1 | 16 | 18 YEARS | 60 YEARS | HEALTHY/PHARM |
| NCT02187575 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 1 | 26 | 20 YEARS | 35 YEARS | HEALTHY/PHARM |
| NCT02189330 | PFIZER | DRUG | 4. COMPLETED | 1 | 24 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02189941 | APOPHARMA | DRUG | 4. COMPLETED | 1 | 12 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02184325 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 2 | 96 | 6 YEARS | 14 YEARS | HEALTHY/PHARM |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See New Studies, Page 8)

New Studies, from Page 7

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-------------------------|-------------------|---------------|--------------------|----------|----------|----------|-------------------------------|
| NCT02187107 | TIBOTEC | DRUG | 4. COMPLETED | 2 | 52 | 18 YEARS | N/A | INFECT HIV/AIDS |
| NCT02187484 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 2 | 23 | 20 YEARS | N/A | CARDIO HYPERTENSION |
| NCT02187497 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 2 | 93 | 20 YEARS | N/A | CARDIO HYPERTENSION |
| NCT02187588 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 2 | 200 | 18 YEARS | 60 YEARS | ANEST PAIN |
| NCT02184351 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 3 | 187 | 18 YEARS | N/A | INFECT CANDIDIA |
| NCT02184364 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 3 | 161 | 40 YEARS | 60 YEARS | O&G MENOPAUSE & POST |
| NCT01047358 | PFIZER | DRUG | 4. COMPLETED | 4 | 214 | N/A | N/A | ONC BREAST |
| NCT02184078 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 4 | 19 | 18 YEARS | 65 YEARS | INFECT HIV/AIDS |
| NCT02184234 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 4 | 65 | 25 YEARS | 75 YEARS | DERM WOUND/ULCER |
| NCT02184273 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 4 | 122 | 6 YEARS | 11 YEARS | ANEST PAIN |
| NCT02184299 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 4 | 138 | 18 YEARS | 65 YEARS | INFECT HIV/AIDS |
| NCT02187705 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 4 | 1,688 | 18 YEARS | N/A | CARDIO HYPERTENSION |
| NCT02184039 | BOEHRINGER INGELHEIM | | 4. COMPLETED | NA | 12,687 | 12 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02184052 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | NA | 121 | N/A | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02184065 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | NA | 22,639 | 12 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02186808 | NOBEL BIOCARE | DEVICE | 4. COMPLETED | NA | 81 | 18 YEARS | N/A | DENTAL PROCEDURE |
| NCT02187237 | YOLO | DEVICE | 4. COMPLETED | NA | 50 | 18 YEARS | 65 YEARS | ENDO METAB/NUTR |
| NCT02187926 | TAKEDA | | 4. COMPLETED | NA | 2,577 | 40 YEARS | N/A | RESP COPD |
| NCT02190877 | PERMINOVA | | 4. COMPLETED | NA | 23 | 21 YEARS | 90 YEARS | CARDIO CARDIOMYOP/ FAILURE |
| NCT02186249 | BMS | DRUG | 7. OTHER | NA | MISSING | 18 YEARS | N/A | ONC DERM: MELANOMA |
| NCT02187354 | AMGEN | DRUG | 7. OTHER | NA | MISSING | N/A | 17 YEARS | ONC HEM: LEUKEMIA |
| NCT02189720 | CATALYST | DRUG | 7. OTHER | NA | MISSING | 10 YEARS | N/A | RHEUM LEMS |
| NCT02184286 | BOEHRINGER INGELHEIM | DRUG | 7. TERMINATED | 1 | 5 | 18 YEARS | 65 YEARS | INFECT HIV/AIDS |
| NCT02184260 | BOEHRINGER INGELHEIM | DRUG | 7. TERMINATED | 4 | 58 | 18 YEARS | N/A | CARDIO STROKE |
| NCT00922571 | ABBOTT | PROCEDURE | 7. TERMINATED | NA | 100 | 50 YEARS | 80 YEARS | OPHTHAL CATARACT |
| NCT02188212 | NOBEL BIOCARE | DEVICE | 7. TERMINATED | NA | 53 | 18 YEARS | 70 YEARS | DENTAL PROCEDURE |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an intervention device trial.

(Return to Page 1)

NEW RESULTS

This table lists all industry-sponsored studies with results posted during the past week.

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-------------------------|-------------------|--------------|--------------------|----------|----------|----------|-------------------------------|
| NCT01081041 | ELI LILLY | DRUG | 3. ONGOING | 2 | 187 | 18 YEARS | N/A | ONC ENT: NPC |
| NCT01634555 | ELI LILLY | BIOLOGICAL | 3. ONGOING | 2 | 29 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT00958191 | STRYKER | DEVICE | 3. ONGOING | NA | 250 | 21 YEARS | 75 YEARS | ORTH HIP/KNEE REPLACEMENT |
| NCT00705536 | HALOZYME | DRUG | 4. COMPLETED | 1 | 26 | 18 YEARS | 55 YEARS | ENDO DIABETES |
| NCT00862849 | HALOZYME | DRUG | 4. COMPLETED | 1 | 22 | 18 YEARS | 55 YEARS | ENDO DIABETES |
| NCT00979875 | HALOZYME | DRUG | 4. COMPLETED | 1 | 14 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT01143051 | AMPHASTAR | DRUG | 4. COMPLETED | 1 | 24 | 18 YEARS | 30 YEARS | ALLERGY ALLERGY |
| NCT01907113 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 1 | 40 | 18 YEARS | 75 YEARS | ENDO DIABETES |
| NCT00237185 | NOVARTIS | DRUG | 4. COMPLETED | 2 | 148 | 18 YEARS | N/A | ONC GI: GASTROINTESTINAL |
| NCT00605722 | HOFFMANN-LA ROCHE | DRUG | 4. COMPLETED | 2 | 51 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT00661778 | HOFFMANN-LA ROCHE | DRUG | 4. COMPLETED | 2 | 50 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT00783198 | MERCK SHARP DOHME | BIOLOGICAL | 4. COMPLETED | 2 | 565 | 18 YEARS | 50 YEARS | ALLERGY RHINITIS |
| NCT00959751 | NEURAXON | DRUG | 4. COMPLETED | 2 | 195 | 18 YEARS | 65 YEARS | NEUR MIGRAINE/ H-ACHE |
| NCT01202578 | ACCLARENT | DEVICE | 4. COMPLETED | 2 | 53 | 6 MONTHS | N/A | INFECT OTITIS |
| NCT01996332 | HOFFMANN-LA ROCHE | DRUG | 4. COMPLETED | 2 | 1,805 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT01998919 | HOFFMANN-LA ROCHE | DRUG | 4. COMPLETED | 2 | 154 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02075632 | GSK | DRUG | 4. COMPLETED | 2 | 310 | 12 YEARS | 65 YEARS | ALLERGY ECZEMA/ DERMATITIS |
| NCT02115984 | PANAGEN | DRUG | 4. COMPLETED | 2 | 80 | 18 YEARS | N/A | ONC BREAST |
| NCT00482612 | MERCK SHARP DOHME | DRUG | 4. COMPLETED | 3 | 526 | 18 YEARS | 65 YEARS | PSYCH INSOMNIA/ SLEEP |
| NCT00617123 | MERCK SHARP DOHME | DRUG | 4. COMPLETED | 3 | 258 | 18 YEARS | N/A | CARDIO PERIPH VASC |
| NCT00705939 | PROTALIX | DRUG | 4. COMPLETED | 3 | 45 | 18 YEARS | N/A | ENDO GAUCHER |
| NCT00713648 | NOVO NORDISK | DRUG | 4. COMPLETED | 3 | 41 | 6 YEARS | N/A | CARDIO THROMB/COAG |
| NCT00791934 | ACCLARENT | DEVICE | 4. COMPLETED | 3 | 63 | 17 YEARS | N/A | INFECT SINUSIT |
| NCT00876447 | ALLERGAN | BIOLOGICAL | 4. COMPLETED | 3 | 397 | 18 YEARS | N/A | UROLOGY INCONTINENCE |
| NCT01179672 | ELI LILLY | DRUG | 4. COMPLETED | 3 | 405 | 18 YEARS | N/A | OPHTHAL DIABETIC |
| NCT01244490 | SHIRE | DRUG | 4. COMPLETED | 3 | 338 | 6 YEARS | 17 YEARS | PSYCH ADHD |
| NCT01289990 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 3 | 2,705 | 18 YEARS | N/A | ENDO DIABETES |
| NCT01610791 | HOFFMANN-LA ROCHE | DRUG | 4. COMPLETED | 3 | 121 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

New Results, from Page 9

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|----------------------|-------------------|---------------|--------------------|----------|-----------|-----------|---------------------------|
| NCT01659853 | GALDERMA | DRUG | 4. COMPLETED | 3 | 70 | 18 YEARS | N/A | DERM ROSACEA |
| NCT01686646 | GSK | DRUG | 4. COMPLETED | 3 | 240 | 18 YEARS | N/A | INFECT INFLUENZA/FLU |
| NCT01702454 | GSK | BIOLOGICAL | 4. COMPLETED | 3 | 470 | 17 MONTHS | 48 MONTHS | INFECT INFLUENZA/FLU |
| NCT01747330 | ABBOTT | DRUG | 4. COMPLETED | 3 | 40 | N/A | 4 YEARS | GI PANCREAS INSUFFICIENCY |
| NCT00424502 | HOFFMANN-LA ROCHE | DRUG | 4. COMPLETED | 4 | 20 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT00545402 | HOFFMANN-LA ROCHE | DRUG | 4. COMPLETED | 4 | 180 | 18 YEARS | N/A | GI LIVER TRANSPLANT |
| NCT01650519 | CUMBERLAND | DRUG | 4. COMPLETED | 4 | 51 | 18 YEARS | N/A | ORTH JOINT DISEASE |
| NCT01650779 | GENZYME | BIOLOGICAL | 4. COMPLETED | 4 | 15 | N/A | N/A | ENDO FABRY |
| NCT01893567 | GALDERMA | DRUG | 4. COMPLETED | 4 | 28 | 18 YEARS | N/A | DERM PSORIASIS |
| NCT00635492 | ASTRAZENECA | DRUG | 4. COMPLETED | NA | 2,515 | 18 YEARS | N/A | ENDO DIABETES |
| NCT00838097 | AMGEN | | 4. COMPLETED | NA | 321 | N/A | 16 YEARS | UROLOGY KIDNEY FAILURE |
| NCT01073462 | ABBVIE | | 4. COMPLETED | NA | 67 | 18 YEARS | N/A | ENDO HYPERPARATHYROIDISM |
| NCT01128426 | PFIZER | OTHER | 4. COMPLETED | NA | 53,902 | 2 MONTHS | 3 YEARS | INFECT PNEUMOCOCCAL |
| NCT01561469 | PFIZER | DRUG | 4. COMPLETED | NA | 188 | 18 YEARS | N/A | INFECT STAPHYLOCOCCUS |
| NCT01736657 | TERUMO | DEVICE | 4. COMPLETED | NA | 73 | 12 YEARS | N/A | HEM ANEMIA SICKLE CELL |
| NCT01505881 | BOEHRINGER INGELHEIM | DRUG | 7. TERMINATED | 2 | 158 | 18 YEARS | 75 YEARS | CARDIO THROMB/COAG |

NEW STUDY STATUS

This table lists studies that reported updates in their status in the past week such as recruiting, ongoing or completed.

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|----------------------|-------------------|---------------|--------------------|----------|----------|-----------|--------------------------|
| NCT01290029 | AMGEN | DRUG | 2. RECRUITING | 1 | 12 | N/A | 2190 DAYS | UROLOGY KIDNEY FAILURE |
| NCT01684215 | PFIZER | DRUG | 2. RECRUITING | 1 | 58 | 20 YEARS | N/A | ONC SOLID TUMOR/CANCER |
| NCT02096718 | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 1 | 32 | 18 YEARS | 79 YEARS | UROLOGY KIDNEY FAILURE |
| NCT02103478 | ASTEX | DRUG | 2. RECRUITING | 1 | 150 | 18 YEARS | N/A | ONC HEM: MYELODYSPLASTIC |
| NCT02121834 | ELI LILLY | DRUG | 2. RECRUITING | 1 | 120 | 30 YEARS | 80 YEARS | HEALTHY/PHARM |
| NCT02123823 | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 1 | 198 | 18 YEARS | N/A | ONC SOLID TUMOR/CANCER |
| NCT02129205 | PFIZER | DRUG | 2. RECRUITING | 1 | 55 | 18 YEARS | N/A | ONC SOLID TUMOR/CANCER |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

New Study Status, from Page 10

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-------------------------|-------------------|---------------|--------------------|----------|----------|----------|---------------------------------|
| NCT02134964 | OLATEC | DRUG | 2. RECRUITING | 1 | 36 | 18 YEARS | 60 YEARS | HEALTHY/PHARM |
| NCT02141659 | TAKEDA | DRUG | 2. RECRUITING | 1 | 30 | 20 YEARS | N/A | ONC UROLOGY: PROSTATE |
| NCT02144285 | ELI LILLY | DRUG | 2. RECRUITING | 1 | 82 | 18 YEARS | N/A | UROLOGY KIDNEY FAILURE |
| NCT02148627 | ELI LILLY | DRUG | 2. RECRUITING | 1 | 58 | 18 YEARS | 65 YEARS | HEALTHY/PHARM |
| NCT02154334 | JANSSEN | DRUG | 2. RECRUITING | 1 | 48 | 18 YEARS | 55 YEARS | ALLERGY RHINITIS |
| NCT02154425 | UCB | PROCEDURE | 2. RECRUITING | 1 | 16 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02156492 | ELI LILLY | DRUG | 2. RECRUITING | 1 | 66 | 18 YEARS | 65 YEARS | HEALTHY/PHARM |
| NCT02159313 | BAYER | DRUG | 2. RECRUITING | 1 | 24 | 18 YEARS | 45 YEARS | HEALTHY/PHARM |
| NCT02161432 | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 1 | 18 | 18 YEARS | 50 YEARS | HEALTHY/PHARM |
| NCT02163161 | PFIZER | DRUG | 2. RECRUITING | 1 | 12 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02163421 | TAKEDA | DRUG | 2. RECRUITING | 1 | 48 | 18 YEARS | 60 YEARS | HEALTHY/PHARM |
| NCT02164266 | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 56 | 18 YEARS | 65 YEARS | HEALTHY/PHARM |
| NCT02164812 | BMS | DRUG | 2. RECRUITING | 1 | 60 | 18 YEARS | 49 YEARS | INFECT HIV/AIDS |
| NCT02168777 | BAYER | DRUG | 2. RECRUITING | 1 | 180 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT02176668 | YUHAN | DRUG | 2. RECRUITING | 1 | 50 | 19 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT01437566 | GENENTECH | DRUG | 2. RECRUITING | 2 | 270 | 18 YEARS | N/A | ONC BREAST |
| NCT01623206 | ELEA | DRUG | 2. RECRUITING | 2 | 30 | 18 YEARS | 80 YEARS | ONC GI: COLORECTAL |
| NCT02040623 | RIGEL | DRUG | 2. RECRUITING | 2 | 60 | 18 YEARS | 85 YEARS | IMMUNE GRAFT VS. HOST |
| NCT02042170 | LG LIFE | DRUG | 2. RECRUITING | 2 | 45 | 4 YEARS | 14 YEARS | ENDO GROWTH DISORDER |
| NCT02055482 | BAYER | DRUG | 2. RECRUITING | 2 | 100 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02074579 | TSUMURA | DRUG | 2. RECRUITING | 2 | 90 | 18 YEARS | 65 YEARS | GI IRRITABLE BOWEL |
| NCT02093221 | GRIFOLS | BIOLOGICAL | 2. RECRUITING | 2 | 75 | 6 YEARS | 35 YEARS | ENDO DIABETES |
| NCT02103062 | CELGENE | DRUG | 2. RECRUITING | 2 | 86 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT02111044 | ITALFARMACO | DRUG | 2. RECRUITING | 2 | 40 | 18 YEARS | 80 YEARS | ENDO ACROMEGALY |
| NCT02125877 | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT02126995 | ALCOBRA | DRUG | 2. RECRUITING | 2 | 60 | 15 YEARS | 55 YEARS | ENDO FRAGILE X |
| NCT02147587 | PFIZER | DRUG | 2. RECRUITING | 2 | 140 | 50 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02174861 | AMGEN | DRUG | 2. RECRUITING | 2 | 490 | 18 YEARS | 60 YEARS | NEUR MIGRAINE/ H-ACHE |
| NCT02034006 | NOVARTIS | DRUG | 2. RECRUITING | 3 | 150 | 18 YEARS | N/A | OPHTHAL MACULAR DEGENERATION |
| NCT02059291 | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02074982 | NOVARTIS | DRUG | 2. RECRUITING | 3 | 640 | 18 YEARS | N/A | DERM PSORIASIS |
| NCT02112656 | CELSION | DRUG | 2. RECRUITING | 3 | 550 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT02132936 | LEO | DRUG | 2. RECRUITING | 3 | 460 | 18 YEARS | N/A | DERM PSORIASIS |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See New Study Status, Page 12)

New Study Status, from Page 11

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|-------------------------------|
| NCT02138916 | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |
| NCT02144012 | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 3 | 561 | 18 YEARS | N/A | ONC BREAST |
| NCT02145000 | EPICENTRE | BIOLOGICAL | 2. RECRUITING | 3 | 7,770 | 6 WEEKS | 2 YEARS | INFECT ROTAVIRUS |
| NCT02149199 | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02151851 | UCB | BIOLOGICAL | 2. RECRUITING | 3 | 400 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02155660 | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,850 | N/A | N/A | RESP COPD |
| NCT02155790 | ABLATIVE | DEVICE | 2. RECRUITING | 3 | 20 | 18 YEARS | 75 YEARS | CARDIO HYPERTENSION |
| NCT02157935 | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 1,700 | 40 YEARS | 95 YEARS | RESP COPD |
| NCT02165397 | PHARMACYCLICS | DRUG | 2. RECRUITING | 3 | 180 | 18 YEARS | N/A | HEM WALDENSTROM |
| NCT02174627 | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 5,200 | 18 YEARS | N/A | UROLOGY KIDNEY FAILURE |
| NCT02174731 | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 2,850 | 18 YEARS | N/A | UROLOGY KIDNEY FAILURE |
| NCT02049814 | TAKEDA | DRUG | 2. RECRUITING | 4 | 380 | 18 YEARS | 75 YEARS | ENDO DIABETES |
| NCT02062463 | TEVA | DRUG | 2. RECRUITING | 4 | 500 | 18 YEARS | 75 YEARS | ALLERGY ALLERGY |
| NCT02147561 | ALLERGAN | BIOLOGICAL | 2. RECRUITING | 4 | 200 | 18 YEARS | N/A | NEUR MIGRAINE/ H-ACHE |
| NCT01381172 | IMPULSE | DEVICE | 2. RECRUITING | NA | 230 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT01928979 | BAYER | OTHER | 2. RECRUITING | NA | 150 | 18 YEARS | N/A | CARDIO ARRHYT/ FIBRILL |
| NCT02015273 | MERCK SERONO | DEVICE | 2. RECRUITING | NA | 100 | 2 YEARS | 18 YEARS | ENDO GROWTH DISORDER |
| NCT02094482 | MEDARTIS | DEVICE | 2. RECRUITING | NA | 55 | 18 YEARS | N/A | RESP SLEEP APNEA |
| NCT02099942 | INTERVALVE | DEVICE | 2. RECRUITING | NA | 100 | N/A | N/A | CARDIO VALVE |
| NCT02115269 | ABBOTT | | 2. RECRUITING | NA | 750 | 18 YEARS | N/A | NEUR MIGRAINE/ H-ACHE |
| NCT02115412 | PHILIPS | | 2. RECRUITING | NA | 750 | 18 YEARS | 89 YEARS | ENDO DIABETES |
| NCT02120794 | MEDTRONIC | DEVICE | 2. RECRUITING | NA | 300 | 2 YEARS | 15 YEARS | ENDO DIABETES |
| NCT02122588 | ASTRAZENECA | | 2. RECRUITING | NA | 300 | N/A | N/A | ONC O&G: OVARY |
| NCT02133417 | CVUS | DEVICE | 2. RECRUITING | NA | 300 | 25 YEARS | N/A | NEUR HEMORRHAGE |
| NCT02143739 | ASTRAZENECA | | 2. RECRUITING | NA | 5,000 | 18 YEARS | N/A | ALLERGY ALLERGY |
| NCT02168764 | AUTONOMIC | DEVICE | 2. RECRUITING | NA | 120 | 22 YEARS | N/A | NEUR MIGRAINE/ H-ACHE |
| NCT02178462 | AJINOMOTO | | 2. RECRUITING | NA | 160 | 20 YEARS | N/A | ONC O&G: OVARY |
| NCT02181686 | BIOTRONIK | | 2. RECRUITING | NA | 135 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT00574288 | GENMAB | DRUG | 3. ONGOING | 1 | 112 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT01271972 | REGENERON | DRUG | 3. ONGOING | 1 | 72 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT01295827 | MERCK SHARP DOHME | DRUG | 3. ONGOING | 1 | 1,137 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See New Study Status, Page 13)

New Study Status, from Page 12

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|----------------------|-------------------|------------|--------------------|----------|----------|----------|----------------------------|
| NCT01386216 | ARTERIOCYTE +C461 | DEVICE | 3. ONGOING | 1 | 20 | 18 YEARS | 85 YEARS | ORTH BACK PAIN |
| NCT01556438 | ELI LILLY | BIOLOGICAL | 3. ONGOING | 1 | 10 | 20 YEARS | N/A | ONC HEM: MYELOMA |
| NCT01672775 | AGENSYS | DRUG | 3. ONGOING | 1 | 34 | 18 YEARS | N/A | ONC UROLOGY: KIDNEY |
| NCT01688960 | REGENERON | DRUG | 3. ONGOING | 1 | 74 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT01801930 | OTSUKA | DRUG | 3. ONGOING | 1 | 18 | 20 YEARS | N/A | ONC GI: COLORECTAL |
| NCT02059148 | ELI LILLY | DRUG | 3. ONGOING | 1 | 25 | 18 YEARS | 65 YEARS | HEALTHY/PHARM |
| NCT02070796 | UCB | DRUG | 3. ONGOING | 1 | 50 | 18 YEARS | 40 YEARS | HEALTHY/PHARM |
| NCT02095691 | BIOSENSE | PROCEDURE | 3. ONGOING | 1 | 19 | 18 YEARS | 85 YEARS | UROLOGY KIDNEY DISEASE |
| NCT02101216 | CELLCEUTIX | DRUG | 3. ONGOING | 1 | 18 | 18 YEARS | 65 YEARS | DERM PSORIASIS |
| NCT02109679 | BOEHRINGER INGELHEIM | DRUG | 3. ONGOING | 1 | 16 | 18 YEARS | 50 YEARS | HEALTHY/PHARM |
| NCT02133339 | THERON | DRUG | 3. ONGOING | 1 | 40 | 18 YEARS | 65 YEARS | RESP COPD |
| NCT02152969 | YUHAN | DRUG | 3. ONGOING | 1 | 60 | 20 YEARS | 45 YEARS | CARDIO HYPERTENSION |
| NCT01442090 | GENENTECH | DRUG | 3. ONGOING | 2 | 85 | 18 YEARS | N/A | ONC UROLOGY: KIDNEY |
| NCT01514864 | BMS | DRUG | 3. ONGOING | 2 | 73 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT01563055 | GSK | DRUG | 3. ONGOING | 2 | 10 | 20 YEARS | N/A | ONC HEM: LEUKEMIA |
| NCT01620255 | PFIZER | DRUG | 3. ONGOING | 2 | 300 | 18 YEARS | 65 YEARS | GI ULCERATIVE COLITIS |
| NCT01703533 | NEUREN | DRUG | 3. ONGOING | 2 | 60 | 16 YEARS | 45 YEARS | ENDO RETTS |
| NCT01749956 | SCRI | RADIATION | 3. ONGOING | 2 | 39 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT01903993 | HOFFMANN-LA ROCHE | DRUG | 3. ONGOING | 2 | 287 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT01938599 | AMDERMA | DRUG | 3. ONGOING | 2 | 92 | 18 YEARS | N/A | DERM PSORIASIS |
| NCT01952574 | AMGEN | DRUG | 3. ONGOING | 2 | 483 | 18 YEARS | 60 YEARS | NEUR MIGRAINE/ H-ACHE |
| NCT01987817 | ALLERGEN | BIOLOGICAL | 3. ONGOING | 2 | 55 | 4 YEARS | 26 YEARS | ALLERGY ECZEMA/ DERMATITIS |
| NCT02044081 | C3 JIAN | DRUG | 3. ONGOING | 2 | 60 | 18 YEARS | 75 YEARS | DENTAL CARIES |
| NCT02059642 | ALCOBRA | DRUG | 3. ONGOING | 2 | 300 | 18 YEARS | 55 YEARS | PSYCH ADHD |
| NCT02079649 | ALCON | DRUG | 3. ONGOING | 2 | 160 | 18 YEARS | N/A | ALLERGY CONJUNCTIVITIS |
| NCT02109406 | PEARL | DRUG | 3. ONGOING | 2 | 30 | 40 YEARS | 80 YEARS | RESP COPD |
| NCT01200758 | HOFFMANN-LA ROCHE | DRUG | 3. ONGOING | 3 | 410 | 18 YEARS | N/A | ONC HEM: LYMPHOMA |
| NCT01358877 | HOFFMANN-LA ROCHE | DRUG | 3. ONGOING | 3 | 4,808 | 18 YEARS | N/A | ONC BREAST |
| NCT01404169 | EISAI | DRUG | 3. ONGOING | 3 | 260 | 50 YEARS | 90 YEARS | NEUR ALZHEIMER/ DEMENT |
| NCT01444092 | ASTRAZENECA | DRUG | 3. ONGOING | 3 | 123 | 5 YEARS | 17 YEARS | GI CROHN |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

New Study Status, from Page 13

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|----------------------|-------------------|------------|--------------------|----------|----------|----------|----------------------------|
| NCT01514240 | ASTRAZENECA | DRUG | 3. ONGOING | 3 | 123 | 18 YEARS | N/A | GI CROHN |
| NCT01539031 | EISAI | DRUG | 3. ONGOING | 3 | 330 | 50 YEARS | N/A | NEUR ALZHEIMER/ DEMENT |
| NCT01618695 | EISAI | DRUG | 3. ONGOING | 3 | 680 | 12 YEARS | N/A | NEUR EPILEPSY/ SEIZURE |
| NCT01641042 | GSK | BIOLOGICAL | 3. ONGOING | 3 | 100 | 1 YEAR | 17 YEARS | INFECT MENINGOCOCCAL |
| NCT01694836 | LETI | BIOLOGICAL | 3. ONGOING | 3 | 634 | 12 YEARS | 70 YEARS | ALLERGY ASTHMA |
| NCT01719003 | BOEHRINGER INGELHEIM | DRUG | 3. ONGOING | 3 | 1,397 | 18 YEARS | N/A | ENDO DIABETES |
| NCT01753570 | MITSUBISHI | DRUG | 3. ONGOING | 3 | 70 | 20 YEARS | 70 YEARS | INFECT HEPATITIS C |
| NCT01755546 | ENDO | DRUG | 3. ONGOING | 3 | 200 | 18 YEARS | N/A | ORTH BACK PAIN |
| NCT01816295 | ELI LILLY | DRUG | 3. ONGOING | 3 | 618 | 18 YEARS | N/A | ENDO MALE HYPOGONADISM |
| NCT01821677 | AMPIO | DRUG | 3. ONGOING | 3 | 355 | 18 YEARS | N/A | OPHTHAL DIABETIC |
| NCT02123654 | BMS | DRUG | 3. ONGOING | 3 | 286 | 20 YEARS | N/A | INFECT HEPATITIS C |
| NCT00805948 | MEDTRONIC | DEVICE | 3. ONGOING | 4 | 256 | 18 YEARS | N/A | CARDIO ANEURYSM |
| NCT01000324 | GSK | PROCEDURE | 3. ONGOING | 4 | 40 | N/A | N/A | INFECT HEPATITIS A |
| NCT01072539 | PFIZER | DRUG | 3. ONGOING | 4 | 742 | 18 YEARS | N/A | INFECT SKIN/SOFT TISSUE |
| NCT01519947 | HOFFMANN-LA ROCHE | DRUG | 3. ONGOING | 4 | 86 | 18 YEARS | N/A | HEM ANEMIA |
| NCT01709110 | ELI LILLY | DRUG | 3. ONGOING | 4 | 1,340 | 45 YEARS | N/A | ENDO OSTEOPOROSIS |
| NCT01756079 | MERCK SHARP DOHME | DRUG | 3. ONGOING | 4 | 80 | 18 YEARS | 75 YEARS | INFECT HEPATITIS C |
| NCT01869881 | YUHAN | DRUG | 3. ONGOING | 4 | 166 | 20 YEARS | N/A | UROLOGY KIDNEY NEPHRITIS |
| NCT00854295 | ZIMMER | DEVICE | 3. ONGOING | NA | 400 | N/A | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01121107 | ST JUDE | DEVICE | 3. ONGOING | NA | 730 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT01263457 | MERCK SERONO | DEVICE | 3. ONGOING | NA | 201 | 2 YEARS | 18 YEARS | ENDO GROWTH DISORDER |
| NCT01267526 | MERCK SERONO | DEVICE | 3. ONGOING | NA | 205 | 2 YEARS | 18 YEARS | ENDO GROWTH DISORDER |
| NCT01447446 | HOFFMANN-LA ROCHE | | 3. ONGOING | NA | 4,449 | 18 YEARS | N/A | INFECT HEPATITIS C |
| NCT01552395 | FERRING | | 3. ONGOING | NA | 4,100 | 18 YEARS | N/A | UROLOGY NOCTURIA |
| NCT01696695 | HOFFMANN-LA ROCHE | | 3. ONGOING | NA | 893 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT01777945 | HOFFMANN-LA ROCHE | | 3. ONGOING | NA | 47 | 18 YEARS | N/A | ONC BREAST |
| NCT01875354 | PHARMANEX | DIETARY SUP. | 3. ONGOING | NA | 140 | 18 YEARS | 65 YEARS | ENDO OBESITY |
| NCT01954004 | MYRIAD | | 3. ONGOING | NA | 1,100 | 18 YEARS | N/A | ONC UROLOGY: PROSTATE |
| NCT02009696 | BIOTRONIK | DEVICE | 3. ONGOING | NA | 245 | 18 YEARS | N/A | RADIOLOGY/IMAGING |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See New Study Status, Page 15)

New Study Status, from Page 14

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|----------------------|-------------------|--------------|--------------------|----------|----------|----------|--------------------------|
| NCT02176421 | ALLERGAN | DEVICE | 3. ONGOING | NA | 80 | 18 YEARS | N/A | DERM LIP ENHANCEMENT |
| NCT02025348 | ASTRAZENECA | DRUG | 4. COMPLETED | 0 | 20 | 18 YEARS | 50 YEARS | HEALTHY/PHARM |
| NCT00621725 | ASTRAZENECA | DRUG | 4. COMPLETED | 1 | 36 | 18 YEARS | N/A | ONC SOLID TUMOR/CANCER |
| NCT00960115 | MERCK SERONO | BIOLOGICAL | 4. COMPLETED | 1 | 205 | 20 YEARS | N/A | ONC RESP: LUNG |
| NCT01290042 | AMGEN | DRUG | 4. COMPLETED | 1 | 43 | 18 YEARS | 65 YEARS | GI ULCERATIVE COLITIS |
| NCT01348958 | GE HEALTHCARE | DEVICE | 4. COMPLETED | 1 | 36 | 30 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT01369589 | PARION | DRUG | 4. COMPLETED | 1 | 24 | 18 YEARS | N/A | ENT DRY MOUTH |
| NCT01390818 | EMD SERONO | DRUG | 4. COMPLETED | 1 | 259 | 18 YEARS | N/A | ONC SOLID TUMOR/CANCER |
| NCT01423058 | GILEAD | DRUG | 4. COMPLETED | 1 | 61 | 18 YEARS | N/A | HEM MYELOFIBROSIS |
| NCT01432353 | GENENTECH | DRUG | 4. COMPLETED | 1 | 39 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT01646567 | TETRALOGIC | DRUG | 4. COMPLETED | 1 | 14 | 18 YEARS | 70 YEARS | DERM PSORIASIS |
| NCT01780246 | ISIS | DRUG | 4. COMPLETED | 1 | 18 | 2 YEARS | 15 YEARS | ORTH MUSCULAR DISEASE |
| NCT01835496 | APOPHARMA | DRUG | 4. COMPLETED | 1 | 8 | 18 YEARS | 45 YEARS | HEM ANEMIA SICKLE CELL |
| NCT01971164 | AKROS | DRUG | 4. COMPLETED | 1 | 29 | 18 YEARS | 75 YEARS | HEM ANEMIA |
| NCT01981928 | ASTELLAS | DRUG | 4. COMPLETED | 1 | 48 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT01995656 | ELI LILLY | DRUG | 4. COMPLETED | 1 | 44 | 21 YEARS | 65 YEARS | ENDO DIABETES |
| NCT02004587 | LG LIFE | DRUG | 4. COMPLETED | 1 | 28 | 18 YEARS | 75 YEARS | GI LIVER FAILURE |
| NCT02030457 | TEVA | DRUG | 4. COMPLETED | 1 | 72 | 18 YEARS | 45 YEARS | HEALTHY/PHARM |
| NCT02039258 | JANSSEN | DRUG | 4. COMPLETED | 1 | 24 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02055287 | LUYE | DRUG | 4. COMPLETED | 1 | 32 | 18 YEARS | 65 YEARS | PSYCH SCHIZOPHRENIA |
| NCT02084875 | PFIZER | DRUG | 4. COMPLETED | 1 | 24 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02093819 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 1 | 60 | 18 YEARS | 50 YEARS | HEALTHY/PHARM |
| NCT02095860 | BMS | DRUG | 4. COMPLETED | 1 | 24 | 18 YEARS | 49 YEARS | INFECT HEPATITIS C |
| NCT02097043 | DONG-A | DRUG | 4. COMPLETED | 1 | 31 | 19 YEARS | 45 YEARS | HEALTHY/PHARM |
| NCT02106247 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 1 | 36 | 18 YEARS | 50 YEARS | HEALTHY/PHARM |
| NCT02106923 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 1 | 72 | 18 YEARS | 50 YEARS | HEALTHY/PHARM |
| NCT02108639 | BMS | DRUG | 4. COMPLETED | 1 | 41 | 18 YEARS | N/A | INFECT HEPATITIS C |
| NCT02110342 | PFIZER | DRUG | 4. COMPLETED | 1 | 6 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02127034 | ASTELLAS | DRUG | 4. COMPLETED | 1 | 26 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT00044343 | GSK | DRUG | 4. COMPLETED | 2 | 80 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT00077025 | ASTRAZENECA | DRUG | 4. COMPLETED | 2 | 174 | 18 YEARS | N/A | ONC BREAST |
| NCT00237185 | NOVARTIS | DRUG | 4. COMPLETED | 2 | 148 | 18 YEARS | N/A | ONC GI: GASTROINTESTINAL |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

New Study Status, from Page 15

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|----------------------|-------------------|--------------|--------------------|----------|----------|----------|----------------------------|
| NCT00263328 | PFIZER | DRUG | 4. COMPLETED | 2 | 43 | 18 YEARS | 70 YEARS | UROLOGY KIDNEY TRANSPLANT |
| NCT00393822 | AMGEN | DRUG | 4. COMPLETED | 2 | 100 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT00853047 | LEXICON | DRUG | 4. COMPLETED | 2 | 23 | 18 YEARS | N/A | ONC ENDO: NEUROENDO |
| NCT01077713 | HOFFMANN-LA ROCHE | DRUG | 4. COMPLETED | 2 | 86 | 70 YEARS | N/A | ONC RESP: LUNG |
| NCT01081119 | RAND | BEHAVIORAL | 4. COMPLETED | 2 | 6,455 | 11 YEARS | 15 YEARS | PSYCH ABUSE ALCOHOL |
| NCT01202578 | ACCLARENT | DEVICE | 4. COMPLETED | 2 | 53 | 6 MONTHS | N/A | INFECT OTITIS |
| NCT01236638 | GILEAD | DRUG | 4. COMPLETED | 2 | 120 | 18 YEARS | N/A | HEM MYELOFIBROSIS |
| NCT01240447 | ELEA | BIOLOGICAL | 4. COMPLETED | 2 | 7 | 21 YEARS | N/A | ONC RESP: LUNG |
| NCT01242813 | NOVARTIS | DRUG | 4. COMPLETED | 2 | 21 | 4 YEARS | N/A | RHEUM AUTOIMMUNE |
| NCT01253629 | NOVARTIS | DRUG | 4. COMPLETED | 2 | 175 | 18 YEARS | 45 YEARS | ENDO FRAGILE X |
| NCT01398410 | EISAI | DRUG | 4. COMPLETED | 2 | 328 | 20 YEARS | N/A | GI GASTRIC ULCER/ BLEEDING |
| NCT01424124 | YUHAN | DRUG | 4. COMPLETED | 2 | 56 | 20 YEARS | N/A | ALLERGY ALLERGY |
| NCT01538849 | YUHAN | DRUG | 4. COMPLETED | 2 | 154 | 20 YEARS | N/A | GI ESOPHAGITIS/ REFLUX |
| NCT01662908 | DAIICHI SANKYO | DRUG | 4. COMPLETED | 2 | 90 | 18 YEARS | N/A | CARDIO THROMB/ COAG |
| NCT01681212 | BMS | BIOLOGICAL | 4. COMPLETED | 2 | 15 | 20 YEARS | N/A | ONC DERM: MELANOMA |
| NCT01684202 | OTSUKA | DRUG | 4. COMPLETED | 2 | 43 | 20 YEARS | 80 YEARS | CARDIO EDEMA |
| NCT01726946 | VERTEX | DRUG | 4. COMPLETED | 2 | 10 | 18 YEARS | 60 YEARS | INFECT HEPATITIS C |
| NCT01750437 | YUHAN | DRUG | 4. COMPLETED | 2 | 149 | 20 YEARS | N/A | GI ESOPHAGITIS/ REFLUX |
| NCT01815450 | BRAINTREE | DRUG | 4. COMPLETED | 2 | 300 | 12 YEARS | 45 YEARS | DERM ACNE |
| NCT01818544 | BAYER | DRUG | 4. COMPLETED | 2 | 92 | 18 YEARS | N/A | RESP COPD |
| NCT01849562 | ACHILLION | DRUG | 4. COMPLETED | 2 | 30 | 18 YEARS | 65 YEARS | INFECT HEPATITIS C |
| NCT01900249 | RIGEL | DRUG | 4. COMPLETED | 2 | 206 | 18 YEARS | 85 YEARS | OPHTHAL DRY EYE |
| NCT01998984 | LEO | DRUG | 4. COMPLETED | 2 | 223 | 18 YEARS | N/A | DERM KERATOSIS |
| NCT02082899 | ELEVEN | DRUG | 4. COMPLETED | 2 | 150 | 18 YEARS | N/A | ALLERGY CONJUNCTIVITIS |
| NCT00725114 | WEX | BIOLOGICAL | 4. COMPLETED | 3 | 165 | 18 YEARS | N/A | ANEST PAIN |
| NCT01229007 | CSL BEHRING | BIOLOGICAL | 4. COMPLETED | 3 | 35 | N/A | 12 YEARS | HEM HAEMOPHILIA A/B |
| NCT01270997 | HANWHA | BIOLOGICAL | 4. COMPLETED | 3 | 294 | 20 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01330316 | BOEHRINGER INGELHEIM | DRUG | 4. COMPLETED | 3 | 119 | 18 YEARS | 70 YEARS | INFECT HEPATITIS C |
| NCT01360489 | XENOPORT | DRUG | 4. COMPLETED | 3 | 218 | 18 YEARS | 70 YEARS | NEUR MULTIPLE SCLEROSIS |
| NCT01396083 | NOVARTIS | DRUG | 4. COMPLETED | 3 | 243 | 18 YEARS | N/A | OPHTHAL BLINDNESS |
| NCT01400828 | YUHAN | DRUG | 4. COMPLETED | 3 | 239 | 12 YEARS | 70 YEARS | ALLERGY RHINITIS |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

New Study Status, from Page 16

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-------------------|-------------------|--------------|--------------------|----------|----------|----------|----------------------------|
| NCT01499849 | TESARO | DRUG | 4. COMPLETED | 3 | 532 | 18 YEARS | N/A | ONC CHEMOTHER EFFECTS |
| NCT01510769 | ARDEA | DRUG | 4. COMPLETED | 3 | 330 | 18 YEARS | 85 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT01513941 | JANSSEN | DRUG | 4. COMPLETED | 3 | 163 | 18 YEARS | 70 YEARS | INFECT HEPATITIS C |
| NCT01521559 | REGENERON | DRUG | 4. COMPLETED | 3 | 183 | 18 YEARS | N/A | OPHTHAL RETINA VEIN |
| NCT01547715 | NOVARTIS | BIOLOGICAL | 4. COMPLETED | 3 | 180 | 2 YEARS | 75 YEARS | INFECT MENINGITIS |
| NCT01558271 | ELI LILLY | DRUG | 4. COMPLETED | 3 | 490 | 20 YEARS | N/A | ENDO DIABETES |
| NCT01662063 | GENENTECH | DRUG | 4. COMPLETED | 3 | 218 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01675167 | ENDO | DRUG | 4. COMPLETED | 3 | 511 | 18 YEARS | N/A | ORTH BACK PAIN |
| NCT01807923 | VERTEX | DRUG | 4. COMPLETED | 3 | 559 | 12 YEARS | 65 YEARS | RESP CYSTIC FIBROSIS |
| NCT01807949 | VERTEX | DRUG | 4. COMPLETED | 3 | 563 | 12 YEARS | 65 YEARS | RESP CYSTIC FIBROSIS |
| NCT01811732 | MELINTA | DRUG | 4. COMPLETED | 3 | 660 | 18 YEARS | N/A | INFECT SKIN/SOFT TISSUE |
| NCT01830140 | ALLERGAN | DRUG | 4. COMPLETED | 3 | 466 | 18 YEARS | N/A | OPHTHAL GLAUCOMA |
| NCT01917357 | CRUCCELL | BIOLOGICAL | 4. COMPLETED | 3 | 400 | 42 DAYS | 64 DAYS | INFECT DIPHTHERIA |
| NCT02125253 | AMNEAL | DRUG | 4. COMPLETED | 3 | 811 | 12 YEARS | N/A | ALLERGY RHINITIS |
| NCT00403520 | EISAI | DRUG | 4. COMPLETED | 4 | 240 | 50 YEARS | N/A | NEUR ALZHEIMER/ DEMENT |
| NCT01149057 | HOFFMANN-LA ROCHE | DRUG | 4. COMPLETED | 4 | 145 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01435317 | ANM ADAPTIVE | DEVICE | 4. COMPLETED | 4 | 200 | 18 YEARS | N/A | ENT TINNITUS |
| NCT01439009 | OTSUKA | DRUG | 4. COMPLETED | 4 | 105 | 20 YEARS | 85 YEARS | CARDIO CARDIOMYOP/ FAILURE |
| NCT01467492 | VERTEX | DRUG | 4. COMPLETED | 4 | 121 | 18 YEARS | 70 YEARS | INFECT HEPATITIS C |
| NCT01485172 | GSK | DRUG | 4. COMPLETED | 4 | 186 | 30 YEARS | N/A | NEUR PARKINSON |
| NCT01508325 | MERCK SERONO | DRUG | 4. COMPLETED | 4 | 187 | 18 YEARS | 70 YEARS | CARDIO HYPERTENSION |
| NCT01603082 | ASTRAZENECA | DRUG | 4. COMPLETED | 4 | 343 | 18 YEARS | N/A | CARDIO CORONARY/ ISCHEMIC |
| NCT01630057 | EISAI | DRUG | 4. COMPLETED | 4 | 200 | 18 YEARS | 75 YEARS | NEUR EPILEPSY/ SEIZURE |
| NCT01926015 | MERCK SHARP DOHME | BIOLOGICAL | 4. COMPLETED | 4 | 190 | 42 DAYS | 76 DAYS | INFECT ROTAVIRUS |
| NCT02046031 | JIANGSU KANION | DRUG | 4. COMPLETED | 4 | 4 | 18 YEARS | 40 YEARS | CARDIO STROKE |
| NCT00635492 | ASTRAZENECA | DRUG | 4. COMPLETED | NA | 2,515 | 18 YEARS | N/A | ENDO DIABETES |
| NCT01019057 | NUVASIVE | PROCEDURE | 4. COMPLETED | NA | 77 | 40 YEARS | N/A | ORTH DISC DEGENERATIVE |
| NCT01065792 | MERCK SHARP DOHME | | 4. COMPLETED | NA | 728 | 3 YEARS | N/A | INFECT HIV/AIDS |
| NCT01128075 | MERCK SERONO | DEVICE | 4. COMPLETED | NA | 198 | 18 YEARS | 65 YEARS | NEUR MULTIPLE SCLEROSIS |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

New Study Status, from Page 17

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-------------|-------------------|--------------|--------------------|----------|----------|-----------|----------------------------|
| NCT01373957 | ASTRAZENECA | | 4. COMPLETED | NA | 600 | 18 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |
| NCT01455402 | MEDIMMUNE | | 4. COMPLETED | NA | 476 | 50 YEARS | N/A | INFECT RESP SYNCYTIAL |
| NCT01511458 | ARIOSA | | 4. COMPLETED | NA | 18,955 | 18 YEARS | 60 YEARS | ENDO DOWN |
| NCT01640236 | CHROMOLOGIC | | 4. COMPLETED | NA | 10 | 18 YEARS | N/A | OPHTHAL EYE DISEASE |
| NCT01694758 | ASTRAZENECA | | 4. COMPLETED | NA | 733 | 18 YEARS | N/A | ENDO DIABETES |
| NCT01714245 | TOPMD | | 4. COMPLETED | NA | 50 | 6 MONTHS | 18 YEARS | ALLERGY ECZEMA/DERMATITIS |
| NCT01732900 | GEMA | OTHER | 4. COMPLETED | NA | 133 | 21 YEARS | 39 YEARS | O&G INFERTILITY |
| NCT01832584 | FRUITURA | DIETARY SUP. | 4. COMPLETED | NA | 45 | 18 YEARS | 65 YEARS | HEALTHY/PHARM |
| NCT01880970 | NESTLE | OTHER | 4. COMPLETED | NA | 477 | N/A | 12 MONTHS | INFECT ENTERITIS |
| NCT01932944 | ABBOTT | DEVICE | 4. COMPLETED | NA | 30 | 18 YEARS | N/A | ENDO DIABETES |
| NCT02010931 | AMGEN | | 4. COMPLETED | NA | 310 | 15 YEARS | N/A | ONC HEM: LEUKEMIA |
| NCT02031783 | NESTLE | DIETARY SUP. | 4. COMPLETED | NA | 74 | 18 YEARS | 60 YEARS | HEALTHY/PHARM |
| NCT02099708 | TAKEDA | DRUG | 4. COMPLETED | NA | 3,502 | N/A | N/A | GI GASTRIC ULCER/ BLEEDING |

STUDIES OPENING A FIRST SITE IN A NEW COUNTRY

This table lists studies that launched a site in a country for the first time in the past week.

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-----------|--------------|-------------------|---------------|--------------------|----------|----------|----------|--------------------------|
| NCT02091752 | ARGENTINA | NOVARTIS | DRUG | 1. PLANNING | 2 | 100 | 18 YEARS | N/A | HEM MYELOFIBROSIS |
| NCT01872260 | ARGENTINA | NOVARTIS | DRUG | 2. RECRUITING | 1 | 300 | 18 YEARS | N/A | ONC BREAST |
| NCT02125877 | ARGENTINA | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT01884675 | ARGENTINA | GSK | DRUG | 2. RECRUITING | 3 | 160 | 18 YEARS | 80 YEARS | CARDIO HYPERTENSION |
| NCT02065791 | ARGENTINA | JANSSEN | DRUG | 2. RECRUITING | 3 | 3,627 | 30 YEARS | N/A | ENDO DIABETES |
| NCT02136134 | AUSTRALIA | JANSSEN | DRUG | 1. PLANNING | 3 | 480 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02060188 | AUSTRALIA | BMS | DRUG | 2. RECRUITING | 1 | 96 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT02189109 | AUSTRALIA | NUVOX | DRUG | 2. RECRUITING | 1 | 25 | 18 YEARS | 70 YEARS | ONC CNS: GLIOMA |
| NCT01761266 | AUSTRALIA | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT01837251 | AUSTRALIA | AGO | DRUG | 2. RECRUITING | 3 | 654 | 18 YEARS | N/A | ONC O&G: OVARY |
| NCT01980888 | AUSTRALIA | GILEAD | DRUG | 2. RECRUITING | 3 | 280 | 18 YEARS | N/A | ONC HEM: LEUKEMIA |
| NCT02094586 | AUSTRALIA | PAXVAX | BIOLOGICAL | 2. RECRUITING | 3 | 2,964 | 18 YEARS | 45 YEARS | INFECT CHOLERA |
| NCT02100631 | AUSTRALIA | PAXVAX | BIOLOGICAL | 2. RECRUITING | 3 | 400 | 46 YEARS | 64 YEARS | INFECT CHOLERA |
| NCT02137850 | AUSTRALIA | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 125 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02141074 | AUSTRALIA | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 50 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02145468 | AUSTRALIA | GSK | DRUG | 2. RECRUITING | 3 | 3,500 | 35 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See **Studies Opening a First Site in a New Country**, Page 19)

Studies Opening a First Site in a New Country, from Page 18

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|-----------|-------------------------|-------------------|---------------|--------------------|----------|----------|----------|---------------------------|
| NCT02189837 | AUSTRALIA | AMGEN | DRUG | 2. RECRUITING | 3 | 80 | 18 YEARS | 65 YEARS | CARDIO CHOLESTEROL/LIPIDS |
| NCT02092467 | AUSTRALIA | PFIZER | DRUG | 2. RECRUITING | 4 | 4,000 | 50 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT02189174 | AUSTRIA | NOVARTIS | DRUG | 1. PLANNING | 1 | 157 | 18 YEARS | N/A | ONC SOLID TUMOR/CANCER |
| NCT01837251 | AUSTRIA | AGO | DRUG | 2. RECRUITING | 3 | 654 | 18 YEARS | N/A | ONC O&G: OVARY |
| NCT02085161 | AUSTRIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 300 | 40 YEARS | 75 YEARS | RESP COPD |
| NCT02185911 | AUSTRIA | AMGEN | | 2. RECRUITING | NA | 300 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02160158 | BELGIUM | PFIZER | DRUG | 1. PLANNING | 1 | 24 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02186977 | BELGIUM | NOVOSANIS | DEVICE | 1. PLANNING | 1 | 33 | 18 YEARS | 35 YEARS | INFECT HEPATITIS B |
| NCT02190604 | BELGIUM | NOVARTIS | DRUG | 1. PLANNING | 2 | 260 | 18 YEARS | 55 YEARS | RESP CYSTIC FIBROSIS |
| NCT02188290 | BELGIUM | KIADIS | | 1. PLANNING | NA | 270 | 18 YEARS | 65 YEARS | ONC HEM: LEUKEMIA |
| NCT02190123 | BELGIUM | ASTRAZENECA | DRUG | 1. PLANNING | NA | 640 | 18 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |
| NCT02163161 | BELGIUM | PFIZER | DRUG | 2. RECRUITING | 1 | 12 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02038647 | BELGIUM | MILLENNIUM | DRUG | 2. RECRUITING | 2 | 166 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT01761266 | BELGIUM | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT02059291 | BELGIUM | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02186145 | BRAZIL | MARJAN | DRUG | 1. PLANNING | 3 | 160 | 18 YEARS | 50 YEARS | INFECT VAGINA |
| NCT02137226 | BULGARIA | BOEHRINGER INGELHEIM | DRUG | 1. PLANNING | 3 | 600 | 18 YEARS | 80 YEARS | RHEUM ARTHRITIS/GOUT |
| NCT02153437 | CANADA | BMS | DRUG | 1. PLANNING | 1 | 20 | 18 YEARS | 75 YEARS | CARDIO ARRHYT/FIBRILL |
| NCT02189174 | CANADA | NOVARTIS | DRUG | 1. PLANNING | 1 | 157 | 18 YEARS | N/A | ONC SOLID TUMOR/CANCER |
| NCT02188251 | CANADA | KGK | DIETARY SUP. | 1. PLANNING | 2 | 100 | 21 YEARS | 55 YEARS | ENDO METAB/NUTR |
| NCT02188290 | CANADA | KIADIS | | 1. PLANNING | NA | 270 | 18 YEARS | 65 YEARS | ONC HEM: LEUKEMIA |
| NCT02036502 | CANADA | MERCK SHARP DOHME | BIOLOGICAL | 2. RECRUITING | 1 | 44 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02165345 | CANADA | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 96 | 2 YEARS | 18 YEARS | RHEUM ARTHRITIS/GOUT |
| NCT02188810 | CANADA | FOLIA | BIOLOGICAL | 2. RECRUITING | 1 | 48 | 18 YEARS | 50 YEARS | INFECT INFLUENZA/FLU |
| NCT01870609 | CANADA | VERASTEM | DRUG | 2. RECRUITING | 2 | 372 | 18 YEARS | N/A | ONC RESP: PLEURA |
| NCT01904058 | CANADA | LUMENA | DRUG | 2. RECRUITING | 2 | 60 | 18 YEARS | 80 YEARS | GI LIVER CIRRHOSIS |
| NCT01998828 | CANADA | GILEAD | DRUG | 2. RECRUITING | 2 | 80 | 18 YEARS | N/A | HEM POLYCYTHEMIA VERA |
| NCT02038647 | CANADA | MILLENNIUM | DRUG | 2. RECRUITING | 2 | 166 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT01761266 | CANADA | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT02059291 | CANADA | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02135692 | CANADA | GSK | BIOLOGICAL | 2. RECRUITING | 3 | 375 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02137850 | CANADA | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 125 | N/A | 6 YEARS | CARDIO THROMB/COAG |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening a First Site in a New Country, *from Page 19*

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-----------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|---------------------------|
| NCT02141074 | CANADA | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 50 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02105961 | CHILE | GSK | DRUG | 2. RECRUITING | 3 | 660 | 40 YEARS | N/A | RESP COPD |
| NCT02188082 | CHINA | JIANGSU HENGRUI | DRUG | 2. RECRUITING | 2 | 336 | 18 YEARS | 75 YEARS | CARDIO CARDIOMYOP/FAILURE |
| NCT02049814 | CHINA | TAKEDA | DRUG | 2. RECRUITING | 4 | 380 | 18 YEARS | 75 YEARS | ENDO DIABETES |
| NCT02189499 | COLOMBIA | AMARANTH | DEVICE | 1. PLANNING | 2 | 50 | 18 YEARS | 84 YEARS | CARDIO CORONARY/ISCHEMIC |
| NCT02155660 | COLOMBIA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,850 | N/A | N/A | RESP COPD |
| NCT02064868 | CROATIA | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/FAILURE |
| NCT02038647 | CZECH REP | MILLENNIUM | DRUG | 2. RECRUITING | 2 | 166 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02111044 | CZECH REP | ITALFARMACO | DRUG | 2. RECRUITING | 2 | 40 | 18 YEARS | 80 YEARS | ENDO ACROMEGALY |
| NCT01976364 | CZECH REP | PFIZER | DRUG | 2. RECRUITING | 3 | 700 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT02065791 | CZECH REP | JANSSEN | DRUG | 2. RECRUITING | 3 | 3,627 | 30 YEARS | N/A | ENDO DIABETES |
| NCT02138916 | CZECH REP | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |
| NCT02185911 | CZECH REP | AMGEN | | 2. RECRUITING | NA | 300 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02190552 | DENMARK | NEURAVI | DEVICE | 1. PLANNING | NA | 100 | 18 YEARS | 80 YEARS | CARDIO STROKE |
| NCT02145468 | DENMARK | GSK | DRUG | 2. RECRUITING | 3 | 3,500 | 35 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |
| NCT02132949 | DENMARK | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | NA | 400 | 18 YEARS | N/A | ONC BREAST |
| NCT02137226 | ESTONIA | BOEHRINGER INGELHEIM | DRUG | 1. PLANNING | 3 | 600 | 18 YEARS | 80 YEARS | RHEUM ARTHRITIS/GOUT |
| NCT02064868 | ESTONIA | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/FAILURE |
| NCT02189174 | FRANCE | NOVARTIS | DRUG | 1. PLANNING | 1 | 157 | 18 YEARS | N/A | ONC SOLID TUMOR/CANCER |
| NCT02168530 | FRANCE | HOFFMANN-LA ROCHE | DRUG | 1. PLANNING | 2 | 129 | 40 YEARS | N/A | RESP PULMONARY FIBROSIS |
| NCT02189707 | FRANCE | DANISCO | DIETARY SUP. | 1. PLANNING | 2 | 228 | 18 YEARS | 70 YEARS | GI CONSTIPATION |
| NCT02190604 | FRANCE | NOVARTIS | DRUG | 1. PLANNING | 2 | 260 | 18 YEARS | 55 YEARS | RESP CYSTIC FIBROSIS |
| NCT02190747 | FRANCE | CLEMENTIA | DRUG | 1. PLANNING | 2 | 24 | 15 YEARS | N/A | ORTH MUSCULAR DISEASE |
| NCT02186041 | FRANCE | MEDTRONIC | DEVICE | 1. PLANNING | NA | 250 | 18 YEARS | N/A | UROLOGY INCONTINENCE |
| NCT02190552 | FRANCE | NEURAVI | DEVICE | 1. PLANNING | NA | 100 | 18 YEARS | 80 YEARS | CARDIO STROKE |
| NCT01904292 | FRANCE | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 48 | 1 YEAR | 17 YEARS | RHEUM ARTHRITIS/GOUT |
| NCT02021409 | FRANCE | BAYER | DRUG | 2. RECRUITING | 2 | 120 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02038647 | FRANCE | MILLENNIUM | DRUG | 2. RECRUITING | 2 | 166 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02055482 | FRANCE | BAYER | DRUG | 2. RECRUITING | 2 | 100 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02111044 | FRANCE | ITALFARMACO | DRUG | 2. RECRUITING | 2 | 40 | 18 YEARS | 80 YEARS | ENDO ACROMEGALY |
| NCT01485614 | FRANCE | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening a First Site in a New Country, Page 21)

Studies Opening a First Site in a New Country, from Page 20

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-----------|---------------|-------------------|---------------|--------------------|----------|----------|----------|-----------------------------|
| NCT01761266 | FRANCE | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT01837251 | FRANCE | AGO | DRUG | 2. RECRUITING | 3 | 654 | 18 YEARS | N/A | ONC O&G: OVARY |
| NCT02059291 | FRANCE | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02132936 | FRANCE | LEO | DRUG | 2. RECRUITING | 3 | 460 | 18 YEARS | N/A | DERM PSORIASIS |
| NCT02145468 | FRANCE | GSK | DRUG | 2. RECRUITING | 3 | 3,500 | 35 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |
| NCT02185534 | GERMANY | ASTRAZENECA | DRUG | 1. PLANNING | 1 | 84 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02190604 | GERMANY | NOVARTIS | DRUG | 1. PLANNING | 2 | 260 | 18 YEARS | 55 YEARS | RESP CYSTIC FIBROSIS |
| NCT02188095 | GERMANY | AESCULAP | | 1. PLANNING | NA | 100 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT02188290 | GERMANY | KIADIS | | 1. PLANNING | NA | 270 | 18 YEARS | 65 YEARS | ONC HEM: LEUKEMIA |
| NCT02190552 | GERMANY | NEURAVI | DEVICE | 1. PLANNING | NA | 100 | 18 YEARS | 80 YEARS | CARDIO STROKE |
| NCT02154334 | GERMANY | JANSSEN | DRUG | 2. RECRUITING | 1 | 48 | 18 YEARS | 55 YEARS | ALLERGY RHINITIS |
| NCT02017717 | GERMANY | BMS | BIOLOGICAL | 2. RECRUITING | 2 | 264 | 18 YEARS | N/A | ONC CNS: GLIOMA |
| NCT02038647 | GERMANY | MILLENNIUM | DRUG | 2. RECRUITING | 2 | 166 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02189577 | GERMANY | CHIESI | DRUG | 2. RECRUITING | 2 | 98 | 40 YEARS | 80 YEARS | RESP COPD |
| NCT01761266 | GERMANY | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT02059291 | GERMANY | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02065791 | GERMANY | JANSSEN | DRUG | 2. RECRUITING | 3 | 3,627 | 30 YEARS | N/A | ENDO DIABETES |
| NCT02105961 | GERMANY | GSK | DRUG | 2. RECRUITING | 3 | 660 | 40 YEARS | N/A | RESP COPD |
| NCT02181686 | GERMANY | BIOTRONIK | | 2. RECRUITING | NA | 135 | 18 YEARS | N/A | CARDIO CARDIOMYOP/FAILURE |
| NCT02185703 | GERMANY | CHORDATE | DEVICE | 2. RECRUITING | NA | 100 | 18 YEARS | 65 YEARS | NEUR MIGRAINE/H-ACHE |
| NCT02186912 | GERMANY | NOBEL BIOCARE | DEVICE | 2. RECRUITING | NA | 56 | 18 YEARS | N/A | DENTAL TOOTHLESS/EXTRACTION |
| NCT02188589 | GERMANY | SPIROX | DEVICE | 2. RECRUITING | NA | 30 | 18 YEARS | N/A | CARDIO SHOCK |
| NCT01999673 | GREECE | PEREGRINE | BIOLOGICAL | 2. RECRUITING | 3 | 582 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT01761266 | HONG KONG | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT02065791 | HONG KONG | JANSSEN | DRUG | 2. RECRUITING | 3 | 3,627 | 30 YEARS | N/A | ENDO DIABETES |
| NCT01994291 | HUNGARY | PFIZER | DRUG | 2. RECRUITING | 2 | 200 | 18 YEARS | N/A | OPHTHAL MACULAR EDEMA |
| NCT02038647 | HUNGARY | MILLENNIUM | DRUG | 2. RECRUITING | 2 | 166 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02111044 | HUNGARY | ITALFARMACO | DRUG | 2. RECRUITING | 2 | 40 | 18 YEARS | 80 YEARS | ENDO ACROMEGALY |
| NCT02059291 | HUNGARY | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02065791 | HUNGARY | JANSSEN | DRUG | 2. RECRUITING | 3 | 3,627 | 30 YEARS | N/A | ENDO DIABETES |
| NCT02185911 | HUNGARY | AMGEN | | 2. RECRUITING | NA | 300 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02190604 | IRELAND | NOVARTIS | DRUG | 1. PLANNING | 2 | 260 | 18 YEARS | 55 YEARS | RESP CYSTIC FIBROSIS |
| NCT02190552 | IRELAND | NEURAVI | DEVICE | 1. PLANNING | NA | 100 | 18 YEARS | 80 YEARS | CARDIO STROKE |
| NCT02059291 | IRELAND | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02189174 | ISRAEL | NOVARTIS | DRUG | 1. PLANNING | 1 | 157 | 18 YEARS | N/A | ONC SOLID TUMOR/CANCER |
| NCT02189772 | ISRAEL | ALCOBRA | DRUG | 1. PLANNING | 2 | 82 | 13 YEARS | 17 YEARS | PSYCH ADHD |
| NCT02190825 | ISRAEL | POP MEDICAL | DEVICE | 1. PLANNING | NA | 10 | 18 YEARS | 80 YEARS | GI PELVIC PROLAPSE |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening a First Site in a New Country, *from Page 21*

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|--------------|-------------------------|-------------------|---------------|--------------------|----------|----------|----------|-------------------------------|
| NCT02188771 | ISRAEL | PROCORE | DEVICE | 2. RECRUITING | 1 | 18 | 45 YEARS | 75 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT02126995 | ISRAEL | ALCOBRA | DRUG | 2. RECRUITING | 2 | 60 | 15 YEARS | 55 YEARS | ENDO FRAGILE X |
| NCT02059291 | ISRAEL | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02155660 | ISRAEL | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,850 | N/A | N/A | RESP COPD |
| NCT02189174 | ITALY | NOVARTIS | DRUG | 1. PLANNING | 1 | 157 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT01904292 | ITALY | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 48 | 1 YEAR | 17 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT02038647 | ITALY | MILLENNIUM | DRUG | 2. RECRUITING | 2 | 166 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02111044 | ITALY | ITALFARMACO | DRUG | 2. RECRUITING | 2 | 40 | 18 YEARS | 80 YEARS | ENDO ACROMEGALY |
| NCT02125877 | ITALY | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT01761266 | ITALY | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT02059291 | ITALY | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02148133 | JAPAN | GSK | DRUG | 1. PLANNING | 2 | 20 | 18 YEARS | 79 YEARS | HEM ANEMIA |
| NCT02185560 | JAPAN | BAYER | DRUG | 1. PLANNING | NA | 200 | N/A | N/A | ONC ENDO: THYROID |
| NCT02190786 | JAPAN | KISSEI | DRUG | 2. RECRUITING | 2 | MISSING | 20 YEARS | 64 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT01761266 | JAPAN | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT01850524 | JAPAN | MILLENNIUM | DRUG | 2. RECRUITING | 3 | 701 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02059291 | JAPAN | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02186171 | JAPAN | AMGEN | DRUG | 2. RECRUITING | 3 | 225 | 55 YEARS | 90 YEARS | ENDO OSTEOPOROSIS |
| NCT02115269 | KAZAKHSTAN | ABBOTT | | 2. RECRUITING | NA | 750 | 18 YEARS | N/A | NEUR MIGRAINE/ H-ACHE |
| NCT02185066 | KOREA, SOUTH | CJ HEALTH- CARE | DRUG | 1. PLANNING | 1 | 42 | 19 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02186483 | KOREA, SOUTH | JEIL | DRUG | 1. PLANNING | 1 | 24 | 19 YEARS | 55 YEARS | CARDIO CHOLESTEROL/LIPIDS |
| NCT02136134 | KOREA, SOUTH | JANSSEN | DRUG | 1. PLANNING | 3 | 480 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02186496 | KOREA, SOUTH | CHONG KUN DANG | DRUG | 2. RECRUITING | 1 | 32 | 20 YEARS | 45 YEARS | CARDIO HYPERTENSION |
| NCT02042170 | KOREA, SOUTH | LG LIFE | DRUG | 2. RECRUITING | 2 | 45 | 4 YEARS | 14 YEARS | ENDO GROWTH DISORDER |
| NCT02032277 | KOREA, SOUTH | ABBVIE | DRUG | 2. RECRUITING | 3 | 624 | 18 YEARS | N/A | ONC BREAST |
| NCT02104947 | KOREA, SOUTH | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT01973790 | LITHUANIA | ZERIA | DRUG | 2. RECRUITING | 3 | 350 | 18 YEARS | N/A | GI DYSPEPSIA |
| NCT02064868 | LITHUANIA | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT01761266 | MALAYSIA | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT02136134 | MEXICO | JANSSEN | DRUG | 1. PLANNING | 3 | 480 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02137226 | MEXICO | BOEHRINGER INGELHEIM | DRUG | 1. PLANNING | 3 | 600 | 18 YEARS | 80 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT01882439 | MEXICO | PFIZER | DRUG | 2. RECRUITING | 3 | 390 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02065791 | MEXICO | JANSSEN | DRUG | 2. RECRUITING | 3 | 3,627 | 30 YEARS | N/A | ENDO DIABETES |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening a First Site in a New Country, Page 23)

Studies Opening a First Site in a New Country, from Page 22

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-------------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|------------------------------|
| NCT02157935 | MEXICO | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 1,700 | 40 YEARS | 95 YEARS | RESP COPD |
| NCT02190604 | NETHERLANDS | NOVARTIS | DRUG | 1. PLANNING | 2 | 260 | 18 YEARS | 55 YEARS | RESP CYSTIC FIBROSIS |
| NCT02188290 | NETHERLANDS | KIADIS | | 1. PLANNING | NA | 270 | 18 YEARS | 65 YEARS | ONC HEM: LEUKEMIA |
| NCT02111044 | NETHERLANDS | ITALFARMACO | DRUG | 2. RECRUITING | 2 | 40 | 18 YEARS | 80 YEARS | ENDO ACROMEGALY |
| NCT01856309 | NETHERLANDS | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02059291 | NETHERLANDS | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02105636 | NETHERLANDS | BMS | DRUG | 2. RECRUITING | 3 | 180 | 18 YEARS | N/A | ONC ENT: NPC |
| NCT02059161 | PERU | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 500 | 18 YEARS | N/A | ENDO DIABETES |
| NCT02174731 | PERU | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 2,850 | 18 YEARS | N/A | UROLOGY KIDNEY FAILURE |
| NCT01761266 | PHILIPPINES | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT02136134 | POLAND | JANSSEN | DRUG | 1. PLANNING | 3 | 480 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02017717 | POLAND | BMS | BIOLOGICAL | 2. RECRUITING | 2 | 264 | 18 YEARS | N/A | ONC CNS: GLIOMA |
| NCT02038647 | POLAND | MILLENNIUM | DRUG | 2. RECRUITING | 2 | 166 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02055482 | POLAND | BAYER | DRUG | 2. RECRUITING | 2 | 100 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02111044 | POLAND | ITALFARMACO | DRUG | 2. RECRUITING | 2 | 40 | 18 YEARS | 80 YEARS | ENDO ACROMEGALY |
| NCT01761266 | POLAND | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT01955733 | POLAND | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | 82 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT02064868 | POLAND | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT02138916 | POLAND | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |
| NCT02149199 | POLAND | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02092467 | POLAND | PFIZER | DRUG | 2. RECRUITING | 4 | 4,000 | 50 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01856309 | PORTUGAL | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02064868 | PORTUGAL | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT02187614 | QATAR | HAMAD MEDICAL | DRUG | 1. PLANNING | 4 | 573 | 18 YEARS | 65 YEARS | UROLOGY KIDNEY STONES |
| NCT02190604 | ROMANIA | NOVARTIS | DRUG | 1. PLANNING | 2 | 260 | 18 YEARS | 55 YEARS | RESP CYSTIC FIBROSIS |
| NCT02111044 | ROMANIA | ITALFARMACO | DRUG | 2. RECRUITING | 2 | 40 | 18 YEARS | 80 YEARS | ENDO ACROMEGALY |
| NCT02065791 | ROMANIA | JANSSEN | DRUG | 2. RECRUITING | 3 | 3,627 | 30 YEARS | N/A | ENDO DIABETES |
| NCT02188277 | RUSSIA | MERZ | DRUG | 2. RECRUITING | 2 | 64 | 2 YEARS | 12 YEARS | NEUR SPASTICITY/ PALS |
| NCT01761266 | RUSSIA | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT01966614 | RUSSIA | SOPHIRIS | DRUG | 2. RECRUITING | 3 | 440 | 50 YEARS | N/A | UROLOGY PROSTATE HYPERPLASIA |
| NCT02059291 | RUSSIA | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02092467 | RUSSIA | PFIZER | DRUG | 2. RECRUITING | 4 | 4,000 | 50 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02122588 | RUSSIA | ASTRAZENECA | | 2. RECRUITING | NA | 300 | N/A | N/A | ONC O&G: OVARY |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening a First Site in a New Country, from Page 23

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|--------------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|------------------------------|
| NCT02064868 | SERBIA | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/FAILURE |
| NCT02189174 | SINGAPORE | NOVARTIS | DRUG | 1. PLANNING | 1 | 157 | 18 YEARS | N/A | ONC SOLID TUMOR/CANCER |
| NCT02104947 | SINGAPORE | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT01634152 | SLOVAKIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT02138916 | SOUTH AFRICA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |
| NCT02189174 | SPAIN | NOVARTIS | DRUG | 1. PLANNING | 1 | 157 | 18 YEARS | N/A | ONC SOLID TUMOR/CANCER |
| NCT02189369 | SPAIN | IGENOMIX | OTHER | 1. PLANNING | NA | 120 | 18 YEARS | 50 YEARS | O&G INFERTILITY |
| NCT02190552 | SPAIN | NEURAVI | DEVICE | 1. PLANNING | NA | 100 | 18 YEARS | 80 YEARS | CARDIO STROKE |
| NCT02123823 | SPAIN | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 1 | 198 | 18 YEARS | N/A | ONC SOLID TUMOR/CANCER |
| NCT01925274 | SPAIN | PFIZER | DRUG | 2. RECRUITING | 2 | 159 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT02038647 | SPAIN | MILLENNIUM | DRUG | 2. RECRUITING | 2 | 166 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02111044 | SPAIN | ITALFARMACO | DRUG | 2. RECRUITING | 2 | 40 | 18 YEARS | 80 YEARS | ENDO ACROMEGALY |
| NCT01761266 | SPAIN | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT01976364 | SPAIN | PFIZER | DRUG | 2. RECRUITING | 3 | 700 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT02059291 | SPAIN | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02138916 | SPAIN | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |
| NCT02190552 | SWEDEN | NEURAVI | DEVICE | 1. PLANNING | NA | 100 | 18 YEARS | 80 YEARS | CARDIO STROKE |
| NCT02190565 | SWEDEN | ORIFLAME | DIETARY SUP. | 1. PLANNING | NA | 200 | 18 YEARS | 40 YEARS | HEM ANEMIA |
| NCT02174861 | SWEDEN | AMGEN | DRUG | 2. RECRUITING | 2 | 490 | 18 YEARS | 60 YEARS | NEUR MIGRAINE/H-ACHE |
| NCT00966979 | SWEDEN | STRYKER | DEVICE | 2. RECRUITING | NA | 184 | 21 YEARS | 75 YEARS | ORTH HIP/KNEE REPLACEMENT |
| NCT02190552 | SWITZERLAND | NEURAVI | DEVICE | 1. PLANNING | NA | 100 | 18 YEARS | 80 YEARS | CARDIO STROKE |
| NCT01107522 | SWITZERLAND | TACTICAL | DRUG | 2. RECRUITING | 1 | MISSING | 18 YEARS | N/A | ONC CNS: GLIOMA |
| NCT01872260 | SWITZERLAND | NOVARTIS | DRUG | 2. RECRUITING | 1 | 300 | 18 YEARS | N/A | ONC BREAST |
| NCT02017717 | SWITZERLAND | BMS | BIOLOGICAL | 2. RECRUITING | 2 | 264 | 18 YEARS | N/A | ONC CNS: GLIOMA |
| NCT02059291 | SWITZERLAND | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02184845 | SWITZERLAND | NOBEL BIOCARE | DEVICE | 2. RECRUITING | NA | 84 | 18 YEARS | N/A | DENTAL PROCEDURE |
| NCT02189551 | SWITZERLAND | CERENEO | BEHAVIORAL | 2. RECRUITING | NA | MISSING | 18 YEARS | N/A | CARDIO STROKE |
| NCT01761266 | TAIWAN | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT01924533 | TAIWAN | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 629 | 18 YEARS | N/A | ONC GI: ESOPHAGEAL/GASTRIC |
| NCT01761266 | THAILAND | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT02059291 | TURKEY | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT01895777 | UKRAINE | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 270 | N/A | 17 YEARS | CARDIO THROMB/COAG |
| NCT01966614 | UKRAINE | SOPHIRIS | DRUG | 2. RECRUITING | 3 | 440 | 50 YEARS | N/A | UROLOGY PROSTATE HYPERPLASIA |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening a First Site in a New Country, from Page 24

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|---------|-------------------------|-------------------|---------------|--------------------|----------|----------|----------|------------------------------|
| NCT02065791 | UKRAINE | JANSSEN | DRUG | 2. RECRUITING | 3 | 3,627 | 30 YEARS | N/A | ENDO DIABETES |
| NCT02105961 | UKRAINE | GSK | DRUG | 2. RECRUITING | 3 | 660 | 40 YEARS | N/A | RESP COPD |
| NCT02149199 | UKRAINE | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02115269 | UKRAINE | ABBOTT | | 2. RECRUITING | NA | 750 | 18 YEARS | N/A | NEUR MIGRAINE/ H-ACHE |
| NCT02064387 | UK | GSK | DRUG | 1. PLANNING | 1 | 80 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02188303 | UK | ELI LILLY | DRUG | 1. PLANNING | 1 | 72 | 18 YEARS | 65 YEARS | HEALTHY/PHARM |
| NCT02190058 | UK | DAIICHI SANKYO | DRUG | 1. PLANNING | 1 | 48 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02190604 | UK | NOVARTIS | DRUG | 1. PLANNING | 2 | 260 | 18 YEARS | 55 YEARS | RESP CYSTIC FIBROSIS |
| NCT02188290 | UK | KIADIS | | 1. PLANNING | NA | 270 | 18 YEARS | 65 YEARS | ONC HEM: LEUKEMIA |
| NCT02123823 | UK | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 1 | 198 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT02163421 | UK | TAKEDA | DRUG | 2. RECRUITING | 1 | 48 | 18 YEARS | 60 YEARS | HEALTHY/PHARM |
| NCT02189733 | UK | ABLIX | BIOLOGICAL | 2. RECRUITING | 1 | 24 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02125877 | UK | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT02189577 | UK | CHIESI | DRUG | 2. RECRUITING | 2 | 98 | 40 YEARS | 80 YEARS | RESP COPD |
| NCT01634139 | UK | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01761266 | UK | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT01980888 | UK | GILEAD | DRUG | 2. RECRUITING | 3 | 280 | 18 YEARS | N/A | ONC HEM: LEUKEMIA |
| NCT02059291 | UK | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02065791 | UK | JANSSEN | DRUG | 2. RECRUITING | 3 | 3,627 | 30 YEARS | N/A | ENDO DIABETES |
| NCT02135692 | UK | GSK | BIOLOGICAL | 2. RECRUITING | 3 | 375 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02145468 | UK | GSK | DRUG | 2. RECRUITING | 3 | 3,500 | 35 YEARS | N/A | CARDIO CORONARY/ ISCHEMIC |
| NCT02165930 | USA | PFIZER | DRUG | 1. PLANNING | 1 | 14 | 21 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02185300 | USA | VIIV | DRUG | 1. PLANNING | 1 | 15 | 18 YEARS | 65 YEARS | INFECT HIV/AIDS |
| NCT02186535 | USA | CONRAD | DIETARY SUP. | 1. PLANNING | 1 | 20 | 21 YEARS | 50 YEARS | ENDO METAB/NUTR |
| NCT02186769 | USA | LUYE | DRUG | 1. PLANNING | 1 | 16 | 18 YEARS | 65 YEARS | PSYCH SCHIZOPHRENIA |
| NCT02187029 | USA | PFIZER | DRUG | 1. PLANNING | 1 | 27 | 18 YEARS | 60 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT02189174 | USA | NOVARTIS | DRUG | 1. PLANNING | 1 | 157 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT02189343 | USA | ACETYLON | DRUG | 1. PLANNING | 1 | 20 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02184988 | USA | EVOLUS | BIOLOGICAL | 1. PLANNING | 2 | 365 | 18 YEARS | N/A | DERM WRINKLES |
| NCT02186119 | USA | ALLERGAN | DRUG | 1. PLANNING | 2 | 140 | 19 YEARS | N/A | OPHTHAL MACULAR EDEMA |
| NCT02186847 | USA | NRG | DRUG | 1. PLANNING | 2 | 168 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02187991 | USA | US ONCOLOGY | DRUG | 1. PLANNING | 2 | 252 | 18 YEARS | N/A | ONC BREAST |
| NCT02190604 | USA | NOVARTIS | DRUG | 1. PLANNING | 2 | 260 | 18 YEARS | 55 YEARS | RESP CYSTIC FIBROSIS |
| NCT02190747 | USA | CLEMENTIA | DRUG | 1. PLANNING | 2 | 24 | 15 YEARS | N/A | ORTH MUSCULAR DISEASE |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening a First Site in a New Country, *from Page 25*

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|---------|-------------------------|-------------------|---------------|--------------------|----------|----------|----------|------------------------------|
| NCT02184195 | USA | ASTRAZENECA | DRUG | 1. PLANNING | 3 | 145 | 18 YEARS | N/A | ONC BREAST |
| NCT02061748 | USA | BOEHRINGER INGELHEIM | | 1. PLANNING | NA | 20,000 | 18 YEARS | N/A | CARDIO ARRHYT/ FIBRILL |
| NCT02185001 | USA | LYMAN | PROCEDURE | 1. PLANNING | NA | 40 | 10 YEARS | N/A | ORTH JOINT DISEASE |
| NCT02185521 | USA | PHILIPS | OTHER | 1. PLANNING | NA | 3,000 | 18 YEARS | N/A | CARDIO SHOCK |
| NCT02185898 | USA | R.J. REYNOLDS | OTHER | 1. PLANNING | NA | 72 | 21 YEARS | N/A | PSYCH ABUSE TOBACCO |
| NCT02187887 | USA | RAND | BEHAVIORAL | 1. PLANNING | NA | 600 | 18 YEARS | 34 YEARS | PSYCH ABUSE ALCOHOL |
| NCT02188173 | USA | ALLERGAN | DRUG | 1. PLANNING | NA | 1,000 | 18 YEARS | N/A | OPHTHAL MACULAR EDEMA |
| NCT02188290 | USA | KIADIS | | 1. PLANNING | NA | 270 | 18 YEARS | 65 YEARS | ONC HEM: LEUKEMIA |
| NCT02189525 | USA | BANYAN | | 1. PLANNING | NA | 500 | 18 YEARS | N/A | NEUR HEAD INJURY/ TRAUMA |
| NCT02189863 | USA | ALCON | DEVICE | 1. PLANNING | NA | 24 | N/A | 70 YEARS | OPHTHAL PRESBYOPIA |
| NCT02190578 | USA | MEDMIRA | DEVICE | 1. PLANNING | NA | 1,500 | 13 YEARS | N/A | INFECT HIV/AIDS |
| NCT01494688 | USA | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 140 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT02103478 | USA | ASTEX | DRUG | 2. RECRUITING | 1 | 150 | 18 YEARS | N/A | ONC HEM: MYELODYSPLASTIC |
| NCT02184156 | USA | AMPIO | BIOLOGICAL | 2. RECRUITING | 1 | 40 | 45 YEARS | 55 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT02184767 | USA | TEVA | DRUG | 2. RECRUITING | 1 | 30 | 10 YEARS | 17 YEARS | PSYCH BIPOLAR |
| NCT02185794 | USA | GILEAD | DRUG | 2. RECRUITING | 1 | 92 | 18 YEARS | 65 YEARS | INFECT HEPATITIS C |
| NCT02187094 | USA | TARGACEPT | DRUG | 2. RECRUITING | 1 | 44 | 18 YEARS | 70 YEARS | GI PARESIS |
| NCT02189304 | USA | PEARL | DRUG | 2. RECRUITING | 1 | 60 | 18 YEARS | 55 YEARS | RESP COPD |
| NCT02126995 | USA | ALCOBRA | DRUG | 2. RECRUITING | 2 | 60 | 15 YEARS | 55 YEARS | ENDO FRAGILE X |
| NCT02135042 | USA | NRG | RADIATION | 2. RECRUITING | 2 | 924 | 18 YEARS | N/A | INFECT HERPES SIMPLEX |
| NCT02147587 | USA | PFIZER | DRUG | 2. RECRUITING | 2 | 140 | 50 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02188160 | USA | KALA | DRUG | 2. RECRUITING | 2 | 150 | 18 YEARS | N/A | OPHTHAL DRY EYE |
| NCT02189850 | USA | BRAINTREE | DRUG | 2. RECRUITING | 2 | 32 | 12 YEARS | 17 YEARS | GI SCOPY |
| NCT02059291 | USA | NOVARTIS | DRUG | 2. RECRUITING | 3 | 180 | 2 YEARS | N/A | INFECT FEVER |
| NCT02145468 | USA | GSK | DRUG | 2. RECRUITING | 3 | 3,500 | 35 YEARS | N/A | CARDIO CORONARY/ ISCHEMIC |
| NCT02157935 | USA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 1,700 | 40 YEARS | 95 YEARS | RESP COPD |
| NCT02174731 | USA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 2,850 | 18 YEARS | N/A | UROLOGY KIDNEY FAILURE |
| NCT02186171 | USA | AMGEN | DRUG | 2. RECRUITING | 3 | 225 | 55 YEARS | 90 YEARS | ENDO OSTEOPOROSIS |
| NCT02184520 | USA | GLOBUS | DEVICE | 2. RECRUITING | 4 | 360 | 18 YEARS | N/A | ORTH SPINAL DISEASE |
| NCT02168764 | USA | AUTONOMIC | DEVICE | 2. RECRUITING | NA | 120 | 22 YEARS | N/A | NEUR MIGRAINE/ H-ACHE |
| NCT02184546 | USA | STEMGENEX | | 2. RECRUITING | NA | 75 | 18 YEARS | N/A | NEUR PARKINSON |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening a First Site in a New Country, Page 27)

Studies Opening a First Site in a New Country, from Page 26

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|---------|------------------|-------------------|---------------|--------------------|----------|----------|----------|---------------------------|
| NCT02187549 | USA | FIDIA | DEVICE | 2. RECRUITING | NA | 332 | 40 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02187653 | USA | DC2 HEALTH-CARE | | 2. RECRUITING | NA | 10,000 | 18 YEARS | N/A | OTHER PROCEDURE |
| NCT02187666 | USA | DC2 HEALTH-CARE | | 2. RECRUITING | NA | 10,000 | N/A | N/A | ORTH SPINAL DISEASE |
| NCT02187770 | USA | INTERSECTION | DEVICE | 2. RECRUITING | NA | 100 | 18 YEARS | N/A | RESP INSUF/FAILURE |
| NCT02188199 | USA | DC2 HEALTH-CARE | | 2. RECRUITING | NA | 10,000 | 18 YEARS | N/A | ORTH HIP/KNEE REPLACEMENT |
| NCT02188797 | USA | RAND | BEHAVIORAL | 2. RECRUITING | NA | 168 | 18 YEARS | 24 YEARS | PSYCH ABUSE SUBSTANCE |
| NCT02189161 | USA | COVIDIEN | DEVICE | 2. RECRUITING | NA | 10 | 18 YEARS | 75 YEARS | ONC GI: COLORECTAL |
| NCT02189798 | USA | ADVANCED BIONICS | DEVICE | 2. RECRUITING | NA | 25 | 18 YEARS | N/A | ENT HEARING LOSS |
| NCT02189980 | USA | BALANCED HEALTH | OTHER | 2. RECRUITING | NA | 300 | 18 YEARS | N/A | ANEST NAUSEA/ VOMITING |
| NCT02190305 | USA | MEDMIRA | DEVICE | 2. RECRUITING | NA | 4,000 | 13 YEARS | N/A | INFECT HIV/AIDS |
| NCT02190591 | USA | TRIHEALTH | DEVICE | 2. RECRUITING | NA | 184 | 18 YEARS | 50 YEARS | O&G PREGNANCY |

STUDIES OPENING ADDITIONAL SITES IN A COUNTRY

This table lists studies that launched additional sites in a country in the past week.

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-----------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|--------------------------|
| NCT02137850 | ALGERIA | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 125 | N/A | 6 YEARS | CARDIO THROMB/ COAG |
| NCT02141074 | ALGERIA | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 50 | N/A | 6 YEARS | CARDIO THROMB/ COAG |
| NCT01904292 | ARGENTINA | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 48 | 1 YEAR | 17 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT01485614 | ARGENTINA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01634152 | ARGENTINA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01856309 | ARGENTINA | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02105636 | ARGENTINA | BMS | DRUG | 2. RECRUITING | 3 | 180 | 18 YEARS | N/A | ONC ENT: NPC |
| NCT02149199 | ARGENTINA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02157935 | ARGENTINA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 1,700 | 40 YEARS | 95 YEARS | RESP COPD |
| NCT02168530 | AUSTRALIA | HOFFMANN-LA ROCHE | DRUG | 1. PLANNING | 2 | 129 | 40 YEARS | N/A | RESP PULMONARY FIBROSIS |
| NCT01872260 | AUSTRALIA | NOVARTIS | DRUG | 2. RECRUITING | 1 | 300 | 18 YEARS | N/A | ONC BREAST |
| NCT01904292 | AUSTRALIA | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 48 | 1 YEAR | 17 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT01870609 | AUSTRALIA | VERASTEM | DRUG | 2. RECRUITING | 2 | 372 | 18 YEARS | N/A | ONC RESP: PLEURA |
| NCT02017717 | AUSTRALIA | BMS | BIOLOGICAL | 2. RECRUITING | 2 | 264 | 18 YEARS | N/A | ONC CNS: GLIOMA |
| NCT02021409 | AUSTRALIA | BAYER | DRUG | 2. RECRUITING | 2 | 120 | 18 YEARS | N/A | HEM ANEMIA |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See **Studies Opening Additional Sites in a Country**, Page 28)

Studies Opening Additional Sites in a Country, from Page 27

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-----------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|------------------------------|
| NCT02055482 | AUSTRALIA | BAYER | DRUG | 2. RECRUITING | 2 | 100 | 18 YEARS | N/A | HEM ANEMIA |
| NCT01485614 | AUSTRALIA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01634152 | AUSTRALIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01882439 | AUSTRALIA | PFIZER | DRUG | 2. RECRUITING | 3 | 390 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01966614 | AUSTRALIA | SOPHIRIS | DRUG | 2. RECRUITING | 3 | 440 | 50 YEARS | N/A | UROLOGY PROSTATE HYPERPLASIA |
| NCT01999673 | AUSTRALIA | PEREGRINE | BIOLOGICAL | 2. RECRUITING | 3 | 582 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02059161 | AUSTRALIA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 500 | 18 YEARS | N/A | ENDO DIABETES |
| NCT02085161 | AUSTRALIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 300 | 40 YEARS | 75 YEARS | RESP COPD |
| NCT02104947 | AUSTRALIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02135692 | AUSTRALIA | GSK | BIOLOGICAL | 2. RECRUITING | 3 | 375 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02149199 | AUSTRALIA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02091752 | AUSTRIA | NOVARTIS | DRUG | 1. PLANNING | 2 | 100 | 18 YEARS | N/A | HEM MYELOFIBROSIS |
| NCT02125877 | AUSTRIA | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT01485614 | AUSTRIA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01856309 | AUSTRIA | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01884675 | AUSTRIA | GSK | DRUG | 2. RECRUITING | 3 | 160 | 18 YEARS | 80 YEARS | CARDIO HYPERTENSION |
| NCT02064868 | AUSTRIA | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT02104947 | AUSTRIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02137850 | AUSTRIA | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 125 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02138916 | AUSTRIA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |
| NCT02141074 | AUSTRIA | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 50 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02060188 | BELGIUM | BMS | DRUG | 2. RECRUITING | 1 | 96 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT02123823 | BELGIUM | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 1 | 198 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT01870609 | BELGIUM | VERASTEM | DRUG | 2. RECRUITING | 2 | 372 | 18 YEARS | N/A | ONC RESP: PLEURA |
| NCT01634152 | BELGIUM | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01856309 | BELGIUM | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01882439 | BELGIUM | PFIZER | DRUG | 2. RECRUITING | 3 | 390 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01973790 | BELGIUM | ZERIA | DRUG | 2. RECRUITING | 3 | 350 | 18 YEARS | N/A | GI DYSPEPSIA |
| NCT01999673 | BELGIUM | PEREGRINE | BIOLOGICAL | 2. RECRUITING | 3 | 582 | 18 YEARS | N/A | ONC RESP: LUNG |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See **Studies Opening Additional Sites in a Country**, Page 29)

Studies Opening Additional Sites in a Country, from Page 28

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|----------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|------------------------------|
| NCT02064868 | BELGIUM | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/FAILURE |
| NCT02085161 | BELGIUM | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 300 | 40 YEARS | 75 YEARS | RESP COPD |
| NCT02104947 | BELGIUM | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02135692 | BELGIUM | GSK | BIOLOGICAL | 2. RECRUITING | 3 | 375 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02145468 | BELGIUM | GSK | DRUG | 2. RECRUITING | 3 | 3,500 | 35 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |
| NCT02155660 | BELGIUM | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,850 | N/A | N/A | RESP COPD |
| NCT01904292 | BRAZIL | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 48 | 1 YEAR | 17 YEARS | RHEUM ARTHRITIS/GOUT |
| NCT01634152 | BRAZIL | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT02149199 | BRAZIL | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02155660 | BRAZIL | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,850 | N/A | N/A | RESP COPD |
| NCT02021409 | BULGARIA | BAYER | DRUG | 2. RECRUITING | 2 | 120 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02055482 | BULGARIA | BAYER | DRUG | 2. RECRUITING | 2 | 100 | 18 YEARS | N/A | HEM ANEMIA |
| NCT01485614 | BULGARIA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01634139 | BULGARIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT02064868 | BULGARIA | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/FAILURE |
| NCT02149199 | BULGARIA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02155660 | BULGARIA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,850 | N/A | N/A | RESP COPD |
| NCT02174731 | BULGARIA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 2,850 | 18 YEARS | N/A | UROLOGY KIDNEY FAILURE |
| NCT02091752 | CANADA | NOVARTIS | DRUG | 1. PLANNING | 2 | 100 | 18 YEARS | N/A | HEM MYELOFIBROSIS |
| NCT01904292 | CANADA | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 48 | 1 YEAR | 17 YEARS | RHEUM ARTHRITIS/GOUT |
| NCT02060188 | CANADA | BMS | DRUG | 2. RECRUITING | 1 | 96 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT01485614 | CANADA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01634139 | CANADA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01634152 | CANADA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01850524 | CANADA | MILLENNIUM | DRUG | 2. RECRUITING | 3 | 701 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT01856309 | CANADA | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT01882439 | CANADA | PFIZER | DRUG | 2. RECRUITING | 3 | 390 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT01884675 | CANADA | GSK | DRUG | 2. RECRUITING | 3 | 160 | 18 YEARS | 80 YEARS | CARDIO HYPERTENSION |
| NCT01966614 | CANADA | SOPHIRIS | DRUG | 2. RECRUITING | 3 | 440 | 50 YEARS | N/A | UROLOGY PROSTATE HYPERPLASIA |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 30)

Studies Opening Additional Sites in a Country, from Page 29

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-----------------------|-------------------------|-------------------|---------------|--------------------|----------|----------|----------|-------------------------------|
| NCT02065791 | CANADA | JANSSEN | DRUG | 2. RECRUITING | 3 | 3,627 | 30 YEARS | N/A | ENDO DIABETES |
| NCT02085161 | CANADA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 300 | 40 YEARS | 75 YEARS | RESP COPD |
| NCT02104947 | CANADA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02105636 | CANADA | BMS | DRUG | 2. RECRUITING | 3 | 180 | 18 YEARS | N/A | ONC ENT: NPC |
| NCT02138916 | CANADA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |
| NCT02149199 | CANADA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT01485614 | CHILE | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT02149199 | CHILE | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02157935 | CHILE | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 1,700 | 40 YEARS | 95 YEARS | RESP COPD |
| NCT01761266 | CHINA | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT01884675 | CHINA | GSK | DRUG | 2. RECRUITING | 3 | 160 | 18 YEARS | 80 YEARS | CARDIO HYPERTENSION |
| NCT01485614 | COLOMBIA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT02059161 | COLOMBIA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 500 | 18 YEARS | N/A | ENDO DIABETES |
| NCT01856309 | CROATIA | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02136134 | CZECH REP | JANSSEN | DRUG | 1. PLANNING | 3 | 480 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT01634152 | CZECH REP | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01882439 | CZECH REP | PFIZER | DRUG | 2. RECRUITING | 3 | 390 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01884675 | CZECH REP | GSK | DRUG | 2. RECRUITING | 3 | 160 | 18 YEARS | 80 YEARS | CARDIO HYPERTENSION |
| NCT02064868 | CZECH REP | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT02104947 | CZECH REP | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02017717 | DENMARK | BMS | BIOLOGICAL | 2. RECRUITING | 2 | 264 | 18 YEARS | N/A | ONC CNS: GLIOMA |
| NCT01485614 | DENMARK | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT02085161 | DENMARK | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 300 | 40 YEARS | 75 YEARS | RESP COPD |
| NCT02105961 | DENMARK | GSK | DRUG | 2. RECRUITING | 3 | 660 | 40 YEARS | N/A | RESP COPD |
| NCT02155660 | DENMARK | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,850 | N/A | N/A | RESP COPD |
| NCT01485614 | DOMINICAN REPUBLIC | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT02104947 | ESTONIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02104947 | FINLAND | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT01494688 | FRANCE | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 140 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See **Studies Opening Additional Sites in a Country**, Page 31)

Studies Opening Additional Sites in a Country, from Page 30

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|---------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|----------------------------|
| NCT01872260 | FRANCE | NOVARTIS | DRUG | 2. RECRUITING | 1 | 300 | 18 YEARS | N/A | ONC BREAST |
| NCT02036502 | FRANCE | MERCK SHARP DOHME | BIOLOGICAL | 2. RECRUITING | 1 | 44 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02060188 | FRANCE | BMS | DRUG | 2. RECRUITING | 1 | 96 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT02123823 | FRANCE | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 1 | 198 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT01870609 | FRANCE | VERASTEM | DRUG | 2. RECRUITING | 2 | 372 | 18 YEARS | N/A | ONC RESP: PLEURA |
| NCT02125877 | FRANCE | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT01850524 | FRANCE | MILLENNIUM | DRUG | 2. RECRUITING | 3 | 701 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT01882439 | FRANCE | PFIZER | DRUG | 2. RECRUITING | 3 | 390 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01999673 | FRANCE | PEREGRINE | BIOLOGICAL | 2. RECRUITING | 3 | 582 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02064868 | FRANCE | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT02104947 | FRANCE | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02105636 | FRANCE | BMS | DRUG | 2. RECRUITING | 3 | 180 | 18 YEARS | N/A | ONC ENT: NPC |
| NCT02137850 | FRANCE | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 125 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02091752 | GERMANY | NOVARTIS | DRUG | 1. PLANNING | 2 | 100 | 18 YEARS | N/A | HEM MYELOFIBROSIS |
| NCT02168530 | GERMANY | HOFFMANN-LA ROCHE | DRUG | 1. PLANNING | 2 | 129 | 40 YEARS | N/A | RESP PULMONARY FIBROSIS |
| NCT01904292 | GERMANY | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 48 | 1 YEAR | 17 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT01994291 | GERMANY | PFIZER | DRUG | 2. RECRUITING | 2 | 200 | 18 YEARS | N/A | OPHTHAL MACULAR EDEMA |
| NCT02021409 | GERMANY | BAYER | DRUG | 2. RECRUITING | 2 | 120 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02055482 | GERMANY | BAYER | DRUG | 2. RECRUITING | 2 | 100 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02125877 | GERMANY | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT01485614 | GERMANY | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01634139 | GERMANY | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01634152 | GERMANY | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01837251 | GERMANY | AGO | DRUG | 2. RECRUITING | 3 | 654 | 18 YEARS | N/A | ONC O&G: OVARY |
| NCT01856309 | GERMANY | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01882439 | GERMANY | PFIZER | DRUG | 2. RECRUITING | 3 | 390 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01884675 | GERMANY | GSK | DRUG | 2. RECRUITING | 3 | 160 | 18 YEARS | 80 YEARS | CARDIO HYPERTENSION |
| NCT01999673 | GERMANY | PEREGRINE | BIOLOGICAL | 2. RECRUITING | 3 | 582 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02064868 | GERMANY | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT02085161 | GERMANY | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 300 | 40 YEARS | 75 YEARS | RESP COPD |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See **Studies Opening Additional Sites in a Country**, Page 32)

Studies Opening Additional Sites in a Country, from Page 31

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-----------|-------------------------|-------------------|---------------|--------------------|----------|----------|----------|-------------------------------|
| NCT02104947 | GERMANY | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02137850 | GERMANY | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 125 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02138916 | GERMANY | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |
| NCT02141074 | GERMANY | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 50 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02145468 | GERMANY | GSK | DRUG | 2. RECRUITING | 3 | 3,500 | 35 YEARS | N/A | CARDIO CORONARY/ ISCHEMIC |
| NCT00966979 | GERMANY | STRYKER | DEVICE | 2. RECRUITING | NA | 184 | 21 YEARS | 75 YEARS | ORTH HIP/KNEE REPLACEMENT |
| NCT02064868 | GREECE | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT01485614 | GUATEMALA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01634139 | GUATEMALA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01634152 | GUATEMALA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01872260 | HONG KONG | NOVARTIS | DRUG | 2. RECRUITING | 1 | 300 | 18 YEARS | N/A | ONC BREAST |
| NCT02104947 | HONG KONG | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02105636 | HONG KONG | BMS | DRUG | 2. RECRUITING | 3 | 180 | 18 YEARS | N/A | ONC ENT: NPC |
| NCT02021409 | HUNGARY | BAYER | DRUG | 2. RECRUITING | 2 | 120 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02055482 | HUNGARY | BAYER | DRUG | 2. RECRUITING | 2 | 100 | 18 YEARS | N/A | HEM ANEMIA |
| NCT01485614 | HUNGARY | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01634139 | HUNGARY | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01634152 | HUNGARY | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01999673 | HUNGARY | PEREGRINE | BIOLOGICAL | 2. RECRUITING | 3 | 582 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02064868 | HUNGARY | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT02138916 | HUNGARY | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |
| NCT02149199 | HUNGARY | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02060188 | IRELAND | BMS | DRUG | 2. RECRUITING | 1 | 96 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT02104947 | IRELAND | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02168530 | ISRAEL | HOFFMANN-LA ROCHE | DRUG | 1. PLANNING | 2 | 129 | 40 YEARS | N/A | RESP PULMONARY FIBROSIS |
| NCT01872260 | ISRAEL | NOVARTIS | DRUG | 2. RECRUITING | 1 | 300 | 18 YEARS | N/A | ONC BREAST |
| NCT01485614 | ISRAEL | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT02141074 | ISRAEL | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 50 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02091752 | ITALY | NOVARTIS | DRUG | 1. PLANNING | 2 | 100 | 18 YEARS | N/A | HEM MYELOFIBROSIS |
| NCT01872260 | ITALY | NOVARTIS | DRUG | 2. RECRUITING | 1 | 300 | 18 YEARS | N/A | ONC BREAST |
| NCT02060188 | ITALY | BMS | DRUG | 2. RECRUITING | 1 | 96 | 18 YEARS | N/A | ONC GI: COLORECTAL |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 33)

Studies Opening Additional Sites in a Country, from Page 32

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|--------------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|----------------------------|
| NCT02017717 | ITALY | BMS | BIOLOGICAL | 2. RECRUITING | 2 | 264 | 18 YEARS | N/A | ONC CNS: GLIOMA |
| NCT02021409 | ITALY | BAYER | DRUG | 2. RECRUITING | 2 | 120 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02055482 | ITALY | BAYER | DRUG | 2. RECRUITING | 2 | 100 | 18 YEARS | N/A | HEM ANEMIA |
| NCT01485614 | ITALY | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT02064868 | ITALY | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/FAILURE |
| NCT02104947 | ITALY | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02105636 | ITALY | BMS | DRUG | 2. RECRUITING | 3 | 180 | 18 YEARS | N/A | ONC ENT: NPC |
| NCT02138916 | ITALY | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |
| NCT02145468 | ITALY | GSK | DRUG | 2. RECRUITING | 3 | 3,500 | 35 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |
| NCT00966979 | ITALY | STRYKER | DEVICE | 2. RECRUITING | NA | 184 | 21 YEARS | 75 YEARS | ORTH HIP/KNEE REPLACEMENT |
| NCT01870609 | JAPAN | VERASTEM | DRUG | 2. RECRUITING | 2 | 372 | 18 YEARS | N/A | ONC RESP: PLEURA |
| NCT01925274 | JAPAN | PFIZER | DRUG | 2. RECRUITING | 2 | 159 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT02021409 | JAPAN | BAYER | DRUG | 2. RECRUITING | 2 | 120 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02055482 | JAPAN | BAYER | DRUG | 2. RECRUITING | 2 | 100 | 18 YEARS | N/A | HEM ANEMIA |
| NCT01856309 | JAPAN | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT01884675 | JAPAN | GSK | DRUG | 2. RECRUITING | 3 | 160 | 18 YEARS | 80 YEARS | CARDIO HYPERTENSION |
| NCT01924533 | JAPAN | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 629 | 18 YEARS | N/A | ONC GI: ESOPHAGEAL/GASTRIC |
| NCT02137850 | JAPAN | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 125 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02168530 | KOREA, SOUTH | HOFFMANN-LA ROCHE | DRUG | 1. PLANNING | 2 | 129 | 40 YEARS | N/A | RESP PULMONARY FIBROSIS |
| NCT02021409 | KOREA, SOUTH | BAYER | DRUG | 2. RECRUITING | 2 | 120 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02055482 | KOREA, SOUTH | BAYER | DRUG | 2. RECRUITING | 2 | 100 | 18 YEARS | N/A | HEM ANEMIA |
| NCT01634139 | KOREA, SOUTH | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01761266 | KOREA, SOUTH | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT01856309 | KOREA, SOUTH | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT01884675 | KOREA, SOUTH | GSK | DRUG | 2. RECRUITING | 3 | 160 | 18 YEARS | 80 YEARS | CARDIO HYPERTENSION |
| NCT01924533 | KOREA, SOUTH | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 629 | 18 YEARS | N/A | ONC GI: ESOPHAGEAL/GASTRIC |
| NCT01999673 | KOREA, SOUTH | PEREGRINE | BIOLOGICAL | 2. RECRUITING | 3 | 582 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02105961 | KOREA, SOUTH | GSK | DRUG | 2. RECRUITING | 3 | 660 | 40 YEARS | N/A | RESP COPD |
| NCT02149199 | KOREA, SOUTH | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT01485614 | LATVIA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01634139 | LATVIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening Additional Sites in a Country, from Page 33

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|-------------|-------------------------|-------------------|---------------|--------------------|----------|----------|----------|-------------------------------|
| NCT01634152 | LATVIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01973790 | LATVIA | ZERIA | DRUG | 2. RECRUITING | 3 | 350 | 18 YEARS | N/A | GI DYSPEPSIA |
| NCT02064868 | LATVIA | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT02104947 | LATVIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02125877 | LEBANON | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT01485614 | LITHUANIA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01634139 | LITHUANIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01634152 | LITHUANIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01856309 | LITHUANIA | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02125877 | MALAYSIA | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT01485614 | MALAYSIA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT02137850 | MALAYSIA | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 125 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02141074 | MALAYSIA | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 50 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02168530 | MEXICO | HOFFMANN-LA ROCHE | DRUG | 1. PLANNING | 2 | 129 | 40 YEARS | N/A | RESP PULMONARY FIBROSIS |
| NCT01904292 | MEXICO | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 48 | 1 YEAR | 17 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT02125877 | MEXICO | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT01485614 | MEXICO | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01856309 | MEXICO | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01884675 | MEXICO | GSK | DRUG | 2. RECRUITING | 3 | 160 | 18 YEARS | 80 YEARS | CARDIO HYPERTENSION |
| NCT02059161 | MEXICO | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 500 | 18 YEARS | N/A | ENDO DIABETES |
| NCT02149199 | MEXICO | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02155660 | MEXICO | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,850 | N/A | N/A | RESP COPD |
| NCT01994291 | MOLDOVA | PFIZER | DRUG | 2. RECRUITING | 2 | 200 | 18 YEARS | N/A | OPHTHAL MACULAR EDEMA |
| NCT02136134 | NETHERLANDS | JANSSEN | DRUG | 1. PLANNING | 3 | 480 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02123823 | NETHERLANDS | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 1 | 198 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT01870609 | NETHERLANDS | VERASTEM | DRUG | 2. RECRUITING | 2 | 372 | 18 YEARS | N/A | ONC RESP: PLEURA |
| NCT01884675 | NETHERLANDS | GSK | DRUG | 2. RECRUITING | 3 | 160 | 18 YEARS | 80 YEARS | CARDIO HYPERTENSION |
| NCT02104947 | NETHERLANDS | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02138916 | NETHERLANDS | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 35)

Studies Opening Additional Sites in a Country, from Page 34

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|-------------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|------------------------------|
| NCT01870609 | NEW ZEALAND | VERASTEM | DRUG | 2. RECRUITING | 2 | 372 | 18 YEARS | N/A | ONC RESP: PLEURA |
| NCT01485614 | NEW ZEALAND | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01966614 | NEW ZEALAND | SOPHIRIS | DRUG | 2. RECRUITING | 3 | 440 | 50 YEARS | N/A | UROLOGY PROSTATE HYPERPLASIA |
| NCT02059161 | NEW ZEALAND | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 500 | 18 YEARS | N/A | ENDO DIABETES |
| NCT02085161 | NEW ZEALAND | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 300 | 40 YEARS | 75 YEARS | RESP COPD |
| NCT02104947 | NEW ZEALAND | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02145468 | NEW ZEALAND | GSK | DRUG | 2. RECRUITING | 3 | 3,500 | 35 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |
| NCT01634139 | NORWAY | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT02145468 | NORWAY | GSK | DRUG | 2. RECRUITING | 3 | 3,500 | 35 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |
| NCT01485614 | PANAMA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT02168530 | PERU | HOFFMANN-LA ROCHE | DRUG | 1. PLANNING | 2 | 129 | 40 YEARS | N/A | RESP PULMONARY FIBROSIS |
| NCT02149199 | PERU | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02155660 | PERU | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,850 | N/A | N/A | RESP COPD |
| NCT01485614 | PHILIPPINES | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT02149199 | PHILIPPINES | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02021409 | POLAND | BAYER | DRUG | 2. RECRUITING | 2 | 120 | 18 YEARS | N/A | HEM ANEMIA |
| NCT01485614 | POLAND | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01634152 | POLAND | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01882439 | POLAND | PFIZER | DRUG | 2. RECRUITING | 3 | 390 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT01976364 | POLAND | PFIZER | DRUG | 2. RECRUITING | 3 | 700 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT01634139 | PORTUGAL | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT02085161 | PORTUGAL | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 300 | 40 YEARS | 75 YEARS | RESP COPD |
| NCT02104947 | PORTUGAL | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02021409 | ROMANIA | BAYER | DRUG | 2. RECRUITING | 2 | 120 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02055482 | ROMANIA | BAYER | DRUG | 2. RECRUITING | 2 | 100 | 18 YEARS | N/A | HEM ANEMIA |
| NCT01485614 | ROMANIA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01634139 | ROMANIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 36)

Studies Opening Additional Sites in a Country, from Page 35

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|--------------|-------------------------|-------------------|---------------|--------------------|----------|----------|----------|-------------------------------|
| NCT01634152 | ROMANIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01999673 | ROMANIA | PEREGRINE | BIOLOGICAL | 2. RECRUITING | 3 | 582 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02064868 | ROMANIA | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT02105961 | ROMANIA | GSK | DRUG | 2. RECRUITING | 3 | 660 | 40 YEARS | N/A | RESP COPD |
| NCT02138916 | ROMANIA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |
| NCT02149199 | ROMANIA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT01904292 | RUSSIA | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 48 | 1 YEAR | 17 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT02125877 | RUSSIA | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT01485614 | RUSSIA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01634139 | RUSSIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01634152 | RUSSIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01856309 | RUSSIA | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01882439 | RUSSIA | PFIZER | DRUG | 2. RECRUITING | 3 | 390 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01884675 | RUSSIA | GSK | DRUG | 2. RECRUITING | 3 | 160 | 18 YEARS | 80 YEARS | CARDIO HYPERTENSION |
| NCT01973790 | RUSSIA | ZERIA | DRUG | 2. RECRUITING | 3 | 350 | 18 YEARS | N/A | GI DYSPEPSIA |
| NCT01999673 | RUSSIA | PEREGRINE | BIOLOGICAL | 2. RECRUITING | 3 | 582 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02064868 | RUSSIA | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT02104947 | RUSSIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02138916 | RUSSIA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |
| NCT02145468 | RUSSIA | GSK | DRUG | 2. RECRUITING | 3 | 3,500 | 35 YEARS | N/A | CARDIO CORONARY/ ISCHEMIC |
| NCT02149199 | RUSSIA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02174731 | RUSSIA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 2,850 | 18 YEARS | N/A | UROLOGY KIDNEY FAILURE |
| NCT02125877 | SAUDI ARABIA | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT01761266 | SINGAPORE | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT01485614 | SLOVAKIA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01882439 | SLOVAKIA | PFIZER | DRUG | 2. RECRUITING | 3 | 390 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01973790 | SLOVAKIA | ZERIA | DRUG | 2. RECRUITING | 3 | 350 | 18 YEARS | N/A | GI DYSPEPSIA |
| NCT02064868 | SLOVAKIA | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT02104947 | SLOVAKIA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See **Studies Opening Additional Sites in a Country**, Page 37)

Studies Opening Additional Sites in a Country, from Page 36

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|--------------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|---------------------------|
| NCT02105961 | SLOVAKIA | GSK | DRUG | 2. RECRUITING | 3 | 660 | 40 YEARS | N/A | RESP COPD |
| NCT02064868 | SLOVENIA | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/FAILURE |
| NCT02059161 | SOUTH AFRICA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 500 | 18 YEARS | N/A | ENDO DIABETES |
| NCT02104947 | SOUTH AFRICA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02149199 | SOUTH AFRICA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02091752 | SPAIN | NOVARTIS | DRUG | 1. PLANNING | 2 | 100 | 18 YEARS | N/A | HEM MYELOFIBROSIS |
| NCT01872260 | SPAIN | NOVARTIS | DRUG | 2. RECRUITING | 1 | 300 | 18 YEARS | N/A | ONC BREAST |
| NCT01904292 | SPAIN | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 48 | 1 YEAR | 17 YEARS | RHEUM ARTHRITIS/GOUT |
| NCT02036502 | SPAIN | MERCK SHARP DOHME | BIOLOGICAL | 2. RECRUITING | 1 | 44 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02165345 | SPAIN | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 96 | 2 YEARS | 18 YEARS | RHEUM ARTHRITIS/GOUT |
| NCT01870609 | SPAIN | VERASTEM | DRUG | 2. RECRUITING | 2 | 372 | 18 YEARS | N/A | ONC RESP: PLEURA |
| NCT02017717 | SPAIN | BMS | BIOLOGICAL | 2. RECRUITING | 2 | 264 | 18 YEARS | N/A | ONC CNS: GLIOMA |
| NCT02021409 | SPAIN | BAYER | DRUG | 2. RECRUITING | 2 | 120 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02055482 | SPAIN | BAYER | DRUG | 2. RECRUITING | 2 | 100 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02125877 | SPAIN | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT01485614 | SPAIN | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01856309 | SPAIN | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT01882439 | SPAIN | PFIZER | DRUG | 2. RECRUITING | 3 | 390 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT01884675 | SPAIN | GSK | DRUG | 2. RECRUITING | 3 | 160 | 18 YEARS | 80 YEARS | CARDIO HYPERTENSION |
| NCT01999673 | SPAIN | PEREGRINE | BIOLOGICAL | 2. RECRUITING | 3 | 582 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02059161 | SPAIN | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 500 | 18 YEARS | N/A | ENDO DIABETES |
| NCT02064868 | SPAIN | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/FAILURE |
| NCT02104947 | SPAIN | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02105636 | SPAIN | BMS | DRUG | 2. RECRUITING | 3 | 180 | 18 YEARS | N/A | ONC ENT: NPC |
| NCT02135692 | SPAIN | GSK | BIOLOGICAL | 2. RECRUITING | 3 | 375 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02137850 | SPAIN | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 125 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02141074 | SPAIN | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 50 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02145468 | SPAIN | GSK | DRUG | 2. RECRUITING | 3 | 3,500 | 35 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |
| NCT02136134 | SWEDEN | JANSSEN | DRUG | 1. PLANNING | 3 | 480 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT01870609 | SWEDEN | VERASTEM | DRUG | 2. RECRUITING | 2 | 372 | 18 YEARS | N/A | ONC RESP: PLEURA |
| NCT01485614 | SWEDEN | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See **Studies Opening Additional Sites in a Country**, Page 38)

Studies Opening Additional Sites in a Country, from Page 37

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|----------------------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|---------------------------|
| NCT01634139 | SWEDEN | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01973790 | SWEDEN | ZERIA | DRUG | 2. RECRUITING | 3 | 350 | 18 YEARS | N/A | GI DYSPEPSIA |
| NCT02064868 | SWEDEN | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/FAILURE |
| NCT02104947 | SWEDEN | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02145468 | SWEDEN | GSK | DRUG | 2. RECRUITING | 3 | 3,500 | 35 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |
| NCT02174731 | SWEDEN | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 2,850 | 18 YEARS | N/A | UROLOGY KIDNEY FAILURE |
| NCT02092467 | SWEDEN | PFIZER | DRUG | 2. RECRUITING | 4 | 4,000 | 50 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT02064868 | SWITZERLAND | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/FAILURE |
| NCT02138916 | SWITZERLAND | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |
| NCT01856309 | TAIWAN | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT01882439 | TAIWAN | PFIZER | DRUG | 2. RECRUITING | 3 | 390 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT01999673 | TAIWAN | PEREGRINE | BIOLOGICAL | 2. RECRUITING | 3 | 582 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02104947 | TAIWAN | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02092467 | TAIWAN | PFIZER | DRUG | 2. RECRUITING | 4 | 4,000 | 50 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT02091752 | THAILAND | NOVARTIS | DRUG | 1. PLANNING | 2 | 100 | 18 YEARS | N/A | HEM MYELOFIBROSIS |
| NCT02125877 | THAILAND | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT01485614 | THAILAND | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT02137850 | THAILAND | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 125 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02141074 | THAILAND | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 50 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02155660 | TURKEY | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,850 | N/A | N/A | RESP COPD |
| NCT02136134 | UKRAINE | JANSSEN | DRUG | 1. PLANNING | 3 | 480 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT01634139 | UKRAINE | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01634152 | UKRAINE | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01856309 | UKRAINE | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT01973790 | UKRAINE | ZERIA | DRUG | 2. RECRUITING | 3 | 350 | 18 YEARS | N/A | GI DYSPEPSIA |
| NCT02145468 | UKRAINE | GSK | DRUG | 2. RECRUITING | 3 | 3,500 | 35 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |
| NCT02125877 | UNITED ARAB EMIRATES | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT01904292 | UK | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 48 | 1 YEAR | 17 YEARS | RHEUM ARTHRITIS/GOUT |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 39)

Studies Opening Additional Sites in a Country, from Page 38

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|---------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|----------------------------|
| NCT02165345 | UK | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 96 | 2 YEARS | 18 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT01870609 | UK | VERASTEM | DRUG | 2. RECRUITING | 2 | 372 | 18 YEARS | N/A | ONC RESP: PLEURA |
| NCT01904058 | UK | LUMENA | DRUG | 2. RECRUITING | 2 | 60 | 18 YEARS | 80 YEARS | GI LIVER CIRRHOSIS |
| NCT02017717 | UK | BMS | BIOLOGICAL | 2. RECRUITING | 2 | 264 | 18 YEARS | N/A | ONC CNS: GLIOMA |
| NCT02021409 | UK | BAYER | DRUG | 2. RECRUITING | 2 | 120 | 18 YEARS | N/A | HEM ANEMIA |
| NCT02055482 | UK | BAYER | DRUG | 2. RECRUITING | 2 | 100 | 18 YEARS | N/A | HEM ANEMIA |
| NCT01856309 | UK | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01882439 | UK | PFIZER | DRUG | 2. RECRUITING | 3 | 390 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01884675 | UK | GSK | DRUG | 2. RECRUITING | 3 | 160 | 18 YEARS | 80 YEARS | CARDIO HYPERTENSION |
| NCT01973790 | UK | ZERIA | DRUG | 2. RECRUITING | 3 | 350 | 18 YEARS | N/A | GI DYSPEPSIA |
| NCT02064868 | UK | NOVARTIS | DRUG | 2. RECRUITING | 3 | 2,685 | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT02085161 | UK | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 300 | 40 YEARS | 75 YEARS | RESP COPD |
| NCT02104947 | UK | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | N/A | HEM HEMORRHAGE |
| NCT02105636 | UK | BMS | DRUG | 2. RECRUITING | 3 | 180 | 18 YEARS | N/A | ONC ENT: NPC |
| NCT02138916 | UK | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |
| NCT02149199 | UK | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02168530 | USA | HOFFMANN-LA ROCHE | DRUG | 1. PLANNING | 2 | 129 | 40 YEARS | N/A | RESP PULMONARY FIBROSIS |
| NCT02136134 | USA | JANSSEN | DRUG | 1. PLANNING | 3 | 480 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT01107522 | USA | TACTICAL | DRUG | 2. RECRUITING | 1 | MISS-ING | 18 YEARS | N/A | ONC CNS: GLIOMA |
| NCT01872260 | USA | NOVARTIS | DRUG | 2. RECRUITING | 1 | 300 | 18 YEARS | N/A | ONC BREAST |
| NCT01904292 | USA | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 48 | 1 YEAR | 17 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT02036502 | USA | MERCK SHARP DOHME | BIOLOGICAL | 2. RECRUITING | 1 | 44 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02060188 | USA | BMS | DRUG | 2. RECRUITING | 1 | 96 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT02165345 | USA | HOFFMANN-LA ROCHE | DRUG | 2. RECRUITING | 1 | 96 | 2 YEARS | 18 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT01870609 | USA | VERASTEM | DRUG | 2. RECRUITING | 2 | 372 | 18 YEARS | N/A | ONC RESP: PLEURA |
| NCT01904058 | USA | LUMENA | DRUG | 2. RECRUITING | 2 | 60 | 18 YEARS | 80 YEARS | GI LIVER CIRRHOSIS |
| NCT01925274 | USA | PFIZER | DRUG | 2. RECRUITING | 2 | 159 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT01994291 | USA | PFIZER | DRUG | 2. RECRUITING | 2 | 200 | 18 YEARS | N/A | OPHTHAL MACULAR EDEMA |
| NCT01998828 | USA | GILEAD | DRUG | 2. RECRUITING | 2 | 80 | 18 YEARS | N/A | HEM POLYCYTHEMIA VERA |
| NCT02017717 | USA | BMS | BIOLOGICAL | 2. RECRUITING | 2 | 264 | 18 YEARS | N/A | ONC CNS: GLIOMA |
| NCT02038647 | USA | MILLENNIUM | DRUG | 2. RECRUITING | 2 | 166 | 18 YEARS | N/A | ONC RESP: LUNG |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening Additional Sites in a Country, from Page 39

| IDENTIFIER ¹ | COUNTRY | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|---------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|------------------------------|
| NCT02125877 | USA | NOVARTIS | DRUG | 2. RECRUITING | 2 | 150 | 10 YEARS | N/A | HEM ANEMIA IRON |
| NCT02174861 | USA | AMGEN | DRUG | 2. RECRUITING | 2 | 490 | 18 YEARS | 60 YEARS | NEUR MIGRAINE/H-ACHE |
| NCT01485614 | USA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 170 | 10 YEARS | 17 YEARS | ENDO DIABETES |
| NCT01634139 | USA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 381 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01634152 | USA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 375 | 6 YEARS | 11 YEARS | ALLERGY ALLERGY |
| NCT01761266 | USA | EISAI | DRUG | 2. RECRUITING | 3 | 940 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT01850524 | USA | MILLENNIUM | DRUG | 2. RECRUITING | 3 | 701 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT01856309 | USA | JANSSEN | DRUG | 2. RECRUITING | 3 | 2,243 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT01882439 | USA | PFIZER | DRUG | 2. RECRUITING | 3 | 390 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT01884675 | USA | GSK | DRUG | 2. RECRUITING | 3 | 160 | 18 YEARS | 80 YEARS | CARDIO HYPERTENSION |
| NCT01955733 | USA | BOEHRINGER INGELHEIM | DRUG | 2. RECRUITING | 3 | 250 | 18 YEARS | 82 YEARS | RHEUM ARTHRITIS/GOUT |
| NCT01966614 | USA | SOPHRIS | DRUG | 2. RECRUITING | 3 | 440 | 50 YEARS | N/A | UROLOGY PROSTATE HYPERPLASIA |
| NCT01976364 | USA | PFIZER | DRUG | 2. RECRUITING | 3 | 700 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT01980888 | USA | GILEAD | DRUG | 2. RECRUITING | 3 | 280 | 18 YEARS | N/A | ONC HEM: LEUKEMIA |
| NCT01999673 | USA | PEREGRINE | BIOLOGICAL | 2. RECRUITING | 3 | 582 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02032277 | USA | ABBVIE | DRUG | 2. RECRUITING | 3 | 624 | 18 YEARS | N/A | ONC BREAST |
| NCT02059161 | USA | MERCK SHARP DOHME | DRUG | 2. RECRUITING | 3 | 500 | 18 YEARS | N/A | ENDO DIABETES |
| NCT02065791 | USA | JANSSEN | DRUG | 2. RECRUITING | 3 | 3,627 | 30 YEARS | N/A | ENDO DIABETES |
| NCT02094586 | USA | PAXVAX | BIOLOGICAL | 2. RECRUITING | 3 | 2,964 | 18 YEARS | 45 YEARS | INFECT CHOLERA |
| NCT02100631 | USA | PAXVAX | BIOLOGICAL | 2. RECRUITING | 3 | 400 | 46 YEARS | 64 YEARS | INFECT CHOLERA |
| NCT02105636 | USA | BMS | DRUG | 2. RECRUITING | 3 | 180 | 18 YEARS | N/A | ONC ENT: NPC |
| NCT02105961 | USA | GSK | DRUG | 2. RECRUITING | 3 | 660 | 40 YEARS | N/A | RESP COPD |
| NCT02135692 | USA | GSK | BIOLOGICAL | 2. RECRUITING | 3 | 375 | 12 YEARS | N/A | ALLERGY ALLERGY |
| NCT02137850 | USA | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 125 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02138916 | USA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 3,758 | 40 YEARS | 85 YEARS | RESP COPD |
| NCT02141074 | USA | NOVO NORDISK | DRUG | 2. RECRUITING | 3 | 50 | N/A | 6 YEARS | CARDIO THROMB/COAG |
| NCT02155660 | USA | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,850 | N/A | N/A | RESP COPD |
| NCT02092467 | USA | PFIZER | DRUG | 2. RECRUITING | 4 | 4,000 | 50 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT00966979 | USA | STRYKER | DEVICE | 2. RECRUITING | NA | 184 | 21 YEARS | 75 YEARS | ORTH HIP/KNEE REPLACEMENT |
| NCT02149199 | VIETNAM | ASTRAZENECA | DRUG | 2. RECRUITING | 3 | 4,875 | 12 YEARS | N/A | ALLERGY ALLERGY |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

STUDY SITES BY COUNTRY

This table lists all countries with first-time and additional study sites that launched in the past week.

| COUNTRY | STUDIES OPENING A FIRST SITE IN A NEW COUNTRY | STUDIES OPENING ADDITIONAL SITES IN A COUNTRY | TOTAL TRIALS | COUNTRY | STUDIES OPENING A FIRST SITE IN A NEW COUNTRY | STUDIES OPENING ADDITIONAL SITES IN A COUNTRY | TOTAL TRIALS |
|-----------------------|---|---|-----------------|-------------------------|---|---|-----------------|
| ALGERIA | 0 | 2 | 2 | MALAYSIA | 1 | 4 | 5 |
| ARGENTINA | 5 | 7 | 12 | MEXICO | 5 | 9 | 14 |
| AUSTRALIA | 13 | 17 | 30 | MOLDOVA, REPUBLIC OF | 0 | 1 | 1 |
| AUSTRIA w | 4 | 10 | 14 | NETHERLANDS | 6 | 6 | 12 |
| BELGIUM | 9 | 14 | 23 | NEW ZEALAND | 0 | 7 | 7 |
| BRAZIL | 1 | 4 | 5 | NORWAY | 0 | 2 | 2 |
| BULGARIA | 1 | 8 | 9 | PANAMA | 0 | 1 | 1 |
| CANADA | 16 | 17 | 33 | PERU | 2 | 3 | 5 |
| CHILE | 1 | 3 | 4 | PHILIPPINES | 1 | 2 | 3 |
| CHINA | 2 | 2 | 4 | POLAND | 11 | 5 | 16 |
| COLOMBIA | 2 | 2 | 4 | PORTUGAL | 2 | 3 | 5 |
| CROATIA | 1 | 1 | 2 | QATAR | 1 | 0 | 1 |
| CZECH REPUBLIC | 6 | 6 | 12 | ROMANIA | 3 | 10 | 13 |
| DENMARK | 3 | 5 | 8 | RUSSIA | 6 | 16 | 22 |
| DOMINICAN REPUBLIC | 0 | 1 | 1 | SAUDI ARABIA | 0 | 1 | 1 |
| ESTONIA | 2 | 1 | 3 | SERBIA | 1 | 0 | 1 |
| FINLAND | 0 | 1 | 1 | SINGAPORE | 2 | 1 | 3 |
| FRANCE | 18 | 14 | 32 | SLOVAKIA | 1 | 6 | 7 |
| GERMANY | 17 | 23 | 40 | SLOVENIA | 0 | 1 | 1 |
| GREECE | 1 | 1 | 2 | SOUTH AFRICA | 1 | 3 | 4 |
| GUATEMALA | 0 | 3 | 3 | SPAIN | 11 | 23 | 34 |
| HONG KONG | 2 | 3 | 5 | SWEDEN | 4 | 10 | 14 |
| HUNGARY | 6 | 9 | 15 | SWITZERLAND | 7 | 2 | 9 |
| IRELAND | 3 | 2 | 5 | TAIWAN | 2 | 5 | 7 |
| ISRAEL | 7 | 4 | 11 | THAILAND | 1 | 5 | 6 |
| ITALY | 7 | 13 | 20 | TURKEY | 1 | 1 | 2 |
| JAPAN | 7 | 8 | 15 | UKRAINE | 6 | 6 | 12 |
| KAZAKHSTAN | 1 | 0 | 1 | UNITED ARAB EMIRATES | 0 | 1 | 1 |
| KOREA, SOUTH | 7 | 11 | 18 | UNITED KINGDOM | 17 | 17 | 34 |
| LATVIA | 0 | 6 | 6 | UNITED STATES | 55 | 44 | 99 |
| LEBANON | 0 | 1 | 1 | VIETNAM | 0 | 1 | 1 |
| LITHUANIA | 2 | 4 | 6 | | | | |

(Return to Page 1)

STUDIES UNDER PLANNING

This table lists all registered studies that are still under planning, have no site location listed and was first registered during the past year. About 10% of the studies listed as in the planning stage are replaced each week.

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|--------------------------|-------------------|-------------|--------------------|----------|----------|----------|--------------------------|
| NCT01949285 | NEUROENABLING | DEVICE | 1. PLANNING | 0 | 24 | 21 YEARS | 65 YEARS | ORTH SPINAL CORD INJURY |
| NCT01882296 | AHN-GOOK | DRUG | 1. PLANNING | 1 | 40 | 20 YEARS | 45 YEARS | HEALTHY/PHARM |
| NCT01902550 | JANSSEN | DRUG | 1. PLANNING | 1 | 12 | 18 YEARS | 45 YEARS | HEALTHY/PHARM |
| NCT01924091 | PARTNERSHIP MICROBICIDES | DRUG | 1. PLANNING | 1 | MISSING | 18 YEARS | N/A | HEALTHY/PHARM |
| NCT01926002 | MERCK SHARP DOHME | DRUG | 1. PLANNING | 1 | 16 | 18 YEARS | 55 YEARS | ALLERGY ALLERGY |
| NCT01938456 | GSK | DRUG | 1. PLANNING | 1 | 6 | 20 YEARS | N/A | ONC RESP: LUNG |
| NCT01952561 | PARTNERSHIP MICROBICIDES | DRUG | 1. PLANNING | 1 | 40 | 18 YEARS | 40 YEARS | HEALTHY/PHARM |
| NCT01953809 | GSK | DRUG | 1. PLANNING | 1 | 24 | 18 YEARS | 45 YEARS | INFECT BACTERIAL |
| NCT02023125 | HOFFMANN-LA ROCHE | DRUG | 1. PLANNING | 1 | 40 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02026271 | ZIOPHARM | BIOLOGICAL | 1. PLANNING | 1 | 48 | 18 YEARS | 75 YEARS | ONC CNS: GLIOMA |
| NCT02034292 | ILDONG | DRUG | 1. PLANNING | 1 | 88 | 20 YEARS | 45 YEARS | CARDIO CORONARY/ISCHEMIC |
| NCT02035358 | NEWLINK GENETICS | BIOLOGICAL | 1. PLANNING | 1 | 20 | 18 YEARS | N/A | ONC UROLOGY: KIDNEY |
| NCT02045732 | PFIZER | BIOLOGICAL | 1. PLANNING | 1 | 60 | 18 YEARS | 55 YEARS | NEUR MULTIPLE SCLEROSIS |
| NCT02056015 | MILLENNIUM | DRUG | 1. PLANNING | 1 | 20 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT02061358 | UNITHER | DRUG | 1. PLANNING | 1 | 64 | 18 YEARS | 45 YEARS | INFECT DENGUE |
| NCT02063360 | BMS | DRUG | 1. PLANNING | 1 | 42 | 18 YEARS | 50 YEARS | INFECT HIV/AIDS |
| NCT02065063 | GSK | DRUG | 1. PLANNING | 1 | 90 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT02073019 | BIOLINERX | DRUG | 1. PLANNING | 1 | 40 | 18 YEARS | 45 YEARS | HEM BONE MARROW |
| NCT02074358 | BMS | DRUG | 1. PLANNING | 1 | 15 | 18 YEARS | 45 YEARS | CARDIO THROMB/ COAG |
| NCT02077452 | HUA MEDICINE | DRUG | 1. PLANNING | 1 | 80 | 18 YEARS | 65 YEARS | ENDO DIABETES |
| NCT02077881 | NEWLINK GENETICS | DRUG | 1. PLANNING | 1 | 98 | 18 YEARS | N/A | ONC GI: PANCREAS |
| NCT02082665 | GSK | DRUG | 1. PLANNING | 1 | 16 | 18 YEARS | 65 YEARS | ONC SOLID TUMOR/ CANCER |
| NCT02088684 | NOVARTIS | DRUG | 1. PLANNING | 1 | 216 | 18 YEARS | N/A | ONC BREAST |
| NCT02089061 | BMS | DRUG | 1. PLANNING | 1 | 26 | 18 YEARS | 55 YEARS | CARDIO CORONARY/ISCHEMIC |
| NCT02089334 | REXAHN | DRUG | 1. PLANNING | 1 | 39 | 18 YEARS | N/A | ONC UROLOGY: KIDNEY |
| NCT02091388 | LUYE | DRUG | 1. PLANNING | 1 | 70 | 18 YEARS | 65 YEARS | PSYCH SCHIZOPHRENIA |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Under Planning, from Page 42

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|----------------------|-------------------|-------------|--------------------|----------|----------|----------|----------------------------|
| NCT02093351 | ASTRAZENECA | DRUG | 1. PLANNING | 1 | 75 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT02095574 | ABBVIE | DRUG | 1. PLANNING | 1 | 4 | 18 YEARS | N/A | ONC HEM: LYMPHOMA |
| NCT02097433 | PFIZER | DRUG | 1. PLANNING | 1 | 14 | 18 YEARS | 45 YEARS | HEALTHY/PHARM |
| NCT02103569 | BMS | DRUG | 1. PLANNING | 1 | 22 | 18 YEARS | 40 YEARS | INFECT HEPATITIS C |
| NCT02104843 | BMS | DRUG | 1. PLANNING | 1 | 18 | 18 YEARS | 45 YEARS | INFECT HEPATITIS C |
| NCT02106000 | GSK | DEVICE | 1. PLANNING | 1 | 40 | 18 YEARS | 30 YEARS | NEUR HEMORRHAGE |
| NCT02106143 | CSA | DEVICE | 1. PLANNING | 1 | 15 | 21 YEARS | 75 YEARS | ONC RESP: LUNG |
| NCT02106897 | BIOGEN | DRUG | 1. PLANNING | 1 | 64 | 18 YEARS | N/A | RHEUM LUPUS ERYTHEM. |
| NCT02109445 | PFIZER | DRUG | 1. PLANNING | 1 | 193 | 18 YEARS | N/A | ONC GI: PANCREAS |
| NCT02110355 | AMGEN | DRUG | 1. PLANNING | 1 | 146 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT02114203 | PFIZER | DRUG | 1. PLANNING | 1 | 64 | 18 YEARS | 65 YEARS | HEM ANEMIA SICKLE CELL |
| NCT02115347 | MERCK SHARP DOHME | DRUG | 1. PLANNING | 1 | 24 | 18 YEARS | 75 YEARS | ENDO DIABETES |
| NCT02118337 | MEDIMMUNE | BIOLOGICAL | 1. PLANNING | 1 | 150 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT02122146 | PFIZER | DRUG | 1. PLANNING | 1 | 130 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT02124213 | PFIZER | DRUG | 1. PLANNING | 1 | 15 | 20 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02124772 | GSK | DRUG | 1. PLANNING | 1 | 94 | 1 MONTH | 17 YEARS | ONC SOLID TUMOR/ CANCER |
| NCT02125084 | SCRI | DRUG | 1. PLANNING | 1 | 43 | 18 YEARS | N/A | ONC UROLOGY: PROSTATE |
| NCT02125227 | YUHAN | DRUG | 1. PLANNING | 1 | 56 | 19 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02130661 | GSK | DRUG | 1. PLANNING | 1 | 30 | 18 YEARS | 65 YEARS | NEUR ALZHEIMER/ DEMENT |
| NCT02132754 | MERCK SHARP DOHME | BIOLOGICAL | 1. PLANNING | 1 | 75 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT02133742 | PFIZER | DRUG | 1. PLANNING | 1 | 60 | 18 YEARS | 95 YEARS | ONC UROLOGY: KIDNEY |
| NCT02135640 | GSK | DRUG | 1. PLANNING | 1 | 64 | 18 YEARS | 65 YEARS | ENDO OSTEOPOROSIS |
| NCT02140554 | BLUEBIRD | GENETIC | 1. PLANNING | 1 | 8 | 18 YEARS | N/A | HEM ANEMIA SICKLE CELL |
| NCT02142920 | PFIZER | DRUG | 1. PLANNING | 1 | 6 | 30 YEARS | 65 YEARS | HEALTHY/PHARM |
| NCT02143466 | ASTRAZENECA | DRUG | 1. PLANNING | 1 | 300 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02145234 | BMS | DRUG | 1. PLANNING | 1 | 144 | 21 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02146391 | REPROS | DRUG | 1. PLANNING | 1 | 12 | 18 YEARS | 60 YEARS | HEALTHY/PHARM |
| NCT02146625 | CJ HEALTHCARE | DRUG | 1. PLANNING | 1 | 40 | 19 YEARS | 45 YEARS | HEALTHY/PHARM |
| NCT02152332 | JANSSEN | DRUG | 1. PLANNING | 1 | 64 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Under Planning, Page 44)

Studies Under Planning, from Page 43

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|-------------------|-------------------|-------------|--------------------|----------|----------|----------|--------------------------|
| NCT02155582 | BAYER | DRUG | 1. PLANNING | 1 | 60 | 18 YEARS | N/A | ONC HEM: LYMPHOMA |
| NCT02157324 | ACERTA | DRUG | 1. PLANNING | 1 | 12 | 18 YEARS | N/A | ONC HEM: LEUKEMIA |
| NCT02157467 | BMS | DRUG | 1. PLANNING | 1 | 22 | 18 YEARS | 40 YEARS | INFECT HIV/AIDS |
| NCT02157558 | LEXICON | DRUG | 1. PLANNING | 1 | 24 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02157883 | ASTRAZENECA | PROCEDURE | 1. PLANNING | 1 | 38 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02159131 | VIIV | DRUG | 1. PLANNING | 1 | 24 | 18 YEARS | 45 YEARS | INFECT HIV/AIDS |
| NCT02161510 | MERCK SHARP DOHME | DRUG | 1. PLANNING | 1 | 30 | 18 YEARS | 65 YEARS | INFECT HEPATITIS C |
| NCT02161770 | ASTRAZENECA | DRUG | 1. PLANNING | 1 | 30 | 18 YEARS | N/A | ONC SOLID TUMOR/CANCER |
| NCT02163733 | ASTRAZENECA | DRUG | 1. PLANNING | 1 | 38 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02163915 | TAKEDA | DRUG | 1. PLANNING | 1 | 50 | 18 YEARS | 55 YEARS | PSYCH ADHD |
| NCT02164045 | BMS | DRUG | 1. PLANNING | 1 | 18 | 18 YEARS | 50 YEARS | INFECT HIV/AIDS |
| NCT02170012 | PFIZER | DRUG | 1. PLANNING | 1 | 60 | 65 YEARS | 85 YEARS | HEALTHY/PHARM |
| NCT02170220 | TAKEDA | DRUG | 1. PLANNING | 1 | 16 | 18 YEARS | 75 YEARS | GI LIVER FAILURE |
| NCT02170337 | AMGEN | DRUG | 1. PLANNING | 1 | 84 | 18 YEARS | 65 YEARS | ENT NASAL POLYPS |
| NCT02173392 | AMGEN | DRUG | 1. PLANNING | 1 | 140 | 18 YEARS | 55 YEARS | HEALTHY/PHARM |
| NCT02174159 | MERCK SHARP DOHME | DRUG | 1. PLANNING | 1 | 18 | 18 YEARS | 60 YEARS | INFECT HIV/AIDS |
| NCT02174172 | HOFFMANN-LA ROCHE | DRUG | 1. PLANNING | 1 | 200 | 18 YEARS | N/A | ONC SOLID TUMOR/CANCER |
| NCT02175433 | AGENSYS | DRUG | 1. PLANNING | 1 | 85 | 18 YEARS | N/A | ONC HEM: LYMPHOMA |
| NCT02175602 | BMS | DRUG | 1. PLANNING | 1 | 41 | 25 YEARS | 55 YEARS | INFECT HEPATITIS C |
| NCT02176486 | TAKEDA | DRUG | 1. PLANNING | 1 | 40 | 18 YEARS | 75 YEARS | RHEUM LUPUS ERYTHEM. |
| NCT02177682 | GSK | DRUG | 1. PLANNING | 1 | 18 | 20 YEARS | N/A | ONC HEM: CANCER |
| NCT02177734 | GSK | BIOLOGICAL | 1. PLANNING | 1 | 420 | 18 YEARS | 60 YEARS | INFECT INFLUENZA/FLU |
| NCT02177812 | GSK | DRUG | 1. PLANNING | 1 | 100 | 18 YEARS | N/A | ONC HEM: LEUKEMIA |
| NCT02178059 | ASTRAZENECA | DRUG | 1. PLANNING | 1 | 34 | 18 YEARS | 65 YEARS | ALLERGY ALLERGY |
| NCT02180061 | MERCK SHARP DOHME | BIOLOGICAL | 1. PLANNING | 1 | 35 | 20 YEARS | N/A | ONC DERM: MELANOMA |
| NCT02181803 | MERCK SHARP DOHME | DRUG | 1. PLANNING | 1 | 48 | 18 YEARS | 60 YEARS | PSYCH SCHIZOPHRENIA |
| NCT01915472 | IMMUNOMEDICS | DRUG | 1. PLANNING | 2 | 50 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT01956669 | GSK | DRUG | 1. PLANNING | 2 | 154 | 1 YEAR | 18 YEARS | ONC SOLID TUMOR/CANCER |
| NCT01967251 | TAKEDA | DRUG | 1. PLANNING | 2 | 950 | 45 YEARS | N/A | UROLOGY ERECTILE |
| NCT01982318 | TISSUE THERAPIES | DRUG | 1. PLANNING | 2 | 250 | 18 YEARS | N/A | DERM WOUND/ULCER |
| NCT01995487 | MEDINOL | DEVICE | 1. PLANNING | 2 | 1,906 | 18 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Under Planning, from Page 44

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-------------------|-------------------|-------------|--------------------|----------|----------|----------|---------------------------|
| NCT01995500 | MEDINOL | DEVICE | 1. PLANNING | 2 | 300 | 18 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |
| NCT02004691 | GENZYME | DRUG | 1. PLANNING | 2 | 15 | 18 YEARS | N/A | ENDO LIPIDOSIS |
| NCT02011269 | CORONADO | BIOLOGICAL | 1. PLANNING | 2 | 25 | 18 YEARS | 75 YEARS | DERM PSORIASIS |
| NCT02021474 | BIOHEALTHONOMICS | DRUG | 1. PLANNING | 2 | 130 | 18 YEARS | 65 YEARS | NEUR MIGRAINE/H-ACHE |
| NCT02037555 | GRIFOLS | BIOLOGICAL | 1. PLANNING | 2 | 404 | 18 YEARS | N/A | CARDIO CARDIOMYOP/FAILURE |
| NCT02038569 | LEO | DRUG | 1. PLANNING | 2 | 100 | 12 YEARS | 17 YEARS | DERM PSORIASIS |
| NCT02044822 | GILEAD | DRUG | 1. PLANNING | 2 | 100 | 18 YEARS | N/A | ONC HEM: LEUKEMIA |
| NCT02049450 | NOVARTIS | DRUG | 1. PLANNING | 2 | 30 | 18 YEARS | N/A | HEM THALASSEMIA |
| NCT02053883 | BIOAXONE | DRUG | 1. PLANNING | 2 | MISSING | 18 YEARS | 62 YEARS | ORTH SPINAL CORD INJURY |
| NCT02075541 | GSK | BIOLOGICAL | 1. PLANNING | 2 | 140 | 40 YEARS | 80 YEARS | RESP DISEASE |
| NCT02085005 | SANOFI | DRUG | 1. PLANNING | 2 | 120 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT02091206 | GW | DRUG | 1. PLANNING | 2 | 30 | 4 YEARS | 10 YEARS | NEUR EPILEPSY/SEIZURE |
| NCT02093468 | MAST THERAPEUTICS | DRUG | 1. PLANNING | 2 | 60 | 30 YEARS | 80 YEARS | CARDIO ARTERIAL DISEASE |
| NCT02104583 | GILEAD | DRUG | 1. PLANNING | 2 | 210 | 18 YEARS | 80 YEARS | CARDIO ARRHYT/FIBRILL |
| NCT02106650 | SPECTRUM | DRUG | 1. PLANNING | 2 | 20 | 18 YEARS | N/A | ONC HEM: LYMPHOMA |
| NCT02108262 | CSL BEHRING | BIOLOGICAL | 1. PLANNING | 2 | 1,200 | 18 YEARS | N/A | CARDIO INFARCT |
| NCT02109016 | CLOVIS ONCOLOGY | DRUG | 1. PLANNING | 2 | 40 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02112838 | RIGEL | DRUG | 1. PLANNING | 2 | 75 | 18 YEARS | 70 YEARS | UROLOGY KIDNEY NEPHRITIS |
| NCT02113735 | QUESTCOR | DRUG | 1. PLANNING | 2 | 210 | 18 YEARS | N/A | RESP RDS |
| NCT02116660 | MERCK SHARP DOHME | DRUG | 1. PLANNING | 2 | 100 | 18 YEARS | N/A | INFECT HIV/AIDS |
| NCT02117570 | PFIZER | BIOLOGICAL | 1. PLANNING | 2 | 707 | 65 YEARS | 85 YEARS | INFECT CLOSTRIDIUM |
| NCT02124668 | ASTELLAS | DRUG | 1. PLANNING | 2 | 30 | N/A | N/A | ONC UROLOGY: PROSTATE |
| NCT02128490 | TAKEDA | DRUG | 1. PLANNING | 2 | 200 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT02128958 | CAN-FITE | DRUG | 1. PLANNING | 2 | 78 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT02129777 | TAKEDA | DRUG | 1. PLANNING | 2 | 100 | 18 YEARS | 70 YEARS | DERM PSORIASIS |
| NCT02130635 | GSK | DRUG | 1. PLANNING | 2 | 30 | 40 YEARS | 75 YEARS | RESP COPD |
| NCT02131142 | BIOSENSORS | DEVICE | 1. PLANNING | 2 | 100 | 18 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |
| NCT02132468 | OXIGENE | DRUG | 1. PLANNING | 2 | 20 | 18 YEARS | N/A | ONC ENDO: NEUROENDO |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Under Planning, from Page 45

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|-------------------|-------------------|-------------|--------------------|----------|----------|----------|---------------------------|
| NCT02135445 | MILLENNIUM | DRUG | 1. PLANNING | 2 | 100 | 18 YEARS | N/A | ONC UROLOGY: PROSTATE |
| NCT02137239 | BMS | DRUG | 1. PLANNING | 2 | 240 | 18 YEARS | 75 YEARS | UROLOGY KIDNEY TRANSPLANT |
| NCT02138786 | KARYOPHARM | DRUG | 1. PLANNING | 2 | 50 | 18 YEARS | N/A | ONC HEM: LEUKEMIA |
| NCT02141282 | ABBVIE | DRUG | 1. PLANNING | 2 | 40 | 18 YEARS | N/A | ONC HEM: LEUKEMIA |
| NCT02142192 | BIOGEN | DRUG | 1. PLANNING | 2 | 113 | 18 YEARS | 65 YEARS | NEUR MULTIPLE SCLEROSIS |
| NCT02142504 | TAKEDA | BIOLOGICAL | 1. PLANNING | 2 | 650 | 18 YEARS | 49 YEARS | INFECT NOROVIRUS |
| NCT02145182 | ALEXION | DRUG | 1. PLANNING | 2 | 286 | 18 YEARS | N/A | IMMUNE GRAFT VS. HOST |
| NCT02150343 | CIRCASSIA | DRUG | 1. PLANNING | 2 | 660 | 18 YEARS | 65 YEARS | ALLERGY CONJUNCTIVITIS |
| NCT02151682 | GRENENTHAL | DRUG | 1. PLANNING | 2 | 200 | 6 YEARS | 17 YEARS | ANEST PAIN |
| NCT02153112 | TAKEDA | BIOLOGICAL | 1. PLANNING | 2 | 1,210 | 6 WEEKS | 8 YEARS | INFECT NOROVIRUS |
| NCT02154087 | SMITH & NEPHEW | BIOLOGICAL | 1. PLANNING | 2 | 25 | 18 YEARS | N/A | DERM WOUND/ULCER |
| NCT02155322 | MERCK SHARP DOHME | BIOLOGICAL | 1. PLANNING | 2 | 30 | 18 YEARS | N/A | ONC DERM: MELANOMA |
| NCT02156076 | BMS | DRUG | 1. PLANNING | 2 | 80 | 18 YEARS | 75 YEARS | CARDIO ARRHYT/ FIBRILL |
| NCT02156804 | BMS | DRUG | 1. PLANNING | 2 | 1,800 | 18 YEARS | N/A | ONC DERM: MELANOMA |
| NCT02157922 | ALGIPHARMA | DRUG | 1. PLANNING | 2 | 76 | 18 YEARS | N/A | RESP CYSTIC FIBROSIS |
| NCT02159365 | BMS | DRUG | 1. PLANNING | 2 | 76 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02161679 | IMMUNOMEDICS | DRUG | 1. PLANNING | 2 | 80 | 18 YEARS | 90 YEARS | ONC BREAST |
| NCT02163876 | STEMCELLS | DRUG | 1. PLANNING | 2 | MISSING | 18 YEARS | 60 YEARS | ORTH SPINAL CORD INJURY |
| NCT02164539 | GSK | DRUG | 1. PLANNING | 2 | 266 | 18 YEARS | N/A | RESP COPD |
| NCT02168101 | SCRI | DRUG | 1. PLANNING | 2 | 38 | 18 YEARS | 70 YEARS | ONC HEM: MYELOMA |
| NCT02174276 | GILEAD | DRUG | 1. PLANNING | 2 | 175 | 18 YEARS | N/A | INFECT HEPATITIS B |
| NCT02175121 | PFIZER | DRUG | 1. PLANNING | 2 | 160 | 18 YEARS | 70 YEARS | ENDO DIABETES |
| NCT02175966 | BMS | DRUG | 1. PLANNING | 2 | 30 | 18 YEARS | N/A | INFECT HEPATITIS C |
| NCT02176863 | GRIFOLS | BIOLOGICAL | 1. PLANNING | 2 | 210 | 18 YEARS | 75 YEARS | INFECT POLIO |
| NCT02177136 | INTERCEPT | DRUG | 1. PLANNING | 2 | 75 | 18 YEARS | 75 YEARS | GI BILIARY DISEASE |
| NCT02181634 | PRECOG | DRUG | 1. PLANNING | 2 | 70 | 18 YEARS | N/A | ONC GI: BILIARY |
| NCT02181738 | BMS | DRUG | 1. PLANNING | 2 | 120 | 18 YEARS | N/A | ONC HEM: LYMPHOMA |
| NCT01875874 | VITAL THER. | DRUG | 1. PLANNING | 3 | 126 | 18 YEARS | 65 YEARS | GI LIVER FAILURE |
| NCT01882712 | GALDERMA | DRUG | 1. PLANNING | 3 | 84 | 18 YEARS | N/A | DERM ROSACEA |
| NCT01911858 | BBRAUN MEDICAL | DEVICE | 1. PLANNING | 3 | 40 | 18 YEARS | N/A | DERM BURNS |
| NCT01913353 | BAVARIAN NORDIC | BIOLOGICAL | 1. PLANNING | 3 | MISSING | 18 YEARS | 40 YEARS | HEALTHY/PHARM |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Under Planning, Page 47)

Studies Under Planning, from Page 46

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|----------------------|-------------------|-------------|--------------------|----------|----------|----------|----------------------------|
| NCT01938144 | PFIZER | DRUG | 1. PLANNING | 3 | 750 | 18 YEARS | N/A | INFECT INFLUENZA/FLU |
| NCT01979510 | MERCK SHARP DOHME | DRUG | 1. PLANNING | 3 | 100 | 18 YEARS | 75 YEARS | ORTH BACK PAIN |
| NCT01980875 | GILEAD | DRUG | 1. PLANNING | 3 | 176 | 65 YEARS | N/A | ONC HEM: LEUKEMIA |
| NCT01984606 | BOEHRINGER INGELHEIM | DRUG | 1. PLANNING | 3 | 834 | 18 YEARS | N/A | ENDO DIABETES |
| NCT01990469 | LG LIFE | DRUG | 1. PLANNING | 3 | 174 | 19 YEARS | N/A | ENDO DIABETES |
| NCT01997268 | SANCILIO | DRUG | 1. PLANNING | 3 | 320 | 18 YEARS | N/A | CARDIO CHOLESTEROL/LIPIDS |
| NCT02003144 | ALEXION | BIOLOGICAL | 1. PLANNING | 3 | 132 | 18 YEARS | N/A | OPHTHAL OPTIC NERV DISEASE |
| NCT02006121 | STADA | DRUG | 1. PLANNING | 3 | 102 | 30 YEARS | N/A | NEUR PARKINSON |
| NCT02009423 | AB SCIENCE | DRUG | 1. PLANNING | 3 | 330 | 18 YEARS | N/A | ONC GI: GASTROINTESTINAL |
| NCT02012959 | OTSUKA | DRUG | 1. PLANNING | 3 | 100 | N/A | 18 YEARS | ENDO HYPONATREMIA |
| NCT02014584 | GSK | DRUG | 1. PLANNING | 3 | 700 | 18 YEARS | 50 YEARS | DERM HAIR LOSS |
| NCT02020278 | OTSUKA | DRUG | 1. PLANNING | 3 | 140 | N/A | 18 YEARS | ENDO HYPONATREMIA |
| NCT02027012 | BOSTON SCIENTIFIC | DEVICE | 1. PLANNING | 3 | 60 | 18 YEARS | 75 YEARS | CARDIO HYPERTENSION |
| NCT02027701 | CSL BEHRING | BIOLOGICAL | 1. PLANNING | 3 | 70 | 18 YEARS | N/A | NEUR NEUROPATHY |
| NCT02040415 | DAEWON | DRUG | 1. PLANNING | 3 | MISSING | 18 YEARS | N/A | ORTH BACK PAIN |
| NCT02040935 | HOFFMANN-LA ROCHE | DRUG | 1. PLANNING | 3 | 128 | 18 YEARS | N/A | ONC BREAST |
| NCT02052219 | ANTHERA | DRUG | 1. PLANNING | 3 | 150 | 18 YEARS | N/A | UROLOGY KIDNEY NEPHRITIS |
| NCT02054702 | OTSUKA | DRUG | 1. PLANNING | 3 | 81 | 18 YEARS | 65 YEARS | PSYCH SCHIZOPHRENIA |
| NCT02058563 | GSK | BIOLOGICAL | 1. PLANNING | 3 | 1,000 | 7 YEARS | N/A | INFECT RUBELLA |
| NCT02070757 | CUBIST | DRUG | 1. PLANNING | 3 | 726 | 18 YEARS | N/A | INFECT PNEUMONIA |
| NCT02073682 | DAIICHI SANKYO | DRUG | 1. PLANNING | 3 | MISSING | 18 YEARS | N/A | CARDIO THROMB/COAG |
| NCT02074020 | ANTHERA | DRUG | 1. PLANNING | 3 | 400 | 18 YEARS | N/A | RHEUM LUPUS ERYTHEM. |
| NCT02075515 | GSK | BIOLOGICAL | 1. PLANNING | 3 | 651 | 50 YEARS | N/A | INFECT HERPES ZOSTER |
| NCT02075593 | GSK | DRUG | 1. PLANNING | 3 | 25 | 18 YEARS | N/A | INFECT HIV/AIDS |
| NCT02076412 | RIGEL | DRUG | 1. PLANNING | 3 | 75 | 18 YEARS | N/A | CARDIO THROMB/COAG |
| NCT02077192 | RIGEL | DRUG | 1. PLANNING | 3 | 150 | 18 YEARS | N/A | CARDIO THROMB/COAG |
| NCT02077868 | MOLOGEN | OTHER | 1. PLANNING | 3 | 540 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT02079727 | IBSA | DRUG | 1. PLANNING | 3 | 600 | 50 YEARS | N/A | RHEUM ARTHRITIS/GOUT |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Under Planning, Page 48)

Studies Under Planning, from Page 47

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|----------------------|-------------------|-------------|--------------------|----------|----------|-----------|---------------------------|
| NCT02080364 | TRANSTECH | DRUG | 1. PLANNING | 3 | 800 | 50 YEARS | N/A | NEUR ALZHEIMER/DEMENT |
| NCT02081391 | JANSSEN | DRUG | 1. PLANNING | 3 | 200 | N/A | 18 YEARS | ANEST PAIN ACUTE |
| NCT02082639 | GSK | BIOLOGICAL | 1. PLANNING | 3 | 990 | 9 YEARS | 14 YEARS | INFECT PAPILOMAVIRUS |
| NCT02090764 | FERRER | DRUG | 1. PLANNING | 3 | MISSING | 2 MONTHS | N/A | INFECT IMPETIGO |
| NCT02091375 | GW | DRUG | 1. PLANNING | 3 | 80 | 2 YEARS | 18 YEARS | NEUR EPILEPSY/SEIZURE |
| NCT02096861 | CELLTRION | BIOLOGICAL | 1. PLANNING | 3 | 214 | 18 YEARS | 75 YEARS | GI CROHN |
| NCT02100514 | PFIZER | DRUG | 1. PLANNING | 3 | 939 | 18 YEARS | N/A | CARDIO CHOLESTEROL/LIPIDS |
| NCT02100618 | GSK | PROCEDURE | 1. PLANNING | 3 | 170 | 15 YEARS | 32 YEARS | INFECT PAPILOMAVIRUS |
| NCT02105688 | MERCK SHARP DOHME | DRUG | 1. PLANNING | 3 | 300 | 18 YEARS | N/A | INFECT HEPATITIS C |
| NCT02105987 | GSK | DRUG | 1. PLANNING | 3 | 538 | 18 YEARS | N/A | INFECT HIV/AIDS |
| NCT02118584 | HOFFMANN-LA ROCHE | DRUG | 1. PLANNING | 3 | 2,600 | 18 YEARS | N/A | GI ULCERATIVE COLITIS |
| NCT02132312 | OMEROS | DRUG | 1. PLANNING | 3 | 60 | N/A | 47 MONTHS | OPHTHAL CATARACT |
| NCT02135029 | PFIZER | DRUG | 1. PLANNING | 3 | 300 | 18 YEARS | N/A | CARDIO CHOLESTEROL/LIPIDS |
| NCT02138422 | XBIOTECH | BIOLOGICAL | 1. PLANNING | 3 | 276 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT02138838 | AMGEN | DRUG | 1. PLANNING | 3 | 48 | 6 YEARS | 17 YEARS | UROLOGY KIDNEY FAILURE |
| NCT02139046 | TAKEDA | DRUG | 1. PLANNING | 3 | 1,750 | 18 YEARS | N/A | RHEUM ARTHRITIS/GOUT |
| NCT02142738 | MERCK SHARP DOHME | DRUG | 1. PLANNING | 3 | 300 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02144610 | ANGES | GENETIC | 1. PLANNING | 3 | 500 | 40 YEARS | 90 YEARS | CARDIO PERIPH VASC |
| NCT02146430 | DAIICHI SANKYO | DRUG | 1. PLANNING | 3 | 1,200 | 18 YEARS | N/A | NEUR FIBROMYALGIA |
| NCT02149108 | BOEHRINGER INGELHEIM | DRUG | 1. PLANNING | 3 | 764 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT02153632 | OSMOTICA | DRUG | 1. PLANNING | 3 | 162 | 30 YEARS | 85 YEARS | NEUR PARKINSON |
| NCT02153645 | OSMOTICA | DRUG | 1. PLANNING | 3 | 162 | 30 YEARS | 85 YEARS | NEUR PARKINSON |
| NCT02155634 | CELGENE | DRUG | 1. PLANNING | 3 | 172 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02155881 | TAKEDA | DRUG | 1. PLANNING | 3 | 80 | 18 YEARS | N/A | ALLERGY RHINITIS |
| NCT02158572 | AGILE | DRUG | 1. PLANNING | 3 | 2,100 | N/A | N/A | HEALTHY/PHARM |
| NCT02159053 | NOVARTIS | BIOLOGICAL | 1. PLANNING | 3 | 275 | 18 YEARS | N/A | RHEUM SPONDYLITIS |
| NCT02162667 | CELLTRION | DRUG | 1. PLANNING | 3 | 532 | 18 YEARS | N/A | ONC BREAST |
| NCT02162771 | CELLTRION | BIOLOGICAL | 1. PLANNING | 3 | 250 | 18 YEARS | N/A | ONC HEM: LYMPHOMA |
| NCT02170727 | BMS | DRUG | 1. PLANNING | 3 | 160 | 18 YEARS | N/A | INFECT HEPATITIS C |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Under Planning, from Page 48

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|-------------------|-------------------|-------------|--------------------|----------|----------|----------|-----------------------------|
| NCT02172950 | CSL BEHRING | BIOLOGICAL | 1. PLANNING | 3 | 200 | N/A | N/A | HEM HAEMOPHILIA A/B |
| NCT02174094 | H LUNDBECK | DRUG | 1. PLANNING | 3 | 54 | 1 YEAR | 16 YEARS | NEUR EPILEPSY/ SEIZURE |
| NCT02178592 | VIIV | DRUG | 1. PLANNING | 3 | 125 | 18 YEARS | N/A | INFECT HIV/AIDS |
| NCT02178956 | BOSTON BIOMEDICAL | DRUG | 1. PLANNING | 3 | 680 | 18 YEARS | N/A | ONC GI: ESOPHAGEAL/ GASTRIC |
| NCT02180165 | MERCK SHARP DOHME | DRUG | 1. PLANNING | 3 | 90 | 18 YEARS | N/A | INFECT ASPERGILLOSIS |
| NCT02180295 | MERCK SHARP DOHME | BIOLOGICAL | 1. PLANNING | 3 | 315 | 50 YEARS | 59 YEARS | INFECT HERPES ZOSTER |
| NCT02181413 | MILLENNIUM | DRUG | 1. PLANNING | 3 | 652 | 18 YEARS | N/A | ONC HEM: MYELOMA |
| NCT02181673 | JANSSEN | DRUG | 1. PLANNING | 3 | 440 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT01896479 | EXELIXIS | DRUG | 1. PLANNING | 4 | 112 | 18 YEARS | N/A | ONC ENDO: THYROID |
| NCT01916200 | GSK | DRUG | 1. PLANNING | 4 | 256 | 18 YEARS | 65 YEARS | PSYCH DEPRESSION |
| NCT01937325 | THE ALFRED | DRUG | 1. PLANNING | 4 | 20 | 16 YEARS | 70 YEARS | RESP CYSTIC FIBROSIS |
| NCT01948791 | NOVARTIS | DRUG | 1. PLANNING | 4 | 186 | 50 YEARS | 85 YEARS | NEUR ALZHEIMER/ DEMENT |
| NCT01977807 | TECHNOLAS PERFECT | DEVICE | 1. PLANNING | 4 | 100 | 18 YEARS | 85 YEARS | OPHTHAL MYOPIA |
| NCT02034877 | PFIZER | BIOLOGICAL | 1. PLANNING | 4 | 1,200 | 6 YEARS | 65 YEARS | INFECT PNEUMONIA |
| NCT02038140 | ZIMMER | DEVICE | 1. PLANNING | 4 | 120 | 18 YEARS | N/A | RHEUM ARTHRITIS/ GOUT |
| NCT02051062 | CANGENE | PROCEDURE | 1. PLANNING | 4 | 10 | N/A | 16 YEARS | INFECT BOTULISM |
| NCT02052635 | ASTRAZENECA | DRUG | 1. PLANNING | 4 | 150 | 18 YEARS | N/A | CARDIO CORONARY/ ISCHEMIC |
| NCT02060487 | PFIZER | DRUG | 1. PLANNING | 4 | 429 | 18 YEARS | 74 YEARS | CARDIO HYPERTENSION PULM |
| NCT02068729 | K2M | | 1. PLANNING | 4 | 222 | 18 YEARS | N/A | ORTH DISC DEGENERATIVE |
| NCT02074137 | SANOFI | DRUG | 1. PLANNING | 4 | 10 | 18 YEARS | N/A | ONC UROLOGY: PROSTATE |
| NCT02090348 | BIOGEN | DRUG | 1. PLANNING | 4 | 320 | 18 YEARS | N/A | NEUR MULTIPLE SCLEROSIS |
| NCT02090413 | BIOGEN | DRUG | 1. PLANNING | 4 | 240 | 18 YEARS | N/A | NEUR MULTIPLE SCLEROSIS |
| NCT02092285 | MERCK SHARP DOHME | DRUG | 1. PLANNING | 4 | 200 | 18 YEARS | N/A | GI ULCERATIVE COLITIS |
| NCT02100228 | PFIZER | DRUG | 1. PLANNING | 4 | 1,500 | 18 YEARS | N/A | CARDIO ARRHYT/ FIBRILL |
| NCT02101164 | AMGEN | BIOLOGICAL | 1. PLANNING | 4 | 100 | 18 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT02101554 | PFIZER | DRUG | 1. PLANNING | 4 | 100 | 7 YEARS | 17 YEARS | ANEST PAIN CHRONIC |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Under Planning, Page 50)

Studies Under Planning, from Page 49

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|-------------------|-------------------|-------------|--------------------|----------|----------|----------|--------------------------|
| NCT02112968 | TECHNOLAS PERFECT | PROCEDURE | 1. PLANNING | 4 | 97 | 18 YEARS | 85 YEARS | OPHTHAL MYOPIA |
| NCT02112981 | MERIL | DEVICE | 1. PLANNING | 4 | 258 | 18 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |
| NCT02121288 | ASTRAZENECA | DRUG | 1. PLANNING | 4 | 100 | 18 YEARS | 59 YEARS | CARDIO PERIPH VASC |
| NCT02124161 | PFIZER | BIOLOGICAL | 1. PLANNING | 4 | 882 | 50 YEARS | N/A | INFECT PNEUMONIA |
| NCT02125604 | BIOGEN | DRUG | 1. PLANNING | 4 | 230 | 18 YEARS | N/A | NEUR MULTIPLE SCLEROSIS |
| NCT02130999 | VANDA | DRUG | 1. PLANNING | 4 | 14 | 18 YEARS | 55 YEARS | PSYCH INSOMNIA/SLEEP |
| NCT02138747 | ASTELLAS | DRUG | 1. PLANNING | 4 | 360 | 18 YEARS | N/A | UROLOGY INCONTINENCE |
| NCT02141204 | GSK | BIOLOGICAL | 1. PLANNING | 4 | 308 | 6 WEEKS | 10 WEEKS | INFECT ENTERITIS |
| NCT02155335 | MERCK SHARP DOHME | DRUG | 1. PLANNING | 4 | 100 | 18 YEARS | N/A | GI ULCERATIVE COLITIS |
| NCT02156895 | PFIZER | DRUG | 1. PLANNING | 4 | 600 | 18 YEARS | N/A | ONC UROLOGY: KIDNEY |
| NCT02162758 | TAKEDA | DRUG | 1. PLANNING | 4 | 150 | 18 YEARS | 80 YEARS | GI ESOPHAGITIS/REFLUX |
| NCT02169817 | SANOFI | DRUG | 1. PLANNING | 4 | 759 | 6 MONTHS | 5 YEARS | INFECT ENTERITIS |
| NCT02177721 | GSK | OTHER | 1. PLANNING | 4 | 100 | N/A | N/A | INFECT BACTERIAL |
| NCT01885585 | BMS | DRUG | 1. PLANNING | NA | 3,000 | 19 YEARS | N/A | CARDIO THROMB/COAG |
| NCT01890447 | GSK | OTHER | 1. PLANNING | NA | 700 | 18 YEARS | N/A | INFECT PERTUSSIS |
| NCT01899573 | GUIDED DELIVERY | DEVICE | 1. PLANNING | NA | 20 | 18 YEARS | N/A | CARDIO VALVE |
| NCT01907048 | BAYER | BEHAVIORAL | 1. PLANNING | NA | 500 | 18 YEARS | N/A | CARDIO THROMB/COAG |
| NCT01911078 | ST JUDE | PROCEDURE | 1. PLANNING | NA | 60 | 18 YEARS | 80 YEARS | ENDO METABOLIC SYNDROME |
| NCT01934452 | PFIZER | DRUG | 1. PLANNING | NA | 120 | 18 YEARS | 80 YEARS | ONC UROLOGY: KIDNEY |
| NCT01944618 | BMS | DRUG | 1. PLANNING | NA | 5,000 | 18 YEARS | 75 YEARS | ENDO DIABETES |
| NCT01959867 | TEI | DEVICE | 1. PLANNING | NA | 160 | 18 YEARS | N/A | ONC BREAST |
| NCT01960491 | CARAG | DEVICE | 1. PLANNING | NA | 10 | 18 YEARS | N/A | CARDIO HEART CONGENITAL |
| NCT01978223 | GSK | PROCEDURE | 1. PLANNING | NA | 1,500 | 12 WEEKS | 5 YEARS | INFECT ENTERITIS |
| NCT02006862 | ELPEN | | 1. PLANNING | NA | 500 | 18 YEARS | 90 YEARS | PSYCH BIPOLAR |
| NCT02013726 | GAMMA MEDICA | DEVICE | 1. PLANNING | NA | 200 | 25 YEARS | N/A | ONC BREAST |
| NCT02025205 | PULMONEX | DEVICE | 1. PLANNING | NA | 56 | 40 YEARS | N/A | RESP COPD |
| NCT02033902 | EISAI | DRUG | 1. PLANNING | NA | 500 | 12 YEARS | N/A | NEUR EPILEPSY/SEIZURE |
| NCT02037373 | OCTAPHARMA | BIOLOGICAL | 1. PLANNING | NA | 300 | 18 YEARS | N/A | CARDIO THROMB/COAG |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an intervention device trial.

(Return to Page 1)

(See Studies Under Planning, Page 51)

Studies Under Planning, from Page 50

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|-------------------|-------------------|-------------|--------------------|----------|----------|----------|----------------------------|
| NCT02044029 | HOFFMANN-LA ROCHE | | 1. PLANNING | NA | 30 | 10 YEARS | N/A | HEALTHY/PHARM |
| NCT02044614 | DAVITA | OTHER | 1. PLANNING | NA | 25 | 18 YEARS | N/A | UROLOGY URINARY SYMPTOMS |
| NCT02049216 | THE ALFRED | OTHER | 1. PLANNING | NA | 72 | 40 YEARS | 80 YEARS | RHEUM ARTHRITIS/ GOUT |
| NCT02050594 | BMS | DRUG | 1. PLANNING | NA | 30 | 18 YEARS | N/A | ONC DERM: MELANOMA |
| NCT02050841 | OCTAPHARMA | BIOLOGICAL | 1. PLANNING | NA | 50 | N/A | 16 YEARS | CARDIO THROMB/ COAG |
| NCT02053337 | SMITH & NEPHEW | DEVICE | 1. PLANNING | NA | 60 | 18 YEARS | N/A | DERM WOUND/ULCER |
| NCT02055183 | CANGENE | | 1. PLANNING | NA | 100 | N/A | N/A | INFECT BOTULISM |
| NCT02062606 | K2M | DEVICE | 1. PLANNING | NA | 204 | 11 YEARS | 21 YEARS | ORTH SPINAL DISEASE |
| NCT02064764 | MEDTRONIC | DRUG | 1. PLANNING | NA | 265 | 18 YEARS | 80 YEARS | CARDIO ARRHYT/ FIBRILL |
| NCT02064855 | K2M | | 1. PLANNING | NA | 213 | 18 YEARS | N/A | ORTH SPINAL STENOSIS |
| NCT02074774 | VAPOTHERM | DEVICE | 1. PLANNING | NA | 30 | N/A | N/A | RESP DISEASE |
| NCT02076386 | VIIV | DRUG | 1. PLANNING | NA | 400 | 18 YEARS | N/A | INFECT HIV/AIDS |
| NCT02085993 | AMGEN | | 1. PLANNING | NA | 40 | 18 YEARS | N/A | CARDIO THROMB/ COAG |
| NCT02087098 | ASTELLAS | DRUG | 1. PLANNING | NA | 2,000 | 18 YEARS | N/A | UROLOGY INCONTINENCE |
| NCT02087189 | BIOTRONIK | DEVICE | 1. PLANNING | NA | 44 | 18 YEARS | N/A | CARDIO PACEMAKER/ICD |
| NCT02091778 | MOLNLYCKE | DEVICE | 1. PLANNING | NA | 25 | 18 YEARS | N/A | ENDO DIABETES FOOT |
| NCT02092389 | ABBVIE | | 1. PLANNING | NA | 70 | 18 YEARS | N/A | GI ULCERATIVE COLITIS |
| NCT02093000 | HOFFMANN-LA ROCHE | | 1. PLANNING | NA | 200 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT02096172 | RENAISSANCE | | 1. PLANNING | NA | 200,000 | 18 YEARS | N/A | UROLOGY BLADDER DISEASE |
| NCT02096276 | GSK | OTHER | 1. PLANNING | NA | 800 | 12 YEARS | 64 YEARS | INFECT PERTUSSIS |
| NCT02097095 | AERAS | | 1. PLANNING | NA | 3,506 | 18 YEARS | 50 YEARS | INFECT TBC |
| NCT02097420 | ST JUDE | DEVICE | 1. PLANNING | NA | 20 | N/A | 5 YEARS | CARDIO VALVE |
| NCT02111031 | JANSSEN | | 1. PLANNING | NA | 350 | 65 YEARS | N/A | ONC BREAST |
| NCT02112773 | NICOX | | 1. PLANNING | NA | 500 | 1 YEAR | N/A | INFECT CONJUNCTIVITIS |
| NCT02112890 | GSK | OTHER | 1. PLANNING | NA | 2,000 | 10 YEARS | 25 YEARS | INFECT HEPATITIS A |
| NCT02113033 | SORIN | DEVICE | 1. PLANNING | NA | MISSING | 18 YEARS | N/A | CARDIO CARDIOMYOP/ FAILURE |
| NCT02113982 | STEMLINE | DRUG | 1. PLANNING | NA | MISSING | 18 YEARS | N/A | ONC CNS: BRAIN |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Under Planning, Page 52)

Studies Under Planning, from Page 51

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-------------------------|-------------------|-------------------|-------------|--------------------|----------|----------|----------|---------------------------|
| NCT02115503 | DATABEAN | | 1. PLANNING | NA | 162 | 18 YEARS | N/A | UROLOGY KIDNEY TRANSPLANT |
| NCT02117622 | NOVO NORDISK | DRUG | 1. PLANNING | NA | 1,000 | N/A | N/A | ENDO DIABETES |
| NCT02118597 | HOFFMANN-LA ROCHE | | 1. PLANNING | NA | 400 | 18 YEARS | N/A | INFECT HEPATITIS C |
| NCT02123667 | CHIESI | | 1. PLANNING | NA | 900 | 18 YEARS | 65 YEARS | ALLERGY ALLERGY |
| NCT02125695 | BIOGEN | PROCEDURE | 1. PLANNING | NA | 40 | 18 YEARS | N/A | HEALTHY/PHARM |
| NCT02127788 | ASTELLAS | DRUG | 1. PLANNING | NA | 150 | N/A | N/A | INFECT FUNGAL |
| NCT02130765 | ST JUDE | DEVICE | 1. PLANNING | NA | 1,453 | 18 YEARS | 75 YEARS | CARDIO ARRHYT/ FIBRILL |
| NCT02135757 | PERIPHARM | | 1. PLANNING | NA | 40 | 18 YEARS | N/A | ONC GI: COLORECTAL |
| NCT02136862 | REGULUS | | 1. PLANNING | NA | 120 | 16 YEARS | N/A | UROLOGY KIDNEY FAILURE |
| NCT02141230 | GSK | DRUG | 1. PLANNING | NA | 1,524 | N/A | N/A | ENDO OBESITY |
| NCT02142088 | GLYSURE | DEVICE | 1. PLANNING | NA | 60 | 18 YEARS | N/A | ENDO DIABETES |
| NCT02142283 | STRYKER | DEVICE | 1. PLANNING | NA | 500 | 18 YEARS | N/A | CARDIO STROKE |
| NCT02143479 | ASTELLAS | DRUG | 1. PLANNING | NA | 400 | 18 YEARS | N/A | GI LIVER TRANSPLANT |
| NCT02147938 | ASTELLAS | DRUG | 1. PLANNING | NA | 600 | 18 YEARS | N/A | UROLOGY KIDNEY TRANSPLANT |
| NCT02148211 | GSK | OTHER | 1. PLANNING | NA | 1,800 | N/A | N/A | INFECT INFLUENZA/ FLU |
| NCT02153346 | GSK | OTHER | 1. PLANNING | NA | 100 | 18 YEARS | N/A | ALLERGY ALLERGY |
| NCT02153424 | BMS | DRUG | 1. PLANNING | NA | 50 | 18 YEARS | N/A | CARDIO ARRHYT/ FIBRILL |
| NCT02155712 | STRYKER | DEVICE | 1. PLANNING | NA | 500 | 18 YEARS | 75 YEARS | ORTH HIP/KNEE REPLACEMENT |
| NCT02155998 | ASTRAZENECA | | 1. PLANNING | NA | 200 | 18 YEARS | N/A | ONC UROLOGY: PROSTATE |
| NCT02158403 | THORATEC | OTHER | 1. PLANNING | NA | 300 | N/A | N/A | CARDIO THROMB/ COAG |
| NCT02159573 | BIOGEN | BIOLOGICAL | 1. PLANNING | NA | 700 | 18 YEARS | N/A | NEUR MULTIPLE SCLEROSIS |
| NCT02161536 | MOTUS GI | DEVICE | 1. PLANNING | NA | MISSING | 18 YEARS | 75 YEARS | GI SCOPY |
| NCT02163239 | MINIMALLY | DEVICE | 1. PLANNING | NA | 100 | 18 YEARS | N/A | GI BILIARY DISEASE |
| NCT02164058 | CARDIACASSIST | DEVICE | 1. PLANNING | NA | 500 | 18 YEARS | N/A | CARDIO INFARCT |
| NCT02173171 | AMGEN | | 1. PLANNING | NA | 450 | 18 YEARS | N/A | ONC DERM: MELANOMA |
| NCT02173379 | ABBOTT | DEVICE | 1. PLANNING | NA | 3,000 | 18 YEARS | N/A | CARDIO CORONARY/ ISCHEMIC |
| NCT02174484 | BIOTRONIK | | 1. PLANNING | NA | 562 | 18 YEARS | N/A | CARDIO ARRHYT/ FIBRILL |
| NCT02178969 | SHIRE | | 1. PLANNING | NA | 30 | N/A | N/A | DERM EPIDERMOLYSIS |

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

STUDIES ENDED OR HALTED

This table lists studies that were terminated, suspended or withdrawn in the past week.

| IDENTIFIER ¹ | SPONSOR | TYPE ² | STATUS | PHASE ³ | SIZE (N) | MIN AGE | MAX AGE | DISEASE/CONDITION |
|-----------------------------|----------------------|-------------------|---------------|--------------------|----------|----------|----------|-------------------------------|
| NCT01848106 | REGADO | DRUG | 5. SUSPENDED | 3 | 13,200 | 18 YEARS | N/A | CARDIO CORONARY/ISCHEMIC |
| NCT02011230 | TRIHEALTH | OTHER | 5. SUSPENDED | NA | 200 | 4 YEARS | N/A | CARDIO DISEASE |
| NCT02145650 | ALLERGAN | OTHER | 5. SUSPENDED | NA | 2,000 | 2 YEARS | N/A | NEUR SPASTICITY/PALSY |
| NCT01440192 | CELGENE | BIOLOGICAL | 7. TERMINATED | 1 | 4 | 18 YEARS | 75 YEARS | RESP SARCOIDOSIS |
| NCT01524406 | HIGH POINT | DRUG | 7. TERMINATED | 1 | 24 | 30 YEARS | 55 YEARS | ORTH MUSCULAR DISEASE |
| NCT02049281 | MERCK SHARP DOHME | DRUG | 7. TERMINATED | 1 | 3 | 20 YEARS | N/A | ONC SOLID TUMOR/ CANCER |
| NCT02184286 | BOEHRINGER INGELHEIM | DRUG | 7. TERMINATED | 1 | 5 | 18 YEARS | 65 YEARS | INFECT HIV/AIDS |
| NCT00709618 | GSK | DRUG | 7. TERMINATED | 2 | 44 | 18 YEARS | N/A | ONC BREAST |
| NCT01489046 | BMS | DRUG | 7. TERMINATED | 2 | 301 | 18 YEARS | N/A | INFECT HIV/AIDS |
| NCT01540864 | HIGH POINT | DRUG | 7. TERMINATED | 2 | 126 | 18 YEARS | 65 YEARS | ENDO OBESITY |
| NCT01566630 | NOVARTIS | DRUG | 7. TERMINATED | 2 | 3 | 18 YEARS | 40 YEARS | O&G PREGNANCY |
| NCT01647308 | ISIS | DRUG | 7. TERMINATED | 2 | 15 | 18 YEARS | 65 YEARS | ENDO DIABETES |
| NCT01904253 | TAIHO | DRUG | 7. TERMINATED | 2 | 18 | 18 YEARS | N/A | ONC RESP: LUNG |
| NCT01911273 | PFIZER | DRUG | 7. TERMINATED | 2 | 180 | 18 YEARS | N/A | ONC GI: LIVER |
| NCT00070707 | MERCK SHARP DOHME | DRUG | 7. TERMINATED | 4 | 188 | 15 YEARS | 75 YEARS | ALLERGY RHINITIS |
| NCT02184260 | BOEHRINGER INGELHEIM | DRUG | 7. TERMINATED | 4 | 58 | 18 YEARS | N/A | CARDIO STROKE |
| NCT00922571 | ABBOTT | PROCEDURE | 7. TERMINATED | NA | 100 | 50 YEARS | 80 YEARS | OPHTHAL CATARACT |
| NCT01095237 | NONWOTECC | DEVICE | 7. TERMINATED | NA | 33 | 18 YEARS | 89 YEARS | CARDIO PERIPH VASC |
| NCT01716182 | BAXANO | | 7. TERMINATED | NA | 200 | 18 YEARS | N/A | ORTH SPINAL STENOSIS |
| NCT01904201 | QIAGEN | | 7. TERMINATED | NA | 57 | 18 YEARS | 65 YEARS | INFECT HIV/AIDS |
| NCT02188212 | NOBEL BIOCARE | DEVICE | 7. TERMINATED | NA | 53 | 18 YEARS | 70 YEARS | DENTAL PROCEEDURE |
| NCT01765556 | HOFFMANN-LA ROCHE | DRUG | 8. WITHDRAWN | 1 | 0 | 18 YEARS | N/A | ONC DERM: MELANOMA |
| NCT02133482 | BOEHRINGER INGELHEIM | DRUG | 8. WITHDRAWN | 1 | 0 | 18 YEARS | 50 YEARS | HEALTHY/PHARM |
| NCT02143622 | NOVARTIS | BIOLOGICAL | 8. WITHDRAWN | 1 | 0 | 18 YEARS | N/A | ONC ENT: NPC |
| NCT02121262 | ALLERGAN | DRUG | 8. WITHDRAWN | 3 | 0 | 18 YEARS | N/A | OPHTHAL MACULAR EDEMA |
| NCT02033590 | ALLERGAN | DEVICE | 8. WITHDRAWN | NA | 0 | 18 YEARS | 65 YEARS | DERM BREAST RECONSTR/ IMPLANT |

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

FDANEWS

Customer Service: Kim Williams
(888) 838-5578 • +1 (703) 538-7600
customerservice@fdanews.com

Editorial: Dan Landrigan
(703) 538-7649
dlandrigan@fdanews.com

Ad Sales: Jim Desborough
(703) 538-7647
jdesborough@fdanews.com

300 N. Washington St., Suite 200 • Falls Church, VA 22046-3431 • Phone: (888) 838-5578 • +1 (703) 538-7600 • Fax: +1 (703) 538-7676
www.fdanews.com

Clinical Trial Magnifier Limited: Managing Director, Johan PE Karlberg
FDAnews: President, Cynthia Carter; **Content Director:** Dan Landrigan; **Executive Editor:** Meg Bryant

Copyright © 2014 by Clinical Trial Magnifier. All rights reserved. *Clinical Trial Magnifier Weekly* is produced jointly by Clinical Trial Magnifier Limited, which is responsible for the content, and FDAnews, which is responsible for production and distribution. *Clinical Trial Magnifier Weekly* (ISSN 2306-8388) monitors all the essential changes made in the U.S. trial registry for industry-sponsored clinical studies. It is published weekly, 52 issues. Price for nonprofit, academic, government, hospital, and study site subscribers, \$697. Price for for-profit, industry, and clinical research organizations, \$1,297. For site license pricing, contact Liz Lentz, llentz@fdanews.com. Photocopying or reproducing in any form, including electronic or facsimile transmission, scanning or electronic storage is a violation of federal copyright law and is strictly prohibited without the publisher's express written permission.